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Abstract 
Chapter 1 — Macrocyclization Through Copper-Catalyzed Castro–Stephens 
Coupling/Alkyne Reduction Tandem Reaction 
Macrocycles, incorporating conjugated polyene subunits within the ring, are 
structural features found in a number of natural products that exhibit diverse and potent 
biological activities. Existing methods for the construction of such structures are limited 
and in many cases inefficient.  We discovered an unprecedented copper-mediated 
reductive ene–yne macrocyclization reaction during our pursuit of the total synthesis of 
oximidine II. The reaction selectively generates an endocyclic Z-double bond through an 
intramolecular coupling of a vinyl iodide and a terminal alkyne fragment followed by in 
situ alkyne reduction. We developed this transformation as a general method for the 
preparation of polyunsaturated macrocycles. The reaction conditions were optimized and 
the scope of the reaction was extensively explored. It was found that the alkyne reduction 
step is driven by the release of the ring strain. Thus, the reaction is particularly efficient 
for suitably strained 11- to 13-membered E,Z-1,3-diene macrocycles. A complementary 
stepwise procedure was employed for the synthesis of larger rings. Finally, a plausible 
reaction mechanism was proposed based on experimental findings. 
   v 
Chapter 2 — Formal Total Synthesis of Lactimidomycin 
Lactimidomycin is a macrocyclic natural product that possesses potent in vitro and in 
vivo anti-tumor activities. We accomplished a facile, 9-step synthesis of an advanced 
intermediate for the total synthesis of lactimidomycin. The crucial 12-membered polyene 
lactone core structure was constructed employing our newly developed Castro–Stephens 
coupling/alkyne reduction tandem reaction. The stereocenters were established via 
asymmetric a vinylogous aldol reaction and a Marshall’s propargylation reaction. 
Chapter 3 — Synthesis and Biological Evaluation of Oximidine II Analogues 
Oximidine II belongs to a family of benzolactone enamide natural products that exert 
their cytotoxic effects through inhibition of V-ATPases. Unlike other members of this 
family, the structure-activity relationship (SAR) of oximidines has not been extensively 
investigated. Guided by computational analysis and previous studies in our group, we 
designed and synthesized two oximidine II analogues with simplified scaffold. The 
simplified benzolactone core was accessed through a ring-closing metathesis (RCM) 
reaction and the enamide side chain was installed via a copper-mediated C–N coupling 
reaction. The analogues were evaluated for their biological activity. The results revealed 
that these molecules were weakly cytotoxic to a number of cancer cell lines. 
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Chapter I. Macrocyclization Through Copper-
Catalyzed Castro–Stephens Coupling/Alkyne 
Reduction Tandem Reaction 
1.1 Background 
Macrocycles are recurring structural units present in a myriad of biologically 
important natural products and more than 100 marketed drugs.1-7 By virtue of their 
intrinsically restrained conformation, macrocyclic compounds have been found to exhibit 
higher binding affinities and selectivities to proteins, and better oral bioavailability than 
their acyclic analogues. Established methods of synthesizing macrocycles include 
lactonization,8-9 lactamization,10 radical cyclizations,11 ring-closing metathesis (RCM),12 
palladium-catalyzed coupling reactions,13 etc. Despite their successful application in 
obtaining certain macrocycles, these methods have some limitations. For example, RCM 
reactions could potentially generate a mixture of stereoisomers and ring-contraction 
products.14-21 Palladium chemistry-based methods usually produce stoichiometric 
amounts of useless, sometimes toxic byproducts, and the introduction of the required 
coupling components (e.g., organoboron, organostannane) is often a multi-step, yet 
inefficient process. Due to the unique drug-like properties of macrocyclic compounds and 
the limitations of existing technology, continuing efforts are aimed at improving the 
efficiency of their chemical synthesis through developing new methodologies. 
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We are particularly interested in macrocycles possessing conjugated E,Z-diene units 
within the ring since this motif exists in a number of natural products with diverse and 
potent bioactivities such as latrunculin A,22-25 radicicol,26-29 lactimidomycin,30-31 and 
oximidine II (Figure 1–1).32 The rigid nature of unsaturated bonds contributes additional 
ring strain, making these compounds even more synthetically challenging than their 
saturated analogues. Most reported total syntheses of these natural products have so far 
relied on variants of RCM reactions.14, 33-41 A palladium-catalyzed Suzuki cross-coupling 
reaction was also employed for the synthesis of oximidine II.42 
O
OHO OH
H
N
O N
OCH3
oximidine II (1.4)
OH
HO
Cl
OO
O
H
HO
radicicol (1.2)
O O
OOHHN
O
O
lactimidomycin (1.3)
O
O
O
latrunculin A (1.1)
HO
S
H
N
H
O
  
Figure 1–1. Selected examples of polyunsaturated macrocyclic natural products. 
1.1.1 Total Syntheses of Latrunculin A 
Latrunculin A (1.1) was first isolated from the Red Sea sponge Negombata magnifica 
(formerly Latrunculia magnifica).22-23 It was shown to bind reversibly to the cytoskeletal 
protein actin with 1:1 stoichiometry and prohibit actin polymerization.43 Thus, latrunculin 
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A and its structurally related congeners have been widely used as chemical probes for 
exploring the biological behavior of the actin cytoskeleton.44 The remarkable biological 
profiles have prompted synthetic investigations and three total syntheses have been 
reported. 
Both of the early two total syntheses in 1990, accomplished by Smith45-46 and 
White47-48 respectively, constructed the E,Z-1,3-diene structure through a Wittig 
olefination reaction and the macrocycle by Mitsunobu lactonization. However, the ring-
closing steps were extremely inefficient with yields of 28-44%. 
Scheme 1–1. Fürstner’s Total Synthesis of Latrunculin A 
O
PMBN
S
O
OMeH
OH
NaO2C 1.6
1.5
1) Tf2O, prydine, CH2Cl2, –78 °C
2) 1.6, 15-crown-5, THF, 74% for 2 steps
O
PMBN
S
O
OMeH
O
O
1.7
2 steps
(44%)
O
TeocN
S
O
OMeH
O
O
1.8
O
TeocN
S
O
OMeH
O
O
1.10
O
TeocN
S
O
OMeH
O
O
1.11
1.1
Mo[N(tBu)(3,5-Me2C6H3)]3 (1.9)
CH2Cl2/PhMe, 80 °C, 70%
H2, Lindlar cat.
quinoline
CH2Cl2, 82%
1. TBAF, THF, 82%
2. HOAc, 60 °C, 80%
 
The more recent total synthesis of latrunculin A (1.1, Figure 1–1) by Fürstner et al. 
employed a ring-closing alkyne metathesis (RCAM) approach (Scheme 1–1).33-34 The 
triflate of alkynyl alcohol 1.5 underwent an SN2 reaction with the sodium salt of alkynyl 
carboxylic acid 1.6 to provide diyne ester 1.7. Replacement of the N-PMB group with a 
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Teoc protecting group set compound 1.8 ready for the key macrocyclization step. 
Chemoselective alkyne metathesis of the two triple bonds of compound 1.8 was 
effectuated upon treatment with molybdenum catalyst 1.9, affording the 16-membered 
enyne lactone 1.10 in 70% percent yield. It was claimed that this is the smallest ring size 
ever to be formed by ring-closing enyne–yne metathesis. Z-Selective semihydrogenation 
of the triple bond with Lindlar’s catalyst and subsequent cleavage of the protecting 
groups completed the total synthesis of latrunculin A. This concise and practical 
synthesis inspired the preparation of a library of natural and unnatural analogues of 
latrunculin A and related biological studies.49-50 
1.1.2 Total Syntheses of Radicicol 
Radicicol (1.2, Figure 1–1) was first isolated decades ago from Monocillium nordinii, 
and later found to have mild sedative and antibiotic activities.26, 28 The initially reported 
biological properties did not attract much interest until the natural product was identified 
in the late 1990s as a potent inhibitor of Hsp90,51-52 which is an appealing target for 
cancer chemotherapy. 
Danishefsky disclosed a concise synthesis of radicicol dimethyl ether based on the  
RCM reaction (Scheme 1–2).35 Enantioenriched alcohol 1.15 was prepared from methyl 
(R)-3-hydroxybutyrate (1.12) in nine steps including a Sharpless asymmetric oxidation 
that set up the chiral epoxide. Chloromethylbenzoic acid 1.17 was conveniently derived 
from commercially available 3,5-dimethoxybenzyl alcohol (1.16). Esterification between 
carboxylic acid 1.17 and alcohol 1.15 proceeded via the acid chloride to afford ester 1.18. 
Chemoselective addition of lithiated allylic dithiane 1.19 to the benzyl chloride center 
provided triene 1.20 ready for ring formation. The RCM reaction of triene 1.20 was 
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catalyzed by the second-generation Grubbs catalyst 1.21 and generated 14-membered 
macrolactone 1.22 in 55% yield. Notably, the transformation tolerated the vinyl expoxide 
and was not poisoned by the two sulfur atoms. Subsequent removal of the dithiane and 
aromatic chlorination finalized the synthesis of the radicicol dimethyl ether 1.23. In a 
subsequent publication, this group reported the total synthesis of the natural product itself 
through the same strategy with modified manipulation of protecting groups.6 
Scheme 1–2. Danishefsky’s Synthesis of Radicicol Dimethyl Ether 
HO OMe
O
TBDPSO
1.12 1.13
(+)-DET, Ti(OiPr)4, TBHP
90%, > 95% eeOH
TBDPSO
1.14
OH
O H
H
HO
1.15
O H
H
OHMeO
OMe
ClMeO
OMe
CO2H
(COCl)2, Et3N
1.15, 80%
OMe
MeO
O
Cl
O
H
HO
1.16 1.17 1.18
OMe
MeO
OO
H
HO
S S
nBuLi, 1.19, 60%
S
S 1.19
1.20
Grubbs II (1.21)
45 °C, 55%
OMe
MeO
OO
H
HO
S S
1.22
1) mCPBA; Et3N
 Ac2O, H2O, 70%
2) Ca(ClO)2, 80%
Ru
PCy3
NNMes Mes
Cl
Cl
Ph
1.21
OMe
MeO
OO
H
HO
1.23
Cl
 
Wissinger presented another RCM based total synthesis of radicicol with improved 
cyclization efficiency (Scheme 1–3).37 Mitsunobu esterification of resorcylic acid 1.24 
and epoxide alcohol 1.25 followed by MOM protection yielded ester 1.26. Addition of 
the deprotonated compound 1.26 to Weinreb amide 1.27 afforded ketone 1.28. Oxidation 
of the thioether 1.28 and subsequent sulfoxide elimination led to triene 1.29. Exposing 
triene 1.29 to RCM conditions in refluxing toluene produced exclusively macrocycle 1.30 
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in a very good yield of 87%. Chlorination of compound 1.30 was accompanied by 
stereospecific epoxide ring opening to give chloride 1.31. Completion of the total 
synthesis was achieved after deprotection of phenols and reforming of the epoxide. 
Scheme 1–3. Wissinger’s Total Synthesis of Radicicol 
OMOM
MOMO
OO
H
HO
1.30
O
Grubbs II (1.21)
110 °C, 87%
OMOM
MOMO
OO
H
HO
1.28
0 °C, 68%
SOCl2
OMOM
MOMO
OO
H
Cl
1.31
O
OH
74%
HCl, 0 °C to rt
OH
HO
OO
H
Cl
pochonin C
O
OH
86%
K2CO3 1.2
OH
HO
OHO
1.24
HO
HO
1.25
+
1) (m-ClC6H4)3P, DIAD, 84%
2) MOMCl, DIPEA, 91%
OMOM
MOMO
OO
H
HO
1.26
LDA, 1.27, –78°C, 81%
N
O
MeO
SPh
1.27
O
SPh H2O2, rt
then 80 °C, 92%
OMOM
MOMO
OO
H
HO
1.29
O
 
1.1.3 Total Syntheses of Lactimidomycin 
Lactimidomycin (1.3, Figure 1–1) was isolated from Streptomyces amphibioporus 
ATCC 53964, which exhibited antiproliferative and cytotoxic activities.30 Fürstner 
developed two total syntheses utilizing different versions of metathesis reactions. The 
first-generation synthesis relied on an RCAM reaction (Scheme 1–4).38-39 Alcohol 1.38 
was synthesized from commercial (R)-ethyl 3-hydroxybutyrate (1.32) in a 10-step 
sequence including an enantioselective Evans aldol reaction and a Z-selective Julia 
olefination. Steglich esterification of alcohol 1.38 with 6-octynoic acid provided diyne 
ester 1.39, which was converted to the 12-membered enyne lactone 1.41 via RCAM 
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reaction in the presence of the molybdenum catalyst 1.40. A ruthenium-catalyzed trans-
hydrosilylation/desilylation sequence commenced with enyne 1.41 and established the 
requisite E,Z-configured 1,3-diene unit to yield lactone 1.42. The enoate moiety was then 
installed by successive α-selenylation and oxidative elimination to give triene cycle 1.43.  
Scheme 1–4. Fürstner’s First-Generation Total Synthesis of Lactimidomycin 
OH
OEt
O TESO
CHO
1.32 1.33
1.34, Bu2BOTf, Et3N
–78 °C to rt, 90%
TESO
1.35
OH
N
O
O
O
Ph
TESO
1.36
OH
O 1.37, KHDMS, –55 °C, 59%
N
S S
O O
1.37
TESO
1.38
OH
6-octynoic acid, EDC
DMAP, 0 °C to rt, 96%
TESO
1.39
O
1.40, 5 Å MS, toluene
TESO
1.41
O O
1) BnMe2SiH, 
    [CpRu(MeCN)3]PF6
2) TBAF, 0 °C to rt
    64% for 2 steps
OH
1.42
O O
1) LDA, –78 °C to rt
2) PhSeBr, –78 °C to rt
3) mCPBA, –78 °C
4) DIPEA, 64% for 4 steps
OH
1.43
O O
87%
DMP O
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O O
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2) 1.45, then 1.46, –78 °C
O
1.47
O O
O
O
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O
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HF·Py, Py
1.3
N
O
O
O
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1.34
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Ph
Ph3SiO
OSiPh3
OEt2
Ph3SiO
1.40
HN
O
O CHO
1.45
N
B
OTs
O
N
H
1.46  
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Dess–Martin oxidation of alcohol 1.43 furnished ketone 1.44. The glutarimide 
fragment was installed via asymmetric Mukaiyama aldol reaction of the silyl enolate of 
ketone 1.44 and aldehyde 1.45 under the catalysis of chiral oxazaborolidine 1.46.  The 
total synthesis of the natural product was accomplished after the final desilylation by 
fluoride in a carefully buffered medium. 
Scheme 1–5. Fürstner’s Second-Generation Synthesis of Lactimidomycin 
OH
OEt
O
1.32
1.49, K2CO3, MeOH
0 °C to rt, 76%
DMBO
1.48
OTES
OHC DMBO
1.50
OTES
vinyl bromide, CuI
(Ph3P)2PdCl2, 88%
DMBO
1.51
TESO 1.52, BuMe2SiH
93%, d.r. = 96:4
DMBO
1.53
OTES
BnMe2Si
1) PPTS, 89%
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    EDC, DMAP, 97%
DMBO
1.54
O
BnMe2Si
1.55, 120 °C
76%
DMBO
1.56
O
BnMe2Si
1) DDQ, 87%
2) TBAF, 60 °C, 85%
OH
1.42
O
1.3
P
N2
OO
MeO
MeO
1.49
Pt
N
N
iPr
iPr
iPr
iPr
O
1.52
NN
Cy
Cy
Ru
O
Ph
Cl
Cl
1.55
  
Their second-generation synthesis of lactimidomycin employed a regio- and stereo-
selective diene–ene RCM reaction with a silyl group on the diene unit (Scheme 1–5).14 
Aldehyde 1.48 was derived from compound 1.32 in similar fashion to aldehyde 1.36 that 
they had described in the first-generation synthesis. The aldehyde was converted to 
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alkyne 1.50 through an Ohira–Bestmann modification of the Seyferth–Gilbert 
homologation. Sonogashira coupling of alkyne 1.50 with vinyl bromide afforded enyne 
1.51, which engaged in a platinum-catalyzed cis-hydrosilylation with excellent regio-
control. O-Desilylation of the resultant compound 1.53 followed by esterification with 6-
heptenoic acid yielded triene ester 1.54. The key RCM reaction of triene 1.54 was 
prompted by ruthenium catalyst 1.55 to furnish the 12-membered lactone 1.56. Ring 
contraction and formation of the Z,Z-isomer were effectively suppressed as a 
consequence of the C-silyl substitution. Deprotection of the dimethoxybenzyl (DMB) 
ether and removal of the stereo-directing silyl substituent delivered alcohol 1.42, which 
could be elaborated to lactimidomycin according to their previously reported total 
synthesis. 
1.1.4 Total Syntheses and Synthetic Studies of Oximidines 
In 1999 Hayakawa and co-workers reported the isolation of oximidines I and II (1.4, 
Figure 1–1) from Pseudomonas sp. Q52002.32 Oximidine III was isolated and its 
structure was elucidated by the same group in 2003.53-54 The oximidines exhibited 
selective cytotoxicity at ng/mL levels for cells transformed with either the ras or src 
oncogens. A variety of macrocyclization strategies including RCM and transition metal 
catalyzed couplings have been investigated to synthesize oximidines. These 
investigations have led to the completion of two total syntheses and one formal total 
synthesis of oximidine II,40, 42, 55 one total synthesis of oximidine III,41 and several model 
studies.56-57 However, these approaches usually suffer from low efficiency for the critical 
ring-forming steps, particularly in the case of oximidine II due to its extremely strained 
structure with three consecutive double bonds. 
   10 
1.1.4.1 Macrolactonization Approaches 
The Maier group reported synthetic studies towards a functionalized oximidine core 
using the Stille coupling/macrolactonization strategy (Scheme 1–6).57 Stille coupling of 
chiral stannane 1.58 with triflate 1.57 generated styrene 1.59. Acidic removal of the 
acetonide followed by basic hydrolysis released a dihydroxy carboxylic acid, which 
underwent Yamaguchi lactonization to afford benzolactones 1.60 and 1.61 in a ratio of 
60:40, in favor of the desired larger 12-membered-ring. 
Scheme 1–6. Maier’s Synthesis of Oximidine’s Macrolactone Core 
CO2Me
OMe
OTf
1.57
+ Bu3Sn
O
O
OPMB
Pd(PPh3)2Cl2, LiCl
100 °C, 90%
1.58
OMe
CO2Me
O
O
PMBO
1.59
1. 80% HOAc, 90%
2. LiOH, MeOH,87%
3. 2,4,6-Cl3C6H2COCl
    DMAP, Et3N, 60%
O
MeO O OH
OPMB
O
MeO O OPMB
HO
1.60 (60) 1.61 (40)
+
:  
Scheme 1–7. Coleman’s Approach to the Oximidine Core Structure 
CO2Et
(CH2)4OH
Zn, EtOH CO2Et (CH2)4OH 1. LiOH, H2O, 94%
2.PPh3, DEAD, 26%LiCl, 88%
1.62 1.63 1.64
O
O
 
Coleman and Garg published their model studies towards oximidines through both 
macrolactonization and Castro–Stephens ene–yne coupling/reduction strategies.56 In the 
macrolactonization approach (Scheme 1–7), enyne 1.62 was partially reduced to diene 
ester 1.63 with zinc metal. Ester 1.63 was then saponified and subjected to a Mitsunobu 
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macrolactonization reaction. The expected diene lactone was successfully formed, 
however in a yield of only 26%. 
1.1.4.2 RCM Approaches 
Scheme 1–8. Porco’s Total Synthesis of Oximidine II 
PMBO CHO
1.65
allyl methoxymethyl ether
sBuLi, (+)-Ipc2BOMe
BF3·OEt2, –78 °C to 0 °C
80%, 90% ee
OMOM
OPMB
HO
OMOM
OPMB
HO
1.66 1.67
O O
O
Me
1.70
i) 1.67, NaHMDS, 0 °C
ii) TBSCl, imidazole, 100%
O
TBSO O OMOM
OPMB
Me
1.71
Grubbs II (1.21)
40 °C, 48% O
TBSO O OMOM
OPMB
1.72
O
TBSO O OTBS
I
1) CuTC, DMEDA
    K2CO3, 50 °C
O
H2N
N
OMe
1.74
1.73
2) HF·Py, pyridine
    44% for 2 steps
1.4
O O
O
OTf
1.68
+
Bu3Sn Me 1.69
Pd2(dba)3, TFP, 1.69
LiCl, 80 °C, 61%
 
Porco reported the first total synthesis of oximidine II that adapted an RCM reaction 
of a well-defined bis-diene substrate (Schem 1–8),40 in which chiral alcohol 1.67 was 
prepared from aldehyde 1.65. The stereocenters were established with a Brown 
asymmetric allylation reaction. E,E-Diene acetonide 1.70 was synthesized from triflate 
1.6858-59 and stannane 1.69 through a Stille coupling reaction. Transesterification of 
salicylate 1.70 with the anion of alcohol 1.67 followed by phenolate silylation provided 
bis-diene 1.71 in a one-pot procedure. RCM reaction of bis-diene 1.71 proceeded upon 
treatment with second-generation Grubbs catalyst to afford the triene lactone core 1.72 in 
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48% yield after one recycle. Positioning the terminal methyl group on the E,E-diene 
fragment was essential for the success of this reaction. Lactone 1.72 was then 
transformed to Z-vinyl iodide 1.73, which underwent copper-mediated C–N coupling 
reaction with oxime amide 1.7460 to install the enamide side chain. The total synthesis 
was finally finished after global deproctetion of the TBS groups. 
Scheme 1–9. Porco’s Total Synthesis of Oximidine III 
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OH
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+
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O
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O
H
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oximidine III  
Shortly afterwards, the same group reported a total synthesis of oximidine III 
following a relay RCM strategy (Scheme 1–9).41 Transesterification reaction of salicylate 
1.70 with alcohol 1.76 and in situ silyl protection of phenol provided tetraene ester 1.77. 
The RCM reaction of tetraene 1.77 afforded diene epoxide macrocycle 1.78 in good 
yield. The introduction of a relay moiety (the three-methylene-spaced terminal olefin) 
helped to initiate the reaction at the epoxide site. Sequential elaboration to vinyl iodide, 
TBS deprotection and side chain installation finalized the total synthesis of oximidine III. 
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1.1.4.3 Suzuki Coupling Approach 
Molander’s formal total synthesis of oximidine II employing a Suzuki-type coupling 
reaction (Scheme 1–10) represented the first application of potassium trifluoroborates to 
natural product synthesis.42 The transesterification between alcohol 1.80 and salicylate 
1.81 was followed by alkyne desilylation and phenol protection to generate ester 1.82. 
The use of Snieckus’ reagent (iP2BH) allowed regioselective hydroboration of the 
terminal alkyne, and the resultant organoborane was readily converted to the 
corresponding potassium trifluoroborate 1.83 in quantitative yield. Palladium-catalyzed 
intramolecular Suzuki coupling of seco-cycle 1.83 furnished the cyclized product 1.84. 
The reprotection of phenol 1.84 and removal of the benzyl protecting group yielded 
alcohol 1.85, a late-stage intermediate in Porco’s synthesis of oximidine II. 
Scheme 1–10. Molander’s Formal Total Synthesis of Oximidine II 
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1.1.4.4 Castro–Stephens Ene–Yne Coupling Approach 
Coleman and Garg also reported an access to oximidine cores structure though a 
copper-catalyzed Castro–Stephens coupling reaction.56 Vinyl iodide 1.86 engaged in an 
intramolecular ene–yne coupling with the alkyne moiety to afford cyclic enyne 1.87 in 
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37% yield. The enyne was chemo- and stereoselectively reduced with activated zinc 
metal, providing E,Z-diene lactone 1.64 in 26% yield over two steps. Similarly, lactone 
1.90 possessing the E,Z,Z-triene subunit of oximidine II was prepared from vinyl iodide 
1.88 in 22% overall yield. 
Scheme 1–11. Coleman’s Ene–Yne Coupling Strategy Model Studies 
O
O
I
CuI, PPh3, K2CO3
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O
O
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1.1.5 General Synthetic Methods 
Scheme 1–12. Denmark’s RCM/Cross-Coupling Method 
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O
O
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N
O
O
iPr iPr
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O
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1.95  
In spite of the successful total syntheses of natural products and related model studies, 
general methods to prepare conjugated polyene macrocycles are underexplored. One 
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example of this exploration is that Denmark described a general 2-step sequence 
combining a RCM reaction and a silicon-assisted cross-coupling reaction for the 
synthesis of 1,3-diene lactones (Scheme 1–12).61 RCM reaction of alkenylsilyl ethers 
1.91 was facilitated by the Schrock catalyst 1.92 to provide alkenylsiloxanes 1.93, which 
participated in an allylpalladium chloride dimer (APC)-catalyzed intramolecular cross-
coupling reaction with the pendent vinyl iodide moiety in the presence of TBAF 
hexahydrate as an activator to furnish macrocycles 1.94. Six examples of 11- to 14-
membered Z,Z-diene lactones were showcased with yields of 76-89% for the RCM step 
and 53-78% for the coupling step. Benzolactone 1.95 with the oximidine core structure 
was also shown as an example of E,Z-diene lactones. 
Scheme 1–13. Fürstner’s Diene–Ene RCM Method 
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In Fürstner’s second-generation synthesis of lactimidomycin, a general method for 
the construction of E,Z-diene lactones through a diene–ene RCM strategy was reported as 
well (Scheme 1–13).14 Although diene–ene RCM reactions have found numerous 
applications in natural product synthesis, an obvious drawback is their susceptibility to 
E/Z isomer formation and ring contraction. This situation was circumvented in Fürstner’s 
approach by the introduction of a C-silyl substituent on the diene unit. The steric 
hindrance of the bulky silyl group would protect the internal double bond against attack 
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by ruthenium species, so that undesired ring contraction would be prevented. At the same 
time, the silyl residue would also exhibit repulsive non-bonding interactions with the 
alkyl chain in the [2+2] cycloaddition intermediate that would lead to the Z,Z-diene (after 
desilylation) isomer. Following this strategy, esters 1.96 were subjected to RCM 
reactions with catalyst 1.97, generating lactones 1.98 that would furnish E,Z-diene cycles 
after desilylation as the only products. Eight examples of 12- to 18-membered lactones 
were synthesized using this method in good to excellent yields. 
In summary, natural products containing conjugated polyene macrocycle structural 
units were successfully synthesized through various ring-closing strategies including 
metathesis, macrolactonization, and metal catalyzed intramolecular cross-couplings. 
However, these methods were not universally efficient, especially for highly strained ring 
systems (yields < 50% for oximidine II). Two general methodologies have been reported, 
both of which required involvement of a silyl substituent Thus, new efficient methods 
that are tolerant of diverse functional groups are still in need to further explore these 
types of structures for biomedical applications. 
1.1.6 Discovery of Ene–Yne Coupling/Alkyne Reduction Tandem Reaction 
Attracted by its promising anti-tumor property, the Georg group has been involved in 
the studies towards the synthesis and medicinal chemistry of oximidine II and its 
synthetic analogues.  The initial plan included a two-step, two-pot procedure similar to 
Coleman’s approach in which a Castro–Stephens coupling would form the macrocycle 
and a chemoselective alkyne-to-alkene reduction would yield the triene system. 
The Georg group’s first-generation synthesis commenced with L-xylose (Scheme 1–
14),62  in which enantio-enriched alcohol 1.99 was prepared over nine steps with two 
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chiral centers derived from L-xylose. A Dess–Martin oxidation of the alcohol followed 
by a Corey–Fuchs reaction and stereoselective debromination provided Z-vinyl bromide 
1.100. Subsequent cleavage of the pivalate, Sonogashira coupling with TMS acetylene 
and desilylation afforded enyne alcohol 1.101. Yamaguchi esterification reaction of 
salicyclic acid derivative 1.102 with alcohol 1.101 engendered ester 1.103 as the 
macrocyclization precursor. The treatment of iodide 1.103 under modified Castro–
Stephens conditions63 formed the macrocyclic dienyne lactone 1.104 in a yield of 31%. 
Unfortunately, the E-C8–C9 double bond had isomerized to the Z-configuration during the 
course of the reaction, resulting in exclusively the undesired Z,Z-diene isomer.  
Scheme 1–14. Synthetic Studies Towards Oximidine II by Georg Group 
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The next step was to complete an exhaustive conformational analyses on model 
structures A-Z,Z and A-E,Z, as well as on the corresponding dihydro analogues B-Z,Z,Z 
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and B-E,Z,Z in order to rationalize this unexpected outcome (Figure 1–2). Both molecular 
mechanics and quantum chemical relative energies indicated that the Z,Z-configuration 
(A-Z,Z) was more stable than its E,Z-counterpart (A-E,Z) by 11-16 kcal/mol for dienyne 
structure A, highlighting the thermodynamic basis for the isomerization. However, upon 
the partial reduction of the C10–C11 alkyne to cis-olefin, the latter triene B-E,Z,Z was 
favored by 2-5 kcal/mol over the all Z-triene compound. 
O
O
8
9
A-Z,Z
A-E,Z
O
O
8
9
B-Z,Z,Z
B-E,Z,Z
10 1011 11
 
Figure 1–2. Model compounds for rationalizing C8–C9 double bond isomerization. 
We therefore resorted to a second-generation synthesis (Scheme 1–15), which led to 
the discovery of the unprecedented ene–yne coupling/alkyne reduction tandem reaction.55 
The synthesis of the alkyne fragment 1.109 began with a Brown asymmetric 
allylation of aldehyde 1.105 and alkene 1.106 in which enantioenriched alcohol 1.107 
was obtained in 81% yield as a single diastereomer with an e.r. of 94:6. TBS protection 
of the alcohol followed by ozonolysis of the resultant intermediate yielded aldehyde 
1.108, which underwent Peterson olefination to give selectively a Z-enyne. Global 
desilylation and mono-reprotection of the diol afforded enyne alcohol 1.109. The 
aromatic vinyl iodide fragment 1.110 was prepared from triflate 1.68 via sequential 
Heck-coupling and iodine-silicon exchange. A one-pot process involving base-induced 
transesterification of salicylate 1.110 with alcohol 1.109 and phenolate methylation 
produced ester 1.111, the key intermediate for the macrocyclization step. 
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Scheme 1–15. Second-Generation Total Synthesis of Oximidine II 
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When seco-cycle 1.111 was subjected to catalytic Castro–Stephens conditions the 
Z,E-dienyne lactone 1.112 was obtained in 18% yield with simultaneous C8–C9 double 
bond isomerization (Scheme 1–15), which was in accordance with previous experimental 
and computational results from the first generation synthesis.62 Careful analysis of the 
reaction mixture revealed the existence of a small amount (8%) of the partially reduced 
triene 1.113 (Scheme 1–15), implying that coupling and alkyne reduction reactions were 
proceeding in a single step. 
The reductant source was hypothesized to be a copper hydride (CuH) species, which 
was verified experimentally. Thus, exposing iodide 1.111 to the reaction conditions 
reported by Stryker64 for the generation of [CuH(PPh3)]6 resulted in the isolation of only 
the reduced triene product 1.113 in 31% yield (Scheme 1–16). The optimal source of 
hydride for this macrocyclization/reduction tandem transformation proved to be sodium 
formate and the reaction with the weaker base K2CO3 increased the yield of triene 1.113 
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to 67%. This cyclization was also mediated by Cu(OAc)2, albeit furnishing a lower yield 
(55%) of triene 1.113, but producing cleaner reactions. 
Scheme 1–16. Castro–Stephens Coupling/Alkyne Reduction Tandem Reactions 
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Scheme 1–17. Completion of the Total Synthesis of Oximidine II 
MeO O
O
OMOM
OTBDPS
1.113
1) TBAF, 94%
2) DMP, 86%
MeO O
O
OMOM
1.114
CHO
1) IPh3CH2I, NaHMDS, 80%
2) CBr4, iPrOH, 96%
TBSO O
O
OTBS
1.116
I
1.4MeO O
O
OH
1.115
I
1) BCl3, –78 °C, 94%
2) TBSOTf, Py, 80%
1) CuTC, 1.74, DMEDA
2) HF·Py, Py, 19% for 2 steps
 
With the crucial triene lactone core structure established, we thereafter completed the 
total synthesis of oximidine II (Scheme 1–17).  Desilylation of triene 1.113, oxidation to 
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the corresponding aldehyde, Stork–Zhao iodo-olefination, and protecting group 
interconversion generated Z-vinyl iodide 1.116 for the penultimate amide coupling. 
Iodide 1.116 was finally converted to oximidine II following the Porco protocol. 
Encouraged by its high efficiency (67% vs. less than 50% using other methods in 
literature) for the cyclization step in the total synthesis of oximidine II, we decided to 
develop the newly discovered one-pot reductive ene–yne coupling reaction as a general 
method for the construction of conjugated polyene macrocycles. To better understand the 
nature of this coupling/reduction cascade, a brief overview of the Castro–Stephens-type 
coupling reactions and CuH-mediated alkyne reductions will be presented in the 
following sections. 
1.1.7 Castro–Stephens-Type Coupling Reactions 
The Castro–Stephens coupling is a copper-mediated C–C bond forming reaction 
between a terminal alkyne and an organic halide.65 The original report in 1963 described 
the coupling of copper(I) acetylides with aryl iodides in refluxing pyridine under a 
nitrogen atmosphere to form disubstituted alkynes in good to excellent yields (Scheme 1–
18).65 The copper(I) acetylide reagent was prepared and isolated beforehand and hence, a 
stoichiometric amount of copper species was needed. 
Scheme 1–18. Castro–Stephens Coupling 
Ar I + Cu Ar'
Py, reflux
Ar Ar' + CuI
75-99%  
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Scheme 1–19. Miura’s Modification Under Catalytic Conditions 
Ar X + H R
CuI, PPh3, K2CO3
Ar R
DMF, 120 °C, 5-96%  
In 1993, Miura and co-workers reported the first Castro–Stephens-type coupling 
reaction under catalytic conditions (Scheme 1–19). The coupling of aryl halides and 
alkynes was catalyzed with the combination of CuI (10 mmol%) and ligand PPh3 (10 
mmol%), using K2CO3 as the base and DMF as the solvent.63 Although aryl iodides were 
found to be efficient for this reaction (37-96% yields), aryl bromides gave decreased 
product formation (5-23% yields). Since this report, the copper catalyzed alkyne coupling 
reaction has spurred numerous studies. The development of new catalytic systems has 
brought about enhanced yields and extension of the reaction scope. 
1.1.7.1 Cross-Coupling Reactions of Terminal Alkynes with Aryl Halides 
Scheme 1–20. Copper-Catalyzed Aryl–Yne Couplings 
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Li and co-workers reported that a catalytic amount of CuI combined with 1,4-
diazabicyclo[2.2.2]octane (DABCO, L1) and Cs2CO3 promoted the smooth coupling of 
alkynes with both electron-rich and electron-poor aryl halides, including aryl chlorides, in 
moderate to quantitative yields (51-99%).66 Ma et al. reported a catalytic system 
consisting of CuI, N,N-dimethylglycine hydrochloride (L2) and K2CO3 in DMF that 
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effected the coupling of alkynes with aryl iodides and bromides in 60-98% yields.67 A 
broad scope of reactants was examined and functional groups such as halo, nitro, 
carbonyl derivatives, carboxylic acids, and alkyl and silyl ethers were tolerated using 
these conditions. A Cu(OAc)2/1,4-diphenyl-1,4-diazabuta-1,3-diene (L3) catalyzed aryl–
yne coupling under aerobic and solvent-free conditions was reported by Li.68 The aryl 
iodides afforded the desired cross-coupling products in decent yields; however, higher 
loadings of catalyst were needed in aryl bromide reactions to suppress the oxidative 
homo-coupling of terminal alkynes.  Li and Zhang developed another solvent free 
methodology utilizing octahedral Cu2O nanoparticles supported by PPh3 and tetra-n-
butylammonium bromide (TBAB).69 Their coupling reaction was compatible with a wide 
range of functionalities, including free alcohols, and the scope was extended to include 
N-heteroaryl halides. It should be noted that this catalyst could be recovered and reused 
several times without loss of activity. 
1.1.7.2 Cross-Coupling Reactions of Terminal Alkynes with Vinyl Halides 
Scheme 1–21. Copper-Catalyzed Ene–Yne Couplings 
X + H R2
Cu cat.
R1ligand, base
R1
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Miura and co-workers reported a stereospecific cross-coupling of alkynes with vinyl 
halides,63 in which the E/Z ratio of the products remained unchanged from that of the 
vinyl halides employed. In this reaction the E-vinyl iodides were more reactive than the 
corresponding Z-isomers. The catalytic system reported by Li (CuI, DABCO, Cs2CO3) 
proved to be efficient for coupling alkyne and vinyl halide substrates as well upon 
   24 
addition of 1 equivalent of TBAB.66 The ene–yne coupling reaction was also effected by 
Ma’s catalytic system (CuI, N,N-dimethylglycine (L2) hydrochloride, Cs2CO3) under 
mild conditions (dioxane, 80 oC). A variety of functional groups were accommodated and 
enyne products were obtained in good to excellent yields (60-91%).70 
1.1.8 CuH-Mediated Alkyne Reductions 
Scheme 1–22. Preparation of CuH Complexes 
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Copper(I) hydride (CuH) complexes have been the topic of interest as both mild and 
selective reducing agents for a broad spectrum of substrates including α,β-unsaturated 
carbonyl derivatives and alkynes.71-73 The most frequently used CuH species is the 
phosphine stabilized hexamer [CuH(PPh3)]6, known as Stryker’s reagent64 or Osborn 
complex.74 In the original report, the compound was prepared by the hydrogenation of 
CuOtBu, which was produced in situ from CuCl and NaOtBu (Scheme 1–22). Alternative 
methods for preparation of Stryker’s reagent and other CuH complexes have been 
developed to avoid the extremely air-sensitive system (Scheme 1–22).75-76 Replacement 
of CuOtBu with Cu(OAc)2·H2O as the copper source allowed the formation of Stryker’s 
reagent in high purity without the need of repeated recrystallization. Hydrosilanes have 
been used as a more convenient hydride source instead of hydrogen gas. At the initial 
stage, CuH-mediated reductions required stoichiometric use of copper species,77-79 but 
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were later discovered to proceed catalytically in copper in the presence of a 
stoichiometric amount of hydride source.80-86 For most reactions, the active CuH species 
was generated in situ prior to the addition of the substrate to be reduced and stabilized 
with phosphines or N-heterocyclic carbenes (NHC) through complexation. 
Scheme 1–23. Alkyne Reduction with Stryker’s Reagent and Isolation of a Vinyl 
Copper(I) Species 
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Stryker reported in 1990 that [CuH(PPh3)]6 could prompt reduction of alkynes to 
furnish the corresponding alkenes with high Z-selectivity (Scheme 1–23).87 This reaction 
was carried out in the presence of water and employed stoichiometric amounts of 
Stryker’s reagent. Functionalities such as esters, tertiary ethers, acetals, and free alcohols 
were unaffected under the conditions. Terminal alkynes were reduced at room 
temperature whereas unactivated internal alkynes reacted only at elevated temperature. 
The reduction was conjectured to proceed via vinyl copper(I) intermediates through 
hydrocupration of alkynes. This hypothesis was later supported by the isolation and 
crystallographic study of a vinyl copper complex 1.117 as a result of the addition of an 
NHC-stabilized CuH species to 3-hexyne (Scheme 1–23).88 
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The catalytic version of the alkyne semi-reduction using CuH species has been 
underdeveloped until very recently. Tsuji revealed in 2012 that partial reduction of 
aromatic internal alkynes could be catalyzed by an in situ generated CuH-bisphosphine 
complex to afford Z-alkenes in high yields (Scheme 124).89 In the example 
polymethylhydrosiloxane (PMHS) was employed as the stoichiometric hydride source. 
The reaction exhibited exceptional tolerance to various functionalities such as hydroxy, 
siloxy, phthalimido, chloro, cyano, and vinylsilane. The catalyst was less reactive with 
dialkyl substrates and terminal alkynes, for which better yields were obtained with the 
NHC ligand ClIPr. 
Scheme 1–24. Catalytic Alkyne Reductions with CuH Complexes 
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Lalic reported later a similar catalytic system using NHC ligand IPr for this 
transformation (Scheme 1–24).90 The method was universally efficient for 
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aliphatic/aromatic internal and terminal alkynes although the reaction of internal alkynes 
required mild heating; thirty examples were showcased with excellent yields of 81-98%. 
Functionalities that are sensitive to hydrogenations such as cyano, nitro, and ketone were 
compatible with the reaction conditions. 
1.2 Reaction Optimization 
Scheme 1–25. Synthesis and Macrocyclization of Model Compound 
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For optimization studies, we investigated the reaction of a model compound vinyl 
iodide 1.119a (Scheme 1–25). The compound was synthesized from salicylate 1.110 
through transesterification with 5-hexyn-1-ol followed by in situ phenolate methylation. 
The coupling/reduction tandem reaction of iodide 1.119a was performed under the 
previously reported conditions55 for the total synthesis of oximidine II (HCO2Na (4 
equiv), K2CO3 (1.5 equiv), Cu(OAc)2 (0.33 equiv), and PPh3 (1 equiv) at 120 °C in DMF 
(0.005 M) for 2 h). We employed Cu(OAc)2 as the metal source rather than CuI, because 
it provided better reproducibility of the reaction on a large scale.91 The reaction furnished 
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the expected 12-membered E,Z-diene lactone 1.120a in a modest 34% yield, along with 
an undesired acyclic product 1.121a as a result of dehalogenation. The ratio of the two 
products was 20:1 favoring the desired lactone product. Extensive screening of various 
reaction conditions was carried out on the model system to increase the yield while 
maintaining the high selectivity for macrocyclization. 
1.2.1 Screening of Reaction Temperature 
The reaction of iodide 1.119a using PPh3 as the ligand was conducted at different 
temperatures; the results are listed in Table 1–1. 
Table 1–1. Optimization of Reaction Temperaturea 
MeO
O
OCu(OAc)2, PPh3
HCO2Na, K2CO3
DMF, temperature, 2 h
MeO O
O
1.120a 1.121a
MeO O
O
I
1.119a
+
 
entry temperature (°C) yield (%)b ratio (1.120a:1.121a)c 
1 120 34 20:1 
2 100 0 N/A 
3 140 19 6:1 
a Reaction conditions: 1.119a (0.005 M), Cu(OAc)2 (0.33 equiv), PPh3 (1 equiv), 
HCO2Na (4 equiv), and K2CO3 (1.5 equiv) in DMF under N2 for 2 h. b Isolated yield as 
mixture of 1.120a and 1.121a. c Calculated from 1H NMR. 
The reaction was found to perform well, but only at a specific temperature (120 °C, 
Table 1–1, entry 1). At lower temperature (110 °C, entry 2), the reaction was not initiated 
and only starting material was recovered. However, at an elevated temperature (140 °C, 
entry 3) a sharp decrease in both yield and selectivity was observed. 
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1.2.2 Screening of Solvent 
A selection of solvents was applied in the reductive ene–yne coupling reaction (Table 
1–2). Employing less polar solvent such as 1,4-dioxane and toluene (Table 1–2, entries 2 
and 3) did not provide any product. All the polar aprotic solvents tested (entries 1, and 4-
6) promoted the reaction with DMF and NMP (entries 1 and 6) slightly more efficient 
than the other two (entries 4 and 5). Considering the higher toxicity and price of NMP, 
the original DMF was our choice of solvent for further optimization studies. 
Table 1–2. Optimization Studies of Solventa 
MeO
O
OCu(OAc)2, PPh3
HCO2Na, K2CO3
solvent, 120 °C, 2 h
MeO O
O
1.120a 1.121a
MeO O
O
I
1.119a
+
 
entry solvent yield (%)b ratio (1.120a:1.121a)c 
1 DMF 34 20:1 
2 1,4-dioxane 0 N/A 
3 toluene 0 N/A 
4 DMA 34 14:1 
5 DMSO 31 20:1 
6 NMP 35 20:1 
a Reaction conditions: 1.119a (0.005 M), Cu(OAc)2 (0.33 equiv), PPh3 (1 equiv), 
HCO2Na (4 equiv), and K2CO3 (1.5 equiv) at 120 °C under N2 for 2 h. b Isolated yield as 
mixture of 1.120a and 1.121a. c Calculated from 1H NMR. 
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1.2.3 Screening of Ligands 
The ligand effect on the Castro–Stephens coupling/alkyne reduction tandem reaction 
was rigorously examined. All the ligands screened were shown to promote the reaction, 
as listed in Table 1–3. The chemical structures of some of the ligands are depicted in 
Figure 1–3. 
Substitutions on PPh3, either with electron-donating (Table 13, entries 2 and 3) or 
electron-withdrawing (entry 4) groups, did not increase the product formation. Alkyl 
phosphines (entries 5, 6 and 8) and a phosphite ligand (entry 7) displayed slightly better 
efficiency than PPh3, but the yields of 40-50% were still not practical. Next, we were 
pleased to find that high yields of over 70% could be achieved with chelating 
bisphosphine ligands (entries 9-11). Among them, dppe (entry 9) was the most 
inexpensive and easy-to-handle due to its high solubility. Although this ligand provided 
lower selectivity for macrocyclization (ratio of 1.120a:1.121a = 11:1), it should be useful 
when a substrate does not generate the acyclic product or the two products are separable. 
Phanephos (entry 11) afforded the best selectivity for the desired diene product 1.120a. 
Chelating O-ligands BINOL and TME (entries 12 and 13) gave comparable yields with 
bisphosphines, but were not as selective. Lastly, we also evaluated a few N-ligands, 
which exhibited inferior reactivities (entries 14-16). 
PCy2
MeO OMe
Sphos
PPh2
PPh2
dppe
PPh2
PPh2
rac-BINAP
PPh2
PPh2
R-phanephos
OH
OH
rac-BINOL
OH OH
OH
TME
N
H
CO2H
L-proline
NHMe
NHMe
DMEDA  
Figure 1–3. Structures of ligands. 
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Table 1–3. Optimization of Liganda 
MeO
O
OCu(OAc)2, ligand
HCO2Na, K2CO3
DMF, 120 °C, 2 h
MeO O
O
1.120a 1.121a
MeO O
O
I
1.119a
+
 
entry ligand yield (%)b ratio (1.120a:1.121a)c 
1 PPh3 34 20:1 
2 P(2-tol)3 37 40:1 
3 P(4-MeOC6H4)3P 19 11:1 
4 P(4-FC6H4)3P 21 20:1 
5d PnBu3 40 7:1 
6 PtBu3 49 20:1 
7 P(OEt)3 53 18:1 
8 Sphos 45 9:1 
9 dppe 73 11:1 
10 rac-BINAP 72 25:1 
11 (R)-phanephos 71 44:1 
12 rac-BINOL 70 5.9:1 
13 TME 69 17:1 
14 2,2’-bipyridyl 25 5:1 
15 DMEDA 39 20:1 
16 L-proline 30 4:1 
a Reaction conditions unless otherwise specified: 1.119a (0.005 M), Cu(OAc)2 (0.33 
equiv), ligand (donor atom/Cu = 3), HCO2Na (4 equiv) and K2CO3 (1.5 equiv) in DMF at 
120 °C under N2 for 2 h. b Isolated yield as mixture of 1.120a and 1.121a. c Calculated 
from 1H NMR. d At 100 °C. 
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1.2.4 Optimization of Catalyst Loading 
Table 1–4. Optimization of Catalyst Loadinga 
MeO
O
OCu(OAc)2, ligand
HCO2Na, K2CO3
DMF, 120 °C, 2 h
MeO O
O
1.120a 1.121a
MeO O
O
I
1.119a
+
 
entry ligand copper loading 
(equiv) 
ligand loading 
(equiv) 
yield  
(%)b 
ratio  
(1.120a:1.121a)c 
1 PPh3 0.33 1 34 20:1 
2 PPh3 1 3 64 90:1 
3 dppe 0.33 0.5 73 11:1 
4 dppe 1 1.5 73 20:1 
5 (R)-phanephos 0.33 0.5 71 44:1 
6 (R)-phanephos 0.2 0.3 73 44:1 
7 (R)-phanephos 0.1 0.15 N/Ad 28:1 
a Reaction conditions: 1.119a (0.005 M), HCO2Na (4 equiv) and K2CO3 (1.5 equiv) 
in DMF at 120 °C under N2 for 2 h. b Isolated yield as mixture of 1.120a and 1.121a. c 
Calculated from 1H NMR. d Proceeded to 70% conversion after 4 h. 
The reductive ene–yne macrocyclization reaction had been operated with 0.33 
equivalent of Cu(OAc)2 catalyst and thus, we next investigated the impact of catalyst 
loading on the reaction (Table 1–4). For reactions employing simple phosphine PPh3, 
stoichiometric amounts of Cu(OAc)2 and 3 equivalents of the ligand resulted in a 
remarkable increase in both yield and selectivity (Table 1–4, entry 2, compared with 
entry 1). Similarly, the stoichiometric use of copper and 1.5 equivalents of bisphosphine 
dppe inhibited the formation of the undesired dehalogenation product 1.121a to an 
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acceptable level (entry 4, compared with entry 3). On the other hand, we hoped to 
decrease the consumption of the expensive ligand phanephos. We were pleased to find 
that the efficiency of this ligand was not diminished under reduced catalyst loading 
(Cu(OAc)2 (0.2 equiv), phanephos (0.3 equiv), entry 6). Further lowering the loading of 
the catalyst (entry 7) led to incomplete reaction even after 4 h. Eventually, conditions for 
entry 6 were identified as the optimal conditions and would be used for exploring the 
scope of the reaction. However, the best conditions for each individual compound may 
vary as will be discussed in the following section. 
1.3 Reaction Scope 
We next applied this coupling/reduction tandem reaction to the synthesis of a diverse 
set of macrocyclic compounds. The scope of this reaction will be discussed here in terms 
of ring size, functionality, and vinyl iodide double bond configuration. 
1.3.1 Ring Size 
Analogues of E,Z-1,3-diene lactone 1.120a with different tether lengths were 
prepared through the Castro–Stephens coupling/alkyne reduction tandem reaction (Table 
1–5). We found that 11- to 13-membered rings 1.120a, 1.120b and 1.120d were obtained 
in good yields (Table 1–5, entries 1, 2 and 4). The 10-membered homologue 1.120c 
(entry 3) was also accessible, albeit in a low efficiency of 26%. The attempt to synthesize 
the 14-membered diene lactone 1.120e (entry 5) was unfruitful. Instead, NMR analysis of 
the crude mixture suggested that the unreduced enyne cycle 1.122e was the major 
component (Scheme 1–26).  
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Table 1–5. Preparation of Macrocycles with Different Ring Sizesa 
I
linker linker
HCO2Na, K2CO3
DMF, 120 °C
Cu(OAc)2·H2O
phosphines linker
1.119 1.120 1.121
+
 
entry product ligand Cu loading 
(equiv) 
time 
(h) 
yield 
(%)b 
ratio 
(1.120:1.121)c 
1 O
OMeO
1.120a
12
 
phanephos 0.2 2 73 44:1 
2A 
O
OMeO
1.120b
11
 
phanephos 0.2 2 62 59:1 
2B BINAP 0.3 2.5 68 36:1 
3 O
OMeO
1.120c
10
 
dppe 0.3 2 28 1.120c only 
4A 
O
OMeO
1.120d
13
 
BINAP 0.3 24 72 12:1 
4B PPh3 1 22 53 1.120d only 
5 
O
OMeO
1.120e
14
 
phanephos 0.2 24 0d N/A 
a Reaction conditions unless otherwise specified: 1.119 (0.005 M), ligand (donor 
atom/Cu = 3), HCO2Na (4 equiv) and K2CO3 (1.5 equiv) in DMF at 120 °C under N2. 
Reaction times were not fully optimized. b Isolated yield as mixture of 1.120 and 1.121. c 
Calculated from 1H NMR. d Only enyne was detected. 
We concluded that the alkyne reduction step of the tandem reaction is driven by the 
release of ring strain from the ene–yne coupling intermediate. For 12-membered or 
smaller rings, this intermediate was highly strained and susceptible to isomerization, as 
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discussed in Section 1.1.6. Thus, the substrates readily underwent alkyne reduction in the 
presence of a reducing agent. In the case of a 13-membered ring system (entry 4), the 
enyne cycle was moderately strained and stable enough to be observed without 
isomerization by NMR after 2 h. An extended reaction time (22-24 h) was needed to 
convert the enyne to the desired diene 1.120d. 14-Membered (entry 5) or larger rings 
formed a stable enyne that might offset the ring strain through conformation changes and 
did not produce any diene even after prolonged reaction time. 
Scheme 1–26. Reaction of Substrate 1.119e 
Cu(OAc)2, phanephos
HCO2Na, K2CO3
DMF, 120 °C
MeO
O
O
1.122e
14
MeO
O
O
1.119e
I
 
1.3.2. Functionality 
The 11- or 12-membered macrocycles with various linkages were synthesized 
employing the coupling/reduction tandem reaction (Table 1–6) demonstrating that a 
methoxy substitution on the aromatic ring was not necessary for implementing the 
macrocyclization (Table 1–6, entry 2 vs. entry 1). A phenyl iodide with an ether linkage 
(entry 3) worked equally well as the ester linkages. Labile functionalities such as an 
unprotected phenol and a secondary amide (entries 4 and 5) were not well tolerated. In 
contrast, a protected amide (entry 6) provided the corresponding lactam 1.120j in a 
decent yield of 79%.  
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Table 1–6. Preparation of Macrocycles with Different Functionalitiesa 
I
linker linker
HCO2Na, K2CO3
DMF, 120 °C
Cu(OAc)2·H2O
phosphines linker
1.119 1.120 1.121
+
 
entry product ligand Cu loading 
(equiv) 
time 
(h) 
yield 
(%)b 
ratio 
(1.120:1.121)c 
1 O
OMeO
1.120a
12
 
phanephos 0.2 2 73 44:1 
2A 
O
O
1.120f
12
 
phanephos 0.2 2 60 5.6:1 
2B PPh3 1 2 60 1.120f only 
3 
O
1.120g
11
 
phanephos 0.1 6 62 1.120g only 
4 
1.120h
O
OHO
12
 
PPh3 1 3 12 1.120h only 
5 N
O
1.120i
H
12
 
phanephos 0.2 2 0e N/A 
6 N
O
1.120j
PMB
12
 
phanephos 0.2 3.5 79 1.120j only 
7A O
1.120k
O
12
 
phanephosd 0.3 3 62 1.120k only 
7B BINAP 0.3 3 70 1.120k only 
8A O
1.120l
11
 
phanephos 0.2 4 71f  
8B dppe 0.3 4 82 1.120l only 
a Reaction conditions unless otherwise specified: 1.119 (0.005 M), ligand (donor 
atom/Cu = 3), HCO2Na (4 equiv) and K2CO3 (1.5 equiv) in DMF at 120 °C under N2. 
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Reaction times were not fully optimized. b Isolated yield as mixture of 1.120 and 1.121. c 
Calculated from 1H NMR. d ligand (donor atom/Cu = 2). e Decomposed. f Combined 
yield of an inseparable mixture of diene 1.120l and enyne 1.123 (ratio 11:1). 
Scheme 1–27. Reaction of Substrate 1.119l 
Cu(OAc)2, phanephos
HCO2Na, K2CO3
DMF, 120 °C
O
1.120l
O
1.119l
I
O
1.123
+
71%, 1.120l:1.123 = 11:1
 
Both vinyl iodide and terminal alkyne coupling partners can be aromatic or aliphatic 
(entries 11 and 12). Vinyl iodide double bond isomerization was observed for substrate 
1.119l (entry 8A and Scheme 1–27), which furnished an inseparable mixture (11:1) of 
diene 1.120l and enyne 1.123. Using dppe as the ligand, diene 1.120l was obtained in 
82% yield as the sole product. In the majority of the above examples (Tables 1–5 and 1–
6), the undesired acyclic product 1.121 was negligible. For those substrates that produce a 
significant quantity of compound 1.121, the use of stoichiometric amounts of copper and 
ligand could completely suppress the side reaction (Table 1–5, entry 4B and Table 1–6, 
entry 2B). 
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1.3.3 Z-Vinyl Iodide Substrates 
Z,Z-Diene macrocycles were difficult to access from the corresponding Z-vinyl iodide 
substrates (Scheme 1–28). The Z-enyne cycle intermediate is much less strained than its 
E-counterpart and therefore, did not undergo alkyne reduction even for the 10-membered 
ring system 1.122m. The 8-membered ring system was strained enough to afford the 
desired diene 1.120n in 30% yield; however, a significant amount of dimer 1.124 (34%) 
was formed at the same time. 
Scheme 1–28. Reactions of Z-Vinyl Iodides 
OPh
1.120n (30%)
Cu(OAc)2, phanephos
HCO2Na, K2CO3
DMF, 120 °C
OPh
1.119n
I
+
O
Ph O
Ph
1.124 (34%)
O O
Ph
1.122m
10
O O
Ph
1.119m
I
Cu(OAc)2, phanephos
HCO2Na, K2CO3
DMF, 120 °C
 
1.4 Stepwise Synthesis for Non-Strained Ring Systems 
Ring systems that were not strained enough to trigger the in situ alkyne reduction 
generated macrocyclic enynes (1.122e and 1.122m). This transformation is worth noting, 
since the intramolecular ene–yne C–C couplings (Sonogashira or Castro–Stephens) have 
not been widely applied to macrocyclizations and most previous reactions employed 
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phenyl iodide substrates.92-98 In addition, the desired diene macrocycles could be obtained 
from the enynes through a separate reduction step.  
Scheme 1–29. Methods for Alkyne Semi-reduction 
R R'
H2,Pd-CaCO3 R R'
Pb(OAc)2, quinoline H H
Hydrogenation with Lindlar catalyst
Transhydrogenation with formic acid
R R'
Pd(0), ligand R R'
H HHCO2H
Reduction with CuH
R R'
Cu salt, ligand R R'R R'
LCu HtBuOH, silane H H  
Convenient protocols for this semi-reduction include hydrogenation using H2 gas and 
the Lindlar catalyst,99-100 palladium-catalyzed trans-hydrogenation using formic acid or 
its ammonium salts,101-107 and CuH-mediated reactions89-90, 108-111 (Scheme 1–29). The 
Lindlar catalyst may suffer from a number of major problems such as partial E/Z 
isomerization, double bond shift, and over-reduction to alkanes.112-114 Therefore, close 
monitoring of the reaction progress is often necessary. Palladium-catalyzed trans-
hydrogenation with formic acid is known to induce double bond isomerization in 
conjugated systems,104 whereas CuH-mediated reductions exhibited excellent efficiency 
and selectivity, giving almost quantitative yields of Z-alkenes as the sole product in most 
cases.90 The conditions were also compatible with a plethora of functional groups, 
including nitro and aromatic iodides that are extremely labile to hydrogenations. Thus, 
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we prepared 14-membered or larger macrocycles through the combination of a Castro–
Stephens coupling and the CuH-mediated alkyne reduction (Scheme 130). 
Scheme 1–30. Stepwise Coupling/Reduction Synthesis of 14- and 17-Membered 
Macrocycles 
I
linker linkerCu(OAc)2, phanephos
MeO MeO
K2CO3, DMF, 120 °C
linker
MeOIPrCuCl, NaOtBu
PMHS, tBuOH
PhMe, 45 °C
MeO
O
O MeO
O
O
1.120e, 68% 1.120p, 46%
14
17
 
The iodides were exposed to the ene–yne coupling conditions in the absence of 
HCO2Na and the crude enyne was then treated with in situ formed CuH.90 The 14-
membered macrolactone 1.120e and 17-membered macrolactone 1.120p were 
synthesized using these conditions and double bond isomerization as seen in palladium-
catalyzed trans-hydrogenation of enyne was not detected herein. 
1.5 Mechanistic Insights 
A series of experiments was conducted in order to gain insights into the possible 
mechanism of the unprecedented reductive ene–yne coupling reaction. We hoped that an 
in-depth understanding of the reaction would give rise to further expansion of its scope 
and applications. We first added radical scavenger butylated hydroxytoluene (BHT, 5 
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equiv) to the reaction of iodide 1.119a under the previously described conditions 
(HCO2Na (4 equiv), K2CO3 (1.5 equiv), Cu(OAc)2 (0.33 equiv), and PPh3 (1 equiv) at 
120 °C in DMF (0.005 M) for 2 h) to determine whether the reaction proceeded through a 
radical or non-radical pathway (Scheme 1–31). Addition of the reagent exerted no 
perceptible effect on the rate, efficiency, or selectivity of the reaction in comparison with 
a control experiment. Both reactions went to completion in 2 h and gave nearly identical 
yields (~38%) and product ratios (1.120a:1.121a = 20:1), suggesting that radicals were 
not likely to be involved in the reaction pathway. 
Scheme 1–31. Reactions with or without BHT 
MeO
O
OCu(OAc)2, PPh3
HCO2Na , K2CO3
DMF, 120 °C, 37%
1.120a:1.121a = 20:1
MeO O
O
1.120a 1.121a
MeO O
O
I
1.119a
+
MeO
O
OCu(OAc)2, PPh3HCO2Na , K2CO3
BHT (5 equiv)
DMF, 120 °C, 38%
1.120a:1.121a = 20:1
MeO O
O
1.120a 1.121a
MeO O
O
I
1.119a
+
 
After ruling out the possibility of radical mechanisms, we postulated two non-radical 
pathways that would lead to the formation of diene lactone 1.120a (Scheme 1–32). Both 
mechanisms consisted of a coupling step and a reduction step via hydrocupration of an 
alkyne with a CuH species. However, we were uncertain whether the hydrocupration 
occurred prior to (path A) or after (path B) the ring-forming coupling reaction. 
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Scheme 1–32. Possible Reaction Mechanisms 
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To determine the plausibility of the hypothesized mechanisms, deuterium-labeling 
experiments for the reductive coupling reaction were carried out through replacing 
HCO2Na, the hydride source, with DCO2Na. We assumed that the active reducing species 
under otherwise the same conditions to be copper deuteride (CuD). If path A was the 
actual mechanistic pathway, the reaction with DCO2Na should generate exclusively the 
11-deuterated product 1.127 (Scheme 1–33). In contrast, if the reaction proceeded 
through path B and the hydrocupration was not absolutely regioselective, both 11-
deuterated product 1.127 and 10-deuterated product 1.128 could be obtained (Scheme 1–
33). In fact, 1HNMR analysis identified the product of the labeling experiment as a 9:1 
mixture of both regioisomers 1.127 and 1.128, implying that path B was more likely the 
operating mechanism. The preference for deuteration at the C11 position might be 
ascribed to the electronic properties of the enyne intermediate. 
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Scheme 1–33. Reaction with DCO2Na 
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In path B, a conjectured vinyl copper intermediate 1.126 (Scheme 1–32) extracts a 
proton to furnish the final product. Since we did not observe the bis-deuterated product in 
the reaction with DCO2Na, we deduced that the vinylcopper intermediate was likely 
quenched by external proton donors present in the solution (for example, Cu(OAc)2·H2O, 
alkynyl proton, or residual water in the solvent). This hypothesis was supported by the 
experiments performed with iodide 1.119a in the presence of anhydrous Cu(OAc)2, 
HCO2Na and D2O (Table 1–7), which resulted in deuterium incorporation at the C10 
position (1.128). The proportion of deuterated product 1.128 increased along with the 
amount of D2O added to the reaction (Table 1–7, entries 1-3). However, 75% of the 
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product remained undeuterated even with large excess of D2O (15 equiv, entry 3). The 
quenching proton might come from the non-dry solvent or diethylamine due to the 
decomposition of DMF at the high reaction temperature. In order to exclude proton 
sources to the greatest extent, one experiment was operated in pre-dried d6-DMSO (entry 
4). A high degree of 68% deuterium incorporation was achieved under these conditions. 
Table 1–7. Reactions with D2Oa 
O
O
I
MeO
1.119a
Cu(OAc)2, PPh3
HCO2Na , K2CO3
O
O
MeO
1.120a
10
H
DMF, D2O, 120 °C
O
O
MeO
1.128
+
D
 
entry solvent amount of D2O 
(equiv) 
yield (%)b ratio 
(1.128:1.120a)c 
1 DMF 2 N/Ad 10:90 
2 DMF 5 N/Ad 25:75 
3 DMF 15 34 29:71 
4 d6-DMSO 15 36 68:32 
a Reaction conditions: 1.119a (0.005 M), anhydrous Cu(OAc)2 (0.33 equiv), PPh3 (1 
equiv), HCO2Na (4 equiv), and K2CO3 (1.5 equiv) at 120 °C under N2 for 2 h. b Isolated 
yield as mixture of 1.128 and 1.120a. c Calculated from 1H NMR. d Not isolated. Crude 
NMR was analyzed. 
One the basis of the above experimental results and literature reports, we proposed 
the detailed catalytic cycle following path B as shown in Scheme 1–34. 
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Scheme 1–34. Proposed Mechanism for Reductive Coupling Reaction 
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The interaction of terminal alkyne 1.119a with the copper catalyst generates copper 
acetylide 1.129 in situ in the presence of the weak base K2CO3. An intramolecular 
Castro–Stephens coupling reaction between the acetylide and the vinyl iodide units forms 
E-enyne 1.131 via a four-centered transition state.63, 115 The copper atom remains 
coordinated to the triple bond through π-complexation, stabilizing the highly strained 
enyne and preventing the C8–C9 olefin isomerization. Subsequent expulsion of CO2 from 
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the copper-formate complex provides the requisite CuH species 1.132, which undergoes 
1,2-addtion across the alkyne to afford vinyl copper 1.133. A final protonation of the 
vinyl copper delivers the desired diene macrocyle 1.120a and regenerates the copper 
catalyst.  
1.6 Summary 
A copper-mediated tandem reaction involving an intramolecular Castro–Stephens 
coupling and in situ alkyne semi-reduction has been developed for the construction of 
macrocycles containing conjugated E,Z-diene units. Both extensive optimization studies 
and scope explorations have been conducted, demonstrating that the reaction is ring strain 
dependent and particularly efficient for 11- to 13-membered rings. The synthesis of larger 
and hence, less strained macrocycles can be achieved through an alternative stepwise 
sequence. The method is tolerant of linkages such as an ether, ester, and tertiary amide, 
but not compatible with acidic functionalities like an unprotected phenol or a secondary 
amide. A plausible mechanism has been proposed based on preliminary experimental 
observations. The deuterium-labeling studies reveal that the coupling reaction precedes 
the alkyne reduction. 
We believe that this facile transformation, which we previously utilized in the total 
synthesis of the benzolactone enamide natural product oximidine II, will be of great 
synthetic value for other complex macrocyclic molecules. In the next chapter, this will be 
demonstrated through an expeditious formal total synthesis of lactimidomycin, a potent 
antiproliferative agent. 
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Chapter II. Formal Total Synthesis of Lactimidomycin 
2.1 Background 
2.1.1 Biological Profile 
The glutarimide-containing macrolide lactimidomycin (1.3, Figure 2–1), isolated in 
1992 from the fermentation broth of Streptomyces amphibiosporus ATCC 53964, 
displays a wide spectrum of biological effects including cytotoxicity, antifungal activity, 
and inhibition of DNA/protein biosynthesis.30 The optimization of the fermentation 
conditions led to the production of lactimidomycin in appreciable quantities and as a 
consequence, the determination of its absolute stereochemistry.31 Further biological 
studies also identified it as an outstanding cell-migration inhibitor with an IC50 value of 
0.6 nM against the highly invasive MDA-MB-231 human breast adenocarcinoma cell 
line.116 However, a more recent report claimed that lactimidomycin was acutely cytotoxic 
and no significant cell-inhibition was observed at sub-toxic doses.39 Regardless of these 
contradictory results, lactimidomycin is still considered to be a promising anticancer drug 
lead because of its potent and selective antiproliferative effect on tumor cells both in vitro 
and in vivo.30, 117 Recently, details of its mechanism of action were unveiled when a 
lactimidomycin co-crystal structure with the 80S ribosome of Saccharomyces cerevisia 
revealed that the natural product binds to the tRNA E-site of the S60 subunit, thereby 
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preventing the binding of tRNA.118 In addition, kinetic experiments showed that 
lactimidomycin targets the first elongation cycle. 
O O
OOHHN
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lactimidomycin (1.3)
O O
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O O
OH
1.42 1.43
2 3
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Figure 2–1. Lactimidomycin (1.3) and its synthetic precursors 1.42 and 1.43. 
2.1.2 Reported Synthesis 
In addition to the continuous interest in its biological and pharmacological properties, 
lactimidomycin has also attracted attention from the organic chemistry community. Two 
total syntheses and two formal total syntheses have been disclosed, all with efforts 
focused on the construction of the unsaturated 12-membered lactone subunit. Fürstner 
developed two distinct approaches through RCM reations,14, 38 as discussed in Section 
1.1.3. The two latest syntheses, independently reported by Nagorny and Kuwahara, were 
published back-to-back in 2013. 
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Scheme 2–1. Nagorny’s Total Synthesis of Lactimidomycin 
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Nagorny et al. carried out their total synthesis by employing a Horner–Wadsworth–
Emmons macrocyclization strategy (Scheme 2–1).119 Here chiral aldehyde 2.2 was 
derived from the known vinylketene silyl N,O-acetal 2.1 in four steps including an 
asymmetric vinylogous aldol reaction, silyl protection, the reductive removal of the 
auxiliary, and a Parikh–Doering oxidation of the resultant alcohol. The aldehyde was then 
subjected to an Evans syn-selective aldol reaction followed by silyl protection to yield the 
protected aldol adduct 2.4. The oxazolidinone auxiliary was removed through sequential 
thioesterification and DIBAL-H reduction to form an aldehyde, which was converted to 
Z-vinyl iodide 2.5 through a Stork–Zhao olefination. The TMS protecting group of 
compound 2.5 was selectively removed and the resultant alcohol underwent an acylation 
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reaction with acyl chloride 2.6 to provide iodovinyl phosphate 2.7. The Suzuki coupling 
reaction of iodide 2.7 with boronic acid 2.8 installed the E,Z-1,3-diene structural unit and 
succeeding Dess–Martin oxidation furnished aldehyde 2.7 ready for the critical ring-
closing step. A Lewis acid Zn(II)-mediated intramolecular HWE reaction of compound 
2.7 generated the desired triene macrolactone 2.10 in a remarkably high yield of 93%. 
Model studies revealed that conventional Brønsted base-mediated conditions (e.g., 
LiHMDS) gave only the dimerized product. Desilylation of compound 2.10 delivered 
alcohol 1.43, which was elaborated to lactimidomycin following Fürstner’s report.38 
Scheme 2–2. Kuwahara’s Formal Total Synthesis of Lactimidomycin 
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Kuwahara’s formal total synthesis of lactimidomycin employed a Yamaguchi 
macrolactonization (Scheme 2–2).120 Aldehyde 2.12 was prepared similarly to aldehyde 
2.2 in the Nagorny’s synthesis. Exposing the aldehyde to ketene silyl S,O-acetal 2.13 in 
the presence of Sn(OTf)2 and chiral amine 2.14 led to the asymmetric formation of 
thioester 2.15. Reduction of thioester 2.15 to aldehyde 2.16 followed by a Z-selective 
Stork–Zhao olefination reaction afforded iodide 2.17, which was converted to Z,E-diene 
2.19 through Stille coupling reaction with stannane 2.18. Saponification of ester 2.19 
under basic conditions also induced the selective deprotection of the TMS ether to give 
directly the seco-acid 2.20. Yamaguchi macrocyclization of hydroxy acid 2.20 followed 
by oxidative elimination of the selenide and simultaneous desilylation furnished the 
triene lactone 1.43 in an excellent yield of 92% over two steps. Since compound 1.43 is a 
known intermediate in Fürstner’s and Nagorny’s total syntheses, this 10-step sequence 
constituted a formal total synthesis of lactimidomycin. 
2.2 Retrosynthesis 
Having developed the Castro–Stephens coupling/alkyne reduction tandem reaction 
for macrocyclization and having found that it was efficient for aliphatic substrates as 
well, we implemented the use of this method for the enantiospecific formal total synthesis 
of lactimidomycin. We selected truncated macrolides 1.42 and 1.43 (Figure 2–1) as the 
synthetic target, since both compounds have been converted to lactimidomycin in 
previously reported total syntheses.  
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Scheme 2–3. Retrosynthesis 
O O
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OR
2.27
N
TBSO
OO
2.1  
The retrosynthetic analysis is depicted in Scheme 2–3. We expected that the 12-
membered macrocycles 1.42 or 1.43 could be obtained from iodides 2.22/2.23 via our 
coupling/reduction tandem reaction. Esters 2.22/2.23 could be readily prepared from 
propargyl alcohol 2.26 and the corresponding carboxylic acids 2.24/2.25 using 
Mitsunobu conditions. Enantioenriched alcohol 2.26 was envisioned to arise from 
aldehyde 2.27 through Marshall’s asymmetric propargylation reaction. We also 
hypothesized that an anti-selective Kobayashi’s vinylogous aldol reaction of the known 
compound 2.1 would be able to deliver aldehyde 2.27. 
2.3 Preparation of Acids 2.24/2.45 
The Acid 2.24 was prepared from 4-pentyn-1-ol (2.28) in a 6-step sequence as shown 
in Scheme 2–4. Radical hydrostannylation of alcohol 2.28 was initiated by AIBN to 
generate vinyl stannane 2.29, which was converted via tin-iodine exchange to the 
corresponding vinyl iodide as a mixture of E/Z isomers.121 The mixture was then treated 
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with NaOMe in refluxing methanol.122 Under these conditions, only the Z-isomer was 
susceptible to an elimination reaction, leaving the untouched E-vinyl iodide 2.30 to be 
isolated in 58% yield over three steps. Next, alcohol 2.30 was oxidized to aldehyde 2.31 
under Swern conditions.123 The Wittig olefination reaction124 of aldehyde 2.31 with 
(ethoxycarbonyl)triphenylphosphorane afforded α,β-unsaturated ester 2.32 in high yield 
and E-selectivity (93%, E/Z > 20:1). While common basic saponification conditions 
failed to cleave the ethyl ester 2.32, this transformation was promoted by bis(tributyl)tin 
oxide with heating, furnishing the acid 2.25 in 71% yield. 
Scheme 2–4. Preparation of Acids 2.24/2.25 
I
HO O
2.24
nBu3Sn
HO
(COCl)2, DMSO, Et3N
DCM, –78 °C, 90%
I
O 93%, E /Z > 20:1
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nBu3Sn
HO
2.34
    reflux, 48% 
    for 3 steps
1) I2, DCM, 0 °C
2) KOH, MeOH
I
HO
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Acid 2.24 was synthesized from 6-heptyn-1-ol (Scheme 2–4). E-iodovinyl alcohol 
2.35 was obtained in a manner analogous to alcohol 2.30. Jones oxidation125 of alcohol 
2.35 gave directly the acid 2.24. 
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2.4 Synthesis of Esters 2.22/2.23 
The preparation of esters 2.22/2.23 was started from the commercially available (E)-
2-methyl-2-pentenoic acid (2.36), which was converted to the known vinylketene silyl 
N,O-acetal 2.1 following literature procedures (Scheme 2–5).126-127 Evans’ oxazolidinone 
2.37 was acylated with the mixed anhydride of acid 2.36 and pivalic acid in the presence 
of LiCl128 to yield chiral imide 2.38 and subsequent enol silyation of imide 2.38 with 
TBSCl generated compound 2.1 in almost quantitative yield. 
Scheme 2–5. Preparation of Ketene N,O-Acetal 2.1 and Its Vinylogous Aldol 
Reactions Reported by Kobayashi 
TBSO
2.1
O
OH + HN
OO
i) 2.36, Et3N
   PivCl, –20 °C
ii) LiCl, 2.37
    rt, 85%
2.36 2.37
O
N
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2.38
NaHMDS, TBSCl
THF, –78 °C, 98% N
OO
TBSO
N
OO
–78 °C to –40 °C
67-99%, d.r. > 50:1
RCHO, TiCl4, DCM
O
N
OO
R
OH
Kobayashi et al.
 
We intended to obtain the aldol adduct 2.39 by coupling compound 2.1 with 
acetaldehyde through a vinylous Mukaiyama-type aldol reaction following Kobayashi’s 
protocol (Scheme 2–5 and Table 2–1).129-130 In the original publication of 2004, 
compound 2.1 was reacted with long-chain or α-branched aldehydes to provide the 
corresponding aldol adducts with exceedingly high stereoselectivity (d.r. > 50:1). We 
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were concerned whether the reaction with acetaldehyde would retain the selectivity 
owing to its small size and lack of steric hindrance. 
Table 2–1. Vinylogous Aldol Reaction of Compound 2.1 with Acetaldehydea 
TBSO
2.1
N
OO
DCM, temperature
CH3CHO, TiCl4
O
N
OO
2.39
OH
 
entry temperature (°C) equiv of CH3CHO yield (%)b d.r.c 
1 –78 to –40 2 39 2.5:1 
2 –78 to –65 2 81 20:1 
3 –78 2 71 > 30:1 
4 –78 4 80 > 30:1 
a Reaction conditions: 2.1 (0.1 M), CH3CHO, and TiCl4 (1 equiv) in DCM under N2 
overnight. b Isolated yield. c Calculated from 1H NMR. 
We first mixed the reactants at –78 °C, allowed the mixture to warm to –40 °C, and 
left the reaction at this temperature overnight (Table 2–1, entry 1). The aldol adduct was 
obtained in 39% yield and this low yield might be attributed to the quality of compound 
2.1, which was improperly stored at room temperature for a few days, resulting in visible 
decomposition by TLC analysis. Nonetheless, the modest selectivity (d.r. = 2.5:1) 
implied the necessity of maintaining the reaction at a lower temperature. Indeed, a drastic 
increase in both diastereomeric ratio (20:1) and yield (81%) was observed when the 
reaction was executed at –65 °C (entry 2). Further enhancement of the stereoselectivity 
(d.r. > 30:1) was achieved by keeping the reaction temperature constant at –78 °C (entry 
3), with somewhat diminished efficiency (71% yield). Finally, we were gratified to obtain 
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compound 2.39 in 80% yield at –78 °C, meanwhile maintaining the selectivity upon 
using an excess amount of acetaldehyde (entry 4). 
Scheme 2–6. Synthesis of Aldehyde 2.27 
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The aldol adduct 2.39 was protected by various silyl protecting groups to afford 
compounds 2.40a-c. The conversion of imides 2.40a-c to the corresponding aldehydes 
2.27a-c was accomplished by reductive removal of the chiral auxiliary while the reaction 
progress was strictly monitored to avoid over-reduction to alcohols. 
We next aimed at the stereoselective installation of the methylpropargyl moiety onto 
the molecule. Marshall developed a series of asymmetric propargylation reactions 
mediated by an assortment of metals (Scheme 27).131-135 Depending on the metal reagent 
employed, the stereochemical outcome can be regulated. In the tin-mediated reactions, an 
aldehyde was coupled with a chiral allenylstannane, yielding an alcohol with the hydroxy 
and adjacent methyl groups syn to each other as the major stereoisomer.131 To the 
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contrary, the zinc/indium-assisted reactions involved allenyl metal species formed in situ 
from chiral mesylates and preferred anti product formation.134   
Scheme 2–7. Marshall’s Asymmetric Propargylation Reactions and Synthesis of 
Propargylation Reagents 
·
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Table 2–2. Propargylation of Aldehyde 2.27 
CHO
conditionsOR
2.27 (4S)-2.26
OH
OR
4
(4R)-2.26
OH
OR
4
R' R'
+
 
entry reactants scalea 
(mg)  
conditionsb product yield 
(%)c 
ratio 
(4S/4R)d 
1 2.27c + 2.43 42.5 A (Sn) OH
TBDPSO
4
2.26c  
ca. 100 44:56 
2 2.27b + (R)-2.42 46.3 B (In) OH
TIPSO
4
2.26b  
76 72:28 
3 2.27c + (R)-2.42 35.0 B (In) 2.26c 84 83:17 
4 2.27c + (R)-2.42 679 B (In) 2.26c 71 63:37 
5 2.27a + 2.45 26.2 C (Zn) OH
TBSO
4
TMS-2.26a
TMS
 
0e N/A 
6 2.27c + 2.45 14.8 C (Zn) OH
TBDPSO
4
TMS-2.26c
TMS
 
0e N/A 
7 2.27c + (R)-2.42 49.3 C (Zn) 2.26c 70 82:18 
8 2.27c + (R)-2.42 382 C (Zn)f 2.26c 79 82:18 
a Weight of aldehyde. b Reaction conditions unless otherwise specified: A: aldehyde 
(0.1 M), stannane (2 equiv), and BF3·OEt2 (3.5 equiv) in DCM at –78 °C under N2 
overnight; B: aldehyde (0.15 M), mesylate (1.2 equiv), Pd(OAc)2 (0.07 equiv), PPh3 
(0.07 equiv), and InI (1.6 equiv) in THF/HMPA (3:1) at 0 °C under N2 for 15 min, then 
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room temperature for 2 h; C: aldehyde (0.05 M), mesylate (1.2 equiv), Pd(OAc)2 (0.05 
equiv), PPh3 (0.05 equiv), and Et2Zn (3 equiv) in THF at –78 °C under N2 for 10 min, 
then –20 °C overnight. c Isolated yield as mixture of diastereomers. d Calculated from 1H 
NMR. e Only starting materials remained. f Dried THF was further treated with 3 Å 
molecular sieves before reaction. 
Thus, propargylation reagents 2.43, (R)-2.42 and 2.45 were prepared from 
enantiomerically pure alcohols (R)- or (S)-2.41 according to literature reports (Scheme 2–
7)136-138 and subjected to propargylation reactions with aldehyde 2.27 (Table 2–2). We 
first investigated the tin-mediated reaction, since the expected major isomer product (4R)-
2.26 possesses the same stereochemical configuration as the lactimidomycin at all chiral 
centers. The reaction of aldehyde 2.27a and allenylstannane 2.43 (Table 2–2, entry 1) 
produced alcohol 2.26c as an inseparable mixture of both (4S)- and (4R)-epimers, in an 
almost quantitative yield. However, the transformation was barely selective with a 
diastereomeric ratio of 44:56. Reactions involving allenylindium intermediates (entries 2-
4) provided alcohols 2.26b and 2.26c in good yields and exhibited appreciable 
selectivities for the (4S)-epimer, but the results were not well reproducible, especially on 
large scales (entry 4). We eventually sought to examine the zinc version reaction. Placing 
a silyl group at the alkyne terminus is known to improve the stereoselectivity of the 
reaction and may help to resolve the diastereomers by column chromatography. Thereby, 
we exposed aldehydes 2.27a and 2.27c to the silylated mesylate 2.45 (entries 5 and 6) and 
anticipated the formation of the corresponding alcohols TMS-2.26a and TMS-2.26c. 
Unfortunately, both attempts met with failure and no conversion of starting materials was 
observed. In contrast, exposure of aldehyde 2.27c to simple mesylate (R)-2.42 furnished 
alcohol 2.26c in a yield of 70% (entry 7). The diatereomeric ratio was 82:18, preferring 
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the (4S)-epimer. The reaction was performed on multi-hundred milligram scale with the 
product ratio unchanged, whereas the yield was increased to 79% upon carefully drying 
the solvent before use (entry 8). 
In order to invert the C4 center of alcohol (4S)-2.26c to match the stereochemistry of 
lactimidomycin C11 center (numbering see Figure 2–1), a Mitsunobu esterification 
reaction139-140 was implemented to install the vinyl iodide fragment (Table 2–3).  
Table 2–3. Mitsunobu Reaction between Alcohol (4S)-2.26c and Acid 2.24 
OH
TBDPSO
4
(4S)-2.26c
I
O O
TBDPSO
2.22
11
conditions TBDPSO
2.46
+
I
HO O
2.24
+
 
entry conditionsa yield of 
2.22 (%)b 
yield of 
2.46 (%)b 
1 (4S)-2.26c (0.1 M), 2.24 (2 equiv), PPh3 (2 equiv),  
and DEAD (2 equiv) in THF, 0 °C to rt 
16 6.4 
2 (4S)-2.26c (0.3 M), 2.24 (3 equiv), PnBu3 (3 equiv), 
and TMAD (3 equiv) in toluene, 0 °C to rt 
65 N/Ac 
3 (4S)-2.26c (0.1 M), 2.24 (3 equiv), PPh3 (3 equiv),  
and DEAD (3 equiv) in toluene, 0 °C to rt 
64 20 
4 (4S)-2.26c (0.3 M), 2.24 (3 equiv), PPh3 (3 equiv),  
and DEAD (3 equiv) in toluene, 0 °C to rt 
50 14 
a All reactions were carried out under N2 overnight. b Isolated yield. c Detected by 
TLC but not isolated. 
The coupling of alcohol (4S)-2.26c and acid 2.24 under routine Mitsunobu conditions 
(DEAD, PPh3, in THF) generated the desired ester 2.22 in an extremely low yield of 16% 
(Table 2–3, entry 1). The alcohol was vulnerable to dehydration, leading to the formation 
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of highly conjugated dienyne 2.46 as a side product. We used modified conditions with 
N,N,N′,N′-tetramethylazodicarboxamide (TMAD)/PnBu3 as the reagent system141 that 
dramatically increased the yield of ester 2.22 to 65% (entry 2). We later found that 
simply conducting the reaction with DEAD/PPh3 system in toluene instead of in THF 
provided a comparable yield (64%) of ester to that with the TMAD/ PnBu3 system (entry 
3). The diastereomeric ratio of the product was 93:7 in favor of the (11R)-ester 
(lactimidomycin numbering). This ratio was greater than that of the starting alcohol 
(82:18), which is presumably due to the higher proclivity of the minor (4R)-epimer of 
alcohol 2.26c to generate the dehydration product.  Elevating the concentration of 
reactants did not exert any positive effects on the reaction (entry 4). Similarly, conjugated 
ester 2.23 was prepared from alcohol 2.26c and acid 2.25 following the same procedure 
as in entry 2 (Scheme 2–8). 
Scheme 2–8. Preparation of Ester 2.23 
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I
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TBDPSO
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11
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2.5 Macrocyclization and Completion of Formal Total Synthesis 
We then subjected esters 2.22/2.23 to the macrocyclization method based on the 
Castro–Stephens coupling and the in situ alkyne reduction (Table 2–4). Ligand 
phanephos induced significant C6–C7 double bond isomerization after cyclization of 
iodide 2.22, producing Z-enyne macrocycle 2.49 in 42% yield, along with 33% of the 
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desired E,Z-diene lactone 2.47 (Table 2–4, entry 1). Switching the ligand to BINAP 
increased the yield of diene 2.47 to around 80% (entry 2). Fortunately, the reaction was 
quite scalable, with 102 mg of the diene lactone obtained from 150 mg of the iodide 
starting material (83%) without incident. We also attempted to convert the conjugated 
ester 2.23 to triene lactone 2.48 under the Cu/BINAP conditions. However, the reaction 
with ester 2.23 resulted in complete decomposition to form a complex mixture of 
unidentifiable components. We hypothesized that the C2–C3 E-conjugated double bond 
might reduce the flexibility of the molecule, so that it could not adapt a conformation in 
which the reacting centers were close enough to facilitate the macrocyclization. 
Table 2–4. Macrocyclizationa 
2.22 C2–C3
2.23 C2=C3
conditions
O O
TBDPSO
2.47 C2–C3
2.48 C2=C3
2 3
O O
TBDPSO
2.49
I
O O
TBDPSO 2 3
7 6
+
 
entry iodide catalyst & loading yield of 
2.47/2.48 (%)b 
yield of 
2.49 (%)b 
1 2.22 Cu(OAc)2 (0.33 equiv), 
phanephos (0.33 equiv) 
33 42 
2 2.22 Cu(OAc)2 (0.33 equiv), 
BINAP (0.5 equiv) 
77-83c N/Ad 
3 2.23 Cu(OAc)2 (0.33 equiv), 
BINAP (0.5 equiv) 
0e 0 
a Reaction conditions unless otherwise specified: iodide (0.005 M), HCO2Na (4 
equiv) and K2CO3 (1.5 equiv) in DMF at 120 °C under N2 for 4h. b Isolated yield. c 
Variation among batches. d Observed by TLC in minor quantities, but not isolated. e 
Decomposed. 
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Table 2–5. TBDPS Deprotection 
2.47
conditions
O O
TBDPSO
O O
OH
1.42
11
 
entry conditionsa yield (%) 
1 2.47, HF (48% aq. solution), in MeCN, 0 °C, overnight 0b 
2 2.47, HF·Py, in MeCN, rt, overnight 0b 
3 2.47, TBAT, in THF, rt, overnight 0c 
4 2.47, TBAF, in THF, rt, overnight N/Ad 
5 2.47, TBAF, in THF, 50 °C, 4 h 91e 
a All reactions were carried out in open air. b Decomposed. c Only starting material 
remained. d New spot detected at low conversion, not isolated. e Combined isolated yields 
of C11-epimers, d.r. = 93:7 by weight. 
Having constructed the 12-membered E,Z-1,3-diene macrocyclic core, we were left 
with only the last desilylation step for the formal total synthesis. A number of fluoride 
sources were explored for the cleavage of the TBDPS protecting group from compound 
2.47 (Table 2–5). The lactone ring was surprisingly sensitive to acidic conditions (Table 
2–5, entries 1 and 2), which provoked complete decomposition even at low temperature. 
A mild fluoride donor tetrabutylammonium difluorotriphenylsilicate (TBAT) did not 
initiate any desilylation at room temperature, even after a long reaction time (entry 3). 
The TBAF-mediated reaction was encouraging, generating a new spot on TLC plate in a 
small but notable amount (entry 4). Finally, we were pleased to find that exposure of 
lactone 2.47 to TBAF at elevated temperature (50 °C, entry 5) furnished the known 
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alcohol 1.42 and its C11 epimer in a combined yield of 91%. The diastereomeric ratio of 
93:7 was identical to that of ester 2.22 and the epimers were separable by column 
chromatography. Spectra data and optical rotation ([α] D
22  = –85 (c, 0.10, CHCl3)) of the 
major isomer were in excellent agreement with those of the same compound reported by 
Fürstner ([α] D
20  = –86 (c, 0.9, CHCl3)).38 Therefore, a formal total synthesis of 
lactimidomycin had been achieved at this point. 
2.6 Summary 
The synthesis of macrolactone 1.42, an advanced intermediate in the total synthesis of 
the antiproliferative natural product lactimidomycin, has been accomplished from 
commercially available starting materials in a total of nine steps (longest linear sequence) 
using minimal functional group protection. To our knowledge, this is the shortest route to 
lactimidomycin intermediates with similar structure. The key step was a copper-catalyzed 
ene–yne coupling/alkyne reduction tandem reaction that formed the 12-membered E,Z-
diene macrocycle. Other featured reactions included a Kobayashi vinylogous aldol 
reaction and a Marshall propargylation reaction to generate the four stereocenters. 
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Chapter III. Synthesis and Biological Evaluation of 
Oximidine II Analogues 
3.1 Background 
Oximidine II (1.4) and its congener oximidine I were isolated in 1999 from the 
fermentation broth of Pseudomonas sp. Q5200232 and belong to a family of benzolactone 
enamide natural products that possess an acyl enamine (enamide) side chain appended to 
a salicylate macrolactone core.142 Other members of this family include 
salicylihalamides,143-144 lobatamides,145-146 CJ-compounds,147 and apicularens148-149 
(representative examples in Figure 3–1). These molecules are potent cytotoxic agents and 
share a unique differential cytotoxicity profile in the NCI 60-cell line human tumor assay 
with no significant correlations to those of any other anti-tumor compounds, which 
implied a new mechanism of action.143, 149-150 Using the COMPARE algorithm,151 Boyd 
and co-workers deduced that the benzolactone enamides target the eukaryotic transport 
protein vacuolar-type (H+)-ATPase (V-ATPase). Further biological assessments revealed 
that these compounds selectively inhibit mammalian types of V-ATPases. V-ATPases are 
important membrane-bound enzymes that energize proton transport processes across 
eukaryotic membranes.152-154 They regulate the pH level of various intracellular and 
intraorganellar compartments, thereby playing a crucial role in the processes of renal 
acidification,155 bone resorption and degradation,156 cytoplasmic pH homeostasis,153 and 
   66 
sperm maturation.157 Malfunction of V-ATPases has been related to an assortment of 
diseases, including HIV, osteoporosis, diabetes, and cancer.153, 158 
O O
O O
Me
HO
HO
HN
O
N
OMe
lobatamide C (3.2)
O
HO O
Me
OH
HN
O
O
HO O
HN
O
O
H
OH
H
(–)-salicylihalamide A (3.1)
apicularen A (3.3)
O
OHO OH
H
N
O N
OCH3
oximidine II (1.4)
 
Figure 3–1. Structures of representative benzolactone enamide natural products. 
Owing to their unique structural architecture and biological properties as V-ATPase 
inhibitors, the benzolactone enamide natural products have been the topic of interest in 
both the synthetic and medicinal chemistry communities. Successful total syntheses142 of 
these molecules facilitated the development of synthetic analogues and subsequent 
exploration of the structure-activity relationships (SARs). 
3.1.1 SAR Studies Towards Salicylihalamides 
The SARs of salicylihalamides have been extensively studied in the De Brabander 
group.159-161 A plethora of analogues of salicylihalamide A were synthesized with 
modifications on both the enamide side chain and the macrolactone core. The Smith 
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group also reported on the synthesis and biological evaluation of two simplified 
congeners.162 The structures of the synthetic analogues are depicted in Figure 3–2. Their 
biological activities are summarized in Table 3–1. 
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Figure 3–2. Structures of salicylihalamide analogues. 
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Table 3–1. Biological Evaluation of Salicylihalamide Analogues 
entry compound V-ATPase IC50 
(nM) 
cytotoxicitya reference 
1 3.1 < 1.0 IC50 = 0.06 µM 
GI50 = 38-81 nMc 
159, 160 
162 
2 3.4 1.0 IC50 = 0.38 µM 159, 160 
3 3.5 <1.0 IC50 = 0.3 µM 
IC50 = 0.018-0.086 µMd 
159, 160 
161 
4 3.6 1.0 IC50 = 0.3 µM 159, 160 
5 3.7 1.6 IC50 = 0.5 µM 159, 160 
6 3.8 1.8 IC50 = 0.45 µM 159, 160 
7 3.9 >1000 IC50 = 1.5 µM 159, 160 
8 3.10 3.0 IC50 = 8 µM 159, 160 
9 3.11 30b IC50 > 20 µM 159, 160 
10 3.12 230 IC50 > 20 µM 159, 160 
11 3.13 7.5b  160 
12 3.14 300 IC50 = 1 µM 159 
13 3.15 180 IC50 >20 µM 159 
14 3.16 4.5 IC50 = 0.20-1.03 µMd 161 
15 3.17  GI50 = 110-870 nMc 162 
16 3.18  GI50 = 370-880 nMc 162 
a Against SK-MEL-5 unless otherwise noted. b Reversible binding. c Against BXPC-
3, MCF-7, SF268, NCI-H460, KM20L2, and DU-145 cell lines. d Against A549 and 
NCI-H460 cell lines. 
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The side-chain-modified analogues retaining the enamide functionality (Table 3–1, 
entries 2-6) all showed the ability to inhibit proton-pumping activity at similar 
concentrations to that of salicylihalamide A.159-160 One exception was the farnesylated 
compound 3.9, which exhibited a 1000-fold drop in activity (entry 7). However, the 
cytotoxicity of these molecules were mostly 5- to 10-fold less potent than the natural 
product. Analogue 3.10 (entry 8) with a saturated macrolactone retained significant 
potency, while the similar carbamate 3.11 (entry 9) lacking the enamide double bond 
displayed a 10-fold decreased activity and a reversible binding mode.159-160 The 
significantly attenuated potency of allyl ester 3.12 (entry 10) emphasized again the 
importance of the enamide moiety.159-160 The α,β-unsaturated ketone 3.13 (entry 11) 
exhibited potent V-ATPase inhibition, but was a revesible inhibitor in a variety of 
assays.160 Benzyl protection at either the phenol (entry 12) or the secondary alcohol 
(entry 13) substantially impaired the biological activities, highlighting the neccesity of 
hydron bonding for the interaction of salicylihalamides with the enzyme.159 The ether 
analogue161 (entry 14) and Smith’s analogues162 (entries 15 and 16) devoid of methyl and 
hydroxy groups appended to the lactone ring retained considerable, although reduced 
activity. This implied that the structural elements on the macrocylic core might be 
important, but not critical. Smith et al. surmised that their function is to orchestrate the 
optimal orientation between the side chain and salicylate substituents for receptor 
binding.162 
3.1.2 SAR Studies Towards Lobatamides 
The Porco group prepared a series of open-chain analogues and one lactone analogue 
of lobatamide C (Figure 3–3).163-165 All of the compounds bear the enamide side chain. 
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Their bioactivity was evaluated by examining the inhibition against bovine V-ATPase 
activity (Table 3–2). 
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Figure 3–3. Structures of lobatamide analogues. 
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Table 3–2. Biological Evaluation of Lobatamide Analogues 
entry compound V-ATPase inhibition (IC50 in µM) reference 
1 3.2 0.002 163 
2 3.19 25% inhibition at 20 µM 163 
3 3.20 200 163 
4 3.21 no effect 163 
5 3.22 1.6 164 
6 3.23 18 163 
7 3.24 0.1 163 
8 3.25 0.21 164 
9 3.26 0.06 164 
10 3.27 0.01 165 
11 3.28 1.2 163 
 
The minimally functionalized analogue 3.19 exhibited only week inhibition against 
proton-pumping activity even at high concentration (Table 3–2, entry 2).163 The 
methylation at either the enamide or the phenol moieties led to an almost total loss of 
biological activity (entries 3 and 4), indicating the importance of the hydrogen bond 
donor.163 The simple salicylate analogue 3.23, lacking an ortho substitution showed 
intensely compromised potency compared to the lobatamide C natural product (entry 
6).163 However, substitution at this position with a methyl (entries 5 and 7), iodo (entry 8) 
or prenyl (entry 9) group regained some inhibitory property.163-164 Notably, primary 
alcohol 3.27 displayed nanomolar inhibition in line with the activity of lobatamide C 
(entry 10).165 The simplified ring-contracted macrolactone 3.28 proved to be 600-fold 
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less potent than the natural product (entry 11), suggesting that a certain ring size and 
substitutions on the ring are indispensable.163 
3.1.3 SAR Studies Towards Apicularens 
Analogues of apicularen A have been prepared by a number of research groups,166-168 
with focus mainly on the enamide side chain (Figure 3–4). The biological property data 
are listed in Table 3–3. 
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Figure 3–4. Structures of apicularen analogues. 
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Table 3–3. Biological Evaluation of Apicularen Analogues 
entry compound cytotoxicity cell line reference 
1 3.3 GI50 = 0.006 µM 
IC50 = 0.78 nM 
IC50 = 2.3 nM 
IC50 = 15.9 nM 
SK-MEL-5 
1A9 
KB-3-1 
KB-V1a 
166 
167 
168 
168 
2 3.29 GI50 > 20 µM SK-MEL-5 166 
3 3.30 GI50 > 20 µM SK-MEL-5 166 
4 3.31 IC50 > 1500 nM 1A9 167 
5 3.32 IC50 = 50 nM 1A9 167 
6 3.33 GI50 = 0.06 µM SK-MEL-5 166 
7 3.34 IC50 = 71 nM 1A9 167 
8 3.35 IC50 = 3.2 nM 1A9 167 
9 3.36 IC50 = 7.1 nM 
IC50 = 2.4 nM 
KB-3-1 
KB-V1 a 
168 
168 
10 3.37 GI50 = 0.45 µM SK-MEL-5 166 
11 3.38 IC50 = 180 nM KB-3-1 168 
12 3.39 IC50 = 1130 nM KB-3-1 168 
a Multiple drug-resistant cell line. 
Similar to the SAR investigation of salicylihalamides, analogue studies of apicularens 
also demonstrated the importance of the enamide functionalized side chain. Analogues 
lacking this moiety exhibited almost no activity (Table 3–3, entries 2 and 3).166 The short 
chain substituent with a bulky phenyl group (entry 4) resulted in more than 1000-fold 
attenuated potency.167 In contrast, the longer chain with a linear conjugated spacer 
between the acyl and phenyl groups (entry 5) restored significant anti-tumor property.167 
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Variations of the double bond configuration on side chain reduced the potency by a factor 
of 10 to 100 (entries 6 and 7).166-167 Acylation (entry 8) or removal (entry 9) of the 11-
hydroxy group had only a marginal effect on the IC50 values.167-168 Particularly, the 11-
deoxy analogue 3.36 was even more potent than apicularen A against the multi-drug-
resistant KB-V1 cell line (entry 9),168 suggesting that this hydroxy group is not 
responsible for activity. However, inversion of this C11 stereocenter (entry 10) led to a 
75-fold decrease in potency.166 Opening of the pyran ring afforded analogue 3.38 similar 
in structure to salicilyhalamide A and analogue 3.39 bears a lobatamide-like side chain. 
Nonetheless, both molecules showed substantially declined cytotoxicity (entries 11 and 
12), underlining the importance of the 3D conformation of the molecule for biological 
activity.168 
3.1.4 SAR Studies Towards Oximidine II in Georg Group 
Unlike the other benzolactone enamide natural products, the SAR of oximidines has 
not been the subject of exhaustive exploration. Albeit the analogue studies of 
salicylihalamide A and lobatamide C indicated the essentiality of the enamide side chain 
for anti-cancer activity, this structural unit is known for its instability under physiological 
conditions.143 The enamide could be hydrolyzed into the corresponding aldehyde and 
amide fragments in aqueous media or more importantly, from a chemotherapeutic 
discovery perspective, be inactivated prior to reaching its intended target. The hydrolysis 
inside the acidic environment of cancer cells is also a possible concern. In an endeavor to 
discover bioactive analogues with better chemical stability, we set out to install 
physiologically stable warheads onto the oximidine framework to create analogues that 
would retain the cytotoxic properties observed with this natural product class. Drawing 
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experience from our syntheses of salicylihalamides and oximidine II,55, 169-171 we 
envisioned that we could rapidly assemble the benzolactone scaffolds and affix different 
side chains for investigation of the anti-cancer properties of the analogues. 
Dr. Schneider prepared oximidine analogue 3.41 with an allylic amide side chain,91 
inspired by the structure of another benzolactone natural product cruentaren A (3.40, 
Figure 3–5). Cruentaren A contains the allylic amide side chain, not a conjugated 
enamide, yet still possesses potent cytotoxicity. On the other hand, Dr. Khownium 
designed and synthesized analogues 3.42 and 3.43 employing a vinyl sulfone as the 
electrophilic functionality group that would mimic the mode-of-action of the enamide.172 
The unique property of the vinyl sulfone groups is that under physiological conditions, 
they do not undergo nucleophilic addition. Nucleophilic addition occurs only when 
hydrogen bonding interactions, typically within an active site of an enzyme, are present 
to activate the functionality.173 These analogues were designed assuming that the acidic 
environment of the V-ATPase enzyme would activate the electrophilic vinyl sulfone 
moiety for nucleophilic addition analogously to the activation of the enamide moiety.160 
For facile preparation of analogues, Dr. Khownium also developed a simplified 
benzolactone scaffold with the aid of computational analysis studies. Using molecular 
modeling data obtained from a previous comparative molecular similarity indices 
analysis (CoMSIA)174/3-dimensional quantitative structure-activity relationship (3D-
QSAR) study completed by our group as the training set,175 a simplified, partially 
saturated, oximidine-like scaffold was identified with predicted V-ATPase activity 
comparable to the parent oximidine II molecule. Thus, analogues 3.44 and 3.45 carrying 
this scaffold were synthesized with the attachment of vinyl sulfone chains. Both 
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compounds, varying in the number of methylene spacers, aligned well with the CoMSIA 
features. Structures of analogues 3.41-3.45 are shown in Figure 3–5. 
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Figure 3–5. Structures of oximidine II, cruentaren A, and oximidine analogues. 
Cytotoxic activity of the analogues was evaluated by testing the compounds against 
melanoma cell lines SK-MEL-5 and SK-MEL-28, leukemia cell line HL-60 and breast 
cancer cell line MCF-7 (Table 3-4). Oximidine II (entry 2) obtained through total 
synthesis exhibited submicromolar activity against SK-MEL-5 cell line (IC50 = 590 nM) 
and much lower potency against SK-MEL-28 cell line (60% inhibition at 100 µM).91 All 
the synthetic analogues showed greatly compromised cytotoxicity compared to the parent 
natural product. The allylic amide analogue displayed only 40% inhibition against SK-
   77 
MEL-5 cell line and was barely active towards SK-MEL-28 cells (entry 3).91 The vinyl 
sulfone analogues were micromolar inhibitors towards SK-MEL-5 cancer cells with IC50 
in the range of 20-60 µM (entries 4-7), slightly more potent than the allylic amide 
counterpart.172 Analogues 3.44 and 3.45 also exerted weak cytotoxic effects against 
leukemia and breast cancer cell lines (entries 6 and 7).172 
Table 3–4. Cytotoxicity Evaluation of Synthesized Analogues91, 172 
entry compound SK-MEL-5 
(IC50 in µM) 
SK-MEL-28 
(IC50 in µM) 
HL-60 
(IC50 in µM) 
MCF-7 
(IC50 in µM) 
1 taxol 2.90 nM N/Aa 2.64 nM 0.282 
2 1.4  0.59 > 20 NDb ND 
3 3.41 > 100 > 100 ND ND 
4 3.42 > 100 ND ND ND 
5 3.43 > 20 ND ND ND 
6 3.44 > 20 > 100 > 20 > 20 
7 3.45 > 20 > 20 > 20 100 
a 10% inhibition at 100 µM. b ND = not determined. 
Although the side chain modifications of oximidine II resulted in significant loss in 
bioactivity, the vinyl sulfone analogues with the simplified lactone core derived from 
CoMSIA/QSAR analysis were equipotent to those bearing the triene core of the natural 
product. We next decided to prepare analogues 3.46 and 3.47 (Figure 3–6) to probe 
whether the simplified scaffold carrying the enamide side chain could retain the anti-
tumor activity of this family of natural products. 
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Figure 3–6. Structures of the newly proposed analogues with enamide side chain. 
3.2 Retrosynthesis of Oximidine II Analogues 
Scheme 3–1. Retrosynthesis of Analogues 3.46 and 3.47 
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The retrosynthetic analysis of the proposed analogues is displayed in Scheme 3–1. 
We envisioned a late-stage installation of the enamide chain through the coupling of bis-
TBS protected iodides 3.48/3.49 with amide 1.74. The iodides would be derived from 
protected triols 3.50/3.51 following Porco’s strategy.40 Compound 3.51 was kindly 
provided by Dr. Khownium, whereas lactone 3.50 could be prepared via the RCM 
reaction of triene ester 3.52. Transesterification of salicylate 3.53 with enantioenriched 
alcohol 1.6640 would presumably provide the RCM precursor. Compound 3.53 could be 
obtained from triflate 1.6858 and vinyl stannane 3.54 through a Stille coupling reaction.  
3.3 Preparation of Oximidine II Analogues 
Scheme 3–2. Synthesis of Lactone 3.50 
O
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We synthesized stannane 3.54 from the known alcohol (E)-2.29176 in two steps 
including a Parikh–Doering oxidation177 and a Wittig olefination reaction (Scheme 3–2). 
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The crude stannane was directly subjected to a palladium-catalyzed Stille coupling 
reaction with triflate 1.68 in the presence of LiCl to form diene acetonide 3.53.178 The 
one-pot transesterification of salicylate 3.53 with alcohol 1.66 and the in situ phenol 
protection furnished the crucial triene intermediate 3.52 for macrocyclization. The RCM 
reaction of triene 3.52 proceeded smoothly with the second-generation Grubbs catalyst179 
to generate the thermodynamically favored product 3.50 in 68% yield. The E-
configuration of the endocyclic double bonds was confirmed by the coupling constants of 
15-16 Hz observed in the 1H NMR spectrum. 
Scheme 3–3. Synthesis of Iodides 3.48/3.49 
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The side chain elaboration commenced with lactones 3.50/3.51 (Scheme 3–3). 
Oxidative cleavage of the PMB ether with DDQ180 followed by Dess–Martin oxidation181 
of the resultant alcohol yielded aldehydes 3.58/3.59, which were converted to vinyl 
iodides 3.60/3.61 via Takai olefination.182 The use of a mixed solvent system of THF and 
1,4-dioxane (1:6)183 provided high yields (> 80%) and good E-selectivity (9:1). MOM 
deprotection under mild acidic conditions (CBr4, iPrOH)184 transformed compounds 
3.60/3.61 into alcohols 3.62/3.63. The alcohols were silylated to prepare the bis-TBS 
ethers 3.48/3.49 for installation of the enamide moiety. 
Scheme 3–4. Failed Enamide Coupling of Iodide 3.62 
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To attach the enamide, we first ventured into the direct coupling of vinyl iodide 3.62 
containing a free alcohol with amide 1.74, since this would bypass a 2-step 
silylation/desilytion sequence to accomplish the synthesis of analogue 3.46 (Scheme 3–
4).  Unfortunately, performing the reaction under either Fürstner’s conditions (CuTC, 
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Rb2CO3, DMA, 90 °C)59 or Buchwald’s conditions (CuI, DMEDA, Cs2CO3, DMA, rt)185 
brought about total decomposition of the iodide. We then sought to use the bis-TBS 
protected substrates 3.48/3.49 (Scheme 3–5). While exposure of iodide 3.49 to Porco’s 
conditions (CuTC, DMEDA, K2CO3, DMA, 50 °C)40 for the total synthesis of oximidine 
II also decomposed the starting material, modified Buchwald’s conditions186 using an 
excess of CuI (2 equiv) successfully facilitated the desired coupling of iodides 3.48/3.49 
with amide 1.74. The resultants enamide intermediates were finally desilylated with a 
buffered solution of HF/Pyridine159 to afford the target molecules 3.46/3.47. 
Scheme 3–5. Enamide Coupling of Iodides 3.48/3.49 and TBS Deprotection 
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3.4 Biological Evaluation of Oximidine II Analogues 
Synthetic analogues 3.46/3.47 were tested against SK-MEL-5, SK-MEL-28, HL-60, 
and MCF-7 cell lines for evaluation of biological activity (Table 3–5). The analogues 
showed 40-55 fold attenuated potency against SK-MEL-5 cells compared to the parent 
natural product oximidine II (entries 4 and 5, vs. entry 1). They are also weak inhibitors 
towards SK-MEL-28, HL-60, MCF-7 cell lines with IC50 values in the range of 20-80 
µM. 
Table 3–5. Biological Evaluation of Oximidine II Analoguesa 
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entry compound SK-MEL-5 
(IC50 in µM) 
SK-MEL-28 
(IC50 in µM) 
HL-60 
(IC50 in µM) 
MCF-7 
(IC50 in µM) 
1 taxol 0.014 0.194 0.00075 0.111 
2 1.4  0.59 > 20 NDb ND 
3 3.44 > 20 > 100 > 20 > 20 
4 3.45 > 20 > 20 > 20 100 
5 3.46 24.2 57 24.9 N/A 
6 3.47 32.2 44.4 50.1 74 
a The assay was performed in triplicate wells. b ND = not determined. 
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3.6 Summary 
Two analogues of the benzolactone enamide natural product oximidine II with a 
simplified core structure have been designed and synthesized based on previous SAR 
studies. The biological assays revealed that the analogues exhibited weak cytotoxic 
activity against leukemia (HL-60), breast (MCF-7) and melanoma (SK-MEL-5 and SK-
MEL-28) cells. 
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Chapter IV. Experimental Data 
4.1 Materials and Methods 
Anhydrous THF, DCM, Et2O and toluene were dried and deoxygenated by passing 
the nitrogen-purged solvents through activated alumina columns on a solvent purification 
system. DMF was similarly dried by passing through a column of activated 4Å molecular 
sieves. All other commercially available reagents and solvents were used as received 
without further purification. Copper acetate (hydrates, 98%) was purchased from Sigma-
Aldrich. (R)-Phanephos (98%) was purchase from Alfa Aesar and all other ligands were 
from Sigma-Aldrich. All reactions were conducted under a nitrogen atmosphere unless 
otherwise noted. Flash column chromatography was carried out on silica gel. TLC was 
conducted on 250 micron, F254 silica gel plates. 1H NMR analyses were performed on a 
400 MHz spectrometer and 13C NMR spectra were recorded on a 100 MHz spectrometer 
with complete proton decoupling. Chemical shifts were reported as ppm relative to the 
solvent residual peak (CHCl3: 7.26 ppm for 1H, 77.2 ppm for 13C; acetone-d6: 2.05 ppm 
for 1H, 29.9 ppm for 13C; D2O: 4.80 ppm for 1H; DMSO-d6: 39.5 ppm for 13C). Data are 
reported as follows: chemical shifts, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, quint = quintet, m = multiplet, br = broad), coupling constant (Hz), and 
integration. IR spectra were obtained on a FT-IR instrument from thin films on a NaCl 
plate. High-resolution mass spectra were acquired on an ESI-TOF instrument using PEG 
or PPG as an internal calibrant. 
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4.2 Chapter 1 
4.2.1 Substrate Synthesis 
Synthesis of Substrates 1.119a-e, 1.119h, and 1.119p 
I
HO
I
O O
O
O
O linker
linkerHO
NaHMDS, THF, 0 °C THF, 0 °C to rt
(one pot) Me2SO4
I
MeO O
O linker
1.110 1.119a-e, 1.119p
I
HO
I
O O
O
O
O
5-hexyn-1-ol
NaHMDS, THF, 0 °C THF, 0 °C to rt
(one pot) Me2SO4
I
MeO O
O
1.110 1.119h 1.119a  
General Procedure 1: Alkynyl alcohol (1.05 equiv) was dissolved in THF (2.67 mL 
per 1 mmol of alcohol) and cooled to 0 °C. A solution of NaHMDS (1.0 M in THF, 1.07 
equiv) was added dropwise to the alcohol solution and the mixture was stirred at 0 °C for 
1 h. (E)-5-(2-Iodovinyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.110)61, 91 (1 
equiv) was dissolved in THF (1.33 mL per 1 mmol of 1.110) and added to the above 
anion solution. The mixture was further stirred at 0 °C for 2 h before Me2SO4 (4 equiv) 
was added. The reaction was then allowed to warm to room temperature, left overnight, 
and quenched with water. The mixture was extracted with EtOAc and separated. The 
combined organic layer was washed with brine, dried over anhydrous MgSO4, and 
concentrated under vacuum. The residue was purified by flash column chromatography 
on silica gel (100:0 — 10:1 hexanes/EtOAc). 
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5-Hexyn-1-yl (E)-2-(2-Iodovinyl)-6-methoxybenzoate (1.119a). General Procedure 
1 was followed using iodide 1.110 (4.29 g, 13.0 mmol), 5-hexyn-1-ol (1.5 mL, 1.3 g, 13.7 
mmol). Compound 1.119a (3.66 g, 73%) was isolated as a yellow oil. 1H NMR (400 
MHz, CDCl3) δ 7.41 (d, J = 14.8 Hz, 1H), 7.32 (t, J = 8.1 Hz, 1H), 7.00 (d, J = 7.9 Hz, 
1H), 6.87 (d, J = 8.2 Hz, 1H), 6.86 (d, J = 14.8 Hz, 1H), 4.39 (t, J =6.3 Hz, 2H), 3.83 (s, 
3H), 2.28 (td, J = 7.0, 2.6 Hz, 2H), 1.97 (t, J = 2.6 Hz, 1H), 1.92 — 1.85 (m, 2H), 1.69 
(quint, J = 7.2 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 167.7, 156.7, 141.9, 136.6, 130.8, 
122.2, 118.1, 111.0, 84.1, 80.4, 69.0, 65.2, 56.2, 27.9, 25.1, 18.3; IR (film, cm–1) 3295, 
3063, 2944, 2116, 1726, 1602, 1571, 1471, 1271, 1117, 1067, 944, 762; HRMS (ESI+) 
m/z calc’d for [M+Na]+ C16H17IO3Na: 407.0115, found 407.0131. 
I
MeO O
O
 
4-Pentyn-1-yl (E)-2-(2-Iodovinyl)-6-methoxybenzoate (1.119b). General Procedure 
1 was followed using iodide 1.110 (118 mg, 0.357 mmol) and 4-pentyn-1-ol (35 µL, 32 
mg, 0.38 mmol). Compound 1.119b (108 mg, 82%) was isolated as a yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 7.41 (d, J = 14.8 Hz, 1H), 7.32 (t, J = 8.1 Hz, 1H), 7.00 (d, J 
= 7.9 Hz, 1H), 6.87 (d, J = 14.8 Hz, 1H), 6.87 (d, J = 8.4 Hz, 1H), 4.46 (t, J = 6.2 Hz, 
2H), 3.83 (s, 3H), 2.37 (td, J = 7.1, 2.6 Hz, 2H), 2.00 (t, J = 2.5 Hz, 1H), 1.98 (quint, J = 
6.7 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 167.5, 156.7, 141.8, 136.5, 130.8, 122.0, 
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118.0, 110.9, 83.1, 80.5, 69.4, 64.1, 56.2, 27.7, 15.3; IR (film, cm–1) 3303, 3058, 2964, 
2119, 1725, 1602, 1571, 1472, 1266, 1117, 1068, 944, 736, 639; HRMS (ESI+) m/z 
calc’d for [M+Na]+ C15H15IO3Na: 392.9958, found 392.9962. 
I
MeO O
O
 
3-Butyn-1-yl (E)-2-(2-Iodovinyl)-6-methoxybenzoate (1.119c). General Procedure 
1 was followed using iodide 1.110 (203 mg, 0.615 mmol) and 3-butyn-1-ol (49 µL, 45 
mg, 0.65 mmol). Compound 1.119c (168 mg, 77%) was isolated as a yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 7.47 (d, J = 14.8 Hz, 1H), 7.32 (t, J = 8.2 Hz, 1H), 7.00 (d, J = 7.9 
Hz, 1H), 6.87 (d, J = 14.7 Hz, 1H), 6.87 (d, J = 8.5 Hz, 1H), 4.46 (t, J = 6.7 Hz, 2H), 3.83 
(s, 3H), 2.66 (td, J = 6.7, 2.4 Hz, 2H), 2.09 (t, J = 2.4 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 167.3, 156.8, 141.7, 136.7, 131.0, 121.7, 118.1, 110.9, 80.6, 80.2, 70.5, 63.3, 
56.3, 19.2; IR (film, cm–1) 3294, 3063, 1729, 1601, 1571, 1472, 1271, 1115, 1070, 944, 
762; HRMS (ESI+) m/z calc’d for [M+Na]+ C14H13IO3Na: 378.9802, found 378.9814. 
I
MeO O
O
 
6-Heptyn-1-yl (E)-2-(2-Iodovinyl)-6-methoxybenzoate (1.119d). General 
Procedure 1 was followed using iodide 1.110 (250 mg, 0.757 mmol) and 6-heptyn-1-ol 
(0.10 mL, 89 mg, 0.80 mmol). Compound 1.119d (235 mg, 78%) was isolated as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 14.8 Hz, 1H), 7.32 (t, J = 8.1 Hz, 
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1H), 6.99 (d, J = 7.8 Hz, 1H), 6.87 (d, J = 8.2 Hz, 1H), 6.86 (d, J = 14.9 Hz, 1H), 4.36 (t, 
J = 6.5 Hz, 2H), 3.83 (s, 3H), 2.23 (td, J = 6.5, 2.4 Hz, 2H), 1.94 (t, J = 2.5 Hz, 1H), 1.78 
(quint, J = 6.8 Hz, 2H), 1.65 — 1.51 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 167.7, 
156.7, 141.9, 136.5, 130.8, 122.3, 118.0, 110.9, 84.5, 80.4, 68.6, 65.6, 56.3, 28.4, 28.3, 
25.4, 18.6; IR (film, cm–1) 3296, 3063, 2940, 2116, 1726, 1602, 1571, 1471, 1271, 1118, 
1069, 944, 762, 623; HRMS (ESI+) m/z calc’d for [M+Na]+ C17H19IO3Na: 421.0271, 
found 421.0275. 
I
MeO O
O
 
(E)-2-Octen-7-yn-1-yl (E)-2-(2-Iodovinyl)-6-methoxybenzoate (1.119e). General 
Procedure 1 was followed using iodide 1.110 (204 mg, 0.619 mmol) and (E)-2-Octen-7-
yn-1-ol187 (82 mg, 0.65 mmol). Compound 1.119e (123 mg, 54%) was isolated as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 14.8 Hz, 1H), 7.31 (t, J = 8.1 Hz, 
1H), 6.99 (d, J = 7.8 Hz, 1H), 6.87 (d, J = 8.3 Hz, 1H), 6.85 (d, J = 14.8 Hz, 1H), 5.92 — 
5.85 (m, 1H), 5.76 — 5.69 (m, 1H), 4.80 (d, J = 6.5 Hz, 2H), 3.83 (s, 3H), 2.23 (quint, J 
= 7.1 Hz, 2H), 2.22 (td, J = 7.1, 2.6 Hz, 2H), 1.95 (t, J = 2.6 Hz, 1H), 1.67 (quint, J = 7.4 
Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 167.3, 156.7, 141.9, 136.6, 136.2, 130.8, 124.6, 
122.0, 118.1, 111.0, 84.3, 80.4, 68.8, 66.2, 56.3, 31.4, 27.8, 18.1; IR (film, cm–1) 3296, 
3063, 3009, 2940, 2116, 1726, 1602, 1571, 1472, 1270, 1113, 1066, 944, 762, 623; 
HRMS (ESI+) m/z calc’d for [M+Na]+ C18H19IO3Na: 433.0271, found 433.0286. 
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I
MeO O
O
 
10-Undecyn-1-yl (E)-2-(2-Iodovinyl)-6-methoxybenzoate (1.119p). General 
Procedure 1 was followed using iodide 1.110 (78.8 mg, 0.239 mmol) and 10-undecyn-1-
ol (48 µL, 42 mg, 0.25 mmol). Compound 1.119p (64.7 mg, 57%) was isolated as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 14.8 Hz, 1H), 7.31 (t, J = 8.1 Hz, 
1H), 6.99 (d, J = 7.8 Hz, 1H), 6.87 (d, J = 7.0 Hz, 1H), 6.86 (d, J = 14.8 Hz, 1H), 4.35 (t, 
J = 6.6 Hz, 2H), 3.83 (s, 3H), 2.17 (td, J = 7.0, 2.6 Hz, 2H), 1.93 (t, J = 2.6 Hz, 1H), 1.75 
(quint, J = 6.8 Hz, 2H), 1.52 (quint, J = 7.5 Hz, 2H), 1.43 — 1.33 (m, 10H); 13C NMR 
(100 MHz, CDCl3) δ 167.7, 156.7, 141.9, 136.5, 130.7, 122.4, 118.0, 110.0, 85.0, 80.3, 
68.3, 65.9, 56.3, 29.6, 29.4, 29.2, 28.9, 28.9, 28.7, 26.2, 18.6; IR (film, cm–1) 3303, 2930, 
1727, 1602, 1571, 1471, 1270, 1071, 943, 761; HRMS (ESI+) m/z calc’d for [M+Na]+ 
C21H27IO3Na: 477.0897, found 477.0911. 
I
HO O
O
 
5-Hexyn-1-yl (E)-2-Hydroxy-6-(2-iodovinyl)benzoate (1.119h). Compound 1.119h 
(0.86 g, 18%) was isolated as the unreacted intermediate during the preparation of 
compound 1.119a, white solid (mp 64 — 65 °C). 1H NMR (400 MHz, CDCl3) δ 11.32 (s, 
1H), 7.93 (d, J = 14.6 Hz, 1H), 7.37 (t, J = 8.0 Hz), 6.97 (d, J = 8.4 Hz, 1H), 6.81 (d, J = 
7.5 Hz, 1H), 6.50 (d, J =14.6 Hz, 1H), 4.40 (t, J = 6.2 Hz, 2H), 2.33 (td, J = 6.9, 2.6 Hz, 
2H), 1,99 — 1.93 (m, 3H), 1.75 (quint, J = 7.0 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 
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171.0, 162.8, 146.5, 141.3, 134.8, 120.3, 118.2, 110.0, 83.9, 77.9, 69.3, 66.0, 27.7, 25.4, 
18.4; IR (film, cm–1) 3282, 3057, 2952, 1665, 1585, 1448, 1254, 1207, 1168, 943, 827; 
HRMS (ESI+) m/z calc’d for [M+Na]+ C15H15IO3Na: 392.9958, found 392.9954. 
Synthesis of Substrates 1.119f, 1.119i, and 1.119j 
CO2Me
TMS
4.1
NIS, MeCN
rt
CO2Me
I
4.2
NaOH, H2O
MeOH, THF, 50 °C
CO2H
I
4.3
5-hexyn-1-ol, PPh3
DEAD, THF, rt
I
1.119f
O
O
O
O
N
1) NaBH4, iPrOH,H2O, rt
2) HOAc, 80 °C, then HCl
4.4
HCl·H2N
4.5
PMPCHO, Et3N, MeOH
then NaBH4, 0 °C to rt
N
H
PMB
4.6
CO2H
I
4.3
+ HCl·HN
4.5
EDCl, DIPEA
HOBt, DCM, rt
I
1.119i
O
N
H
CO2H
I
4.3
+ N
H
4.6
EDCl, DIPEA
HOBt, DCM, rt
I
1.119j
O
N
PMB
PMB
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CO2Me
I  
Methyl (E)-2-(2-Iodovinyl)benzoate (4.2). To a solution of methyl (E)-2-(2-
(trimethylsilyl)vinyl)benzoate (4.1)188 (857 mg, 3.65 mmol) in MeCN (37 mL) was added 
N-iodosuccinimide (4.12 g, 18.3 mmol). The mixture was then stirred at room 
temperature for 30 min before it was quenched with saturated Na2S2O3 solution. The 
aqueous layer was extracted with EtOAc. The combined organic layer was washed with 
brine, dried over MgSO4, and concentrated under vacuum. The residue was purified by 
flash column chromatography on silica gel (100:0 — 90:10 hexanes/EtOAc). Compound 
4.2 (959 mg, 91%) was isolated as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.22 (d, J 
= 14.8 Hz, 1H), 7.91 (d, J = 7.9 Hz, 1H), 7.49 (t, J = 7.4 Hz, 1H), 7.43 (d, J = 7.3 Hz, 
1H), 7.36 (t, J = 7.7 Hz, 1H), 6.75 (d, J = 14.8 Hz, 1H), 3.92 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 167.4, 144.3, 139.6, 132.6, 130.8, 128.2, 127.7, 127.7, 79.2, 52.5; IR 
(film, cm–1) 3066, 2950, 1719, 1560, 1433, 1259, 1131, 1078, 738; HRMS (ESI+) m/z 
calc’d for [M+Na]+ C10H9IO2Na: 310.9539, found 310.9547. 
CO2H
I  
(E)-2-(2-iodovinyl)benzoic Acid (4.3). Ester 4.2 (909 mg, 3.15 mmol) was dissolved 
in THF (8 mL) and MeOH (8 mL). An aqueous solution of NaOH was prepared by 
dissolving NaOH (3.78 g, 94.4 mmol) in water (19 mL) and added to the ester solution. 
The mixture was heated to 50 °C and stirred overnight. The organic solvent was 
evaporated and the residue was neutralized with 10% HCl solution. The precipitated 
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product was extracted with DCM, washed with brine and dried over Na2SO4. Compound 
4.3 (785 mg, 91%) was obtained as yellow crystals (mp 173 °C) after removing the 
solvent, and used directly without further purification. 1H NMR (400 MHz, acetone-d6, 
COO-H missing) δ 8.36 (d, J = 14.8 Hz, 1H), 7.98 (d, J = 7.7 Hz, 1H), 7.64 (d, J = 7.7 
Hz, 1H), 7.58 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.4 Hz, 1H), 7.04 (d, J = 14.8 Hz, 1H); 13C 
NMR (100 MHz, acetone-d6) δ 168.3, 144.9, 140.0, 133.3, 131.7, 129.1, 128.8, 128.2, 
80.2; HRMS (ESI+) m/z calc’d for [M-H+2Na]+ C9H6IO2Na2: 318.9202, found 318.9212. 
I
O
O
 
5-Hexyn-1-yl (E)-2-(2-Iodovinyl)benzoate (1.119f). Acid 4.3 (70.0 mg, 0.255 
mmol), 5-hexyn-1-ol (28 µL, 25 mg, 0.26 mmol), and PPh3 (66.9 mg, 0.730 mmol) were 
dissolved in THF (2.6 mL) and the solution was cooled to 0 °C. A solution of DEAD 
(40% in toluene, 0.12 mL, 45 mg, 0.26 mmol) was added and the mixture was stirred for 
5 min before the cold bath was removed. The reaction was left overnight and the solvent 
was removed under vacuum. The residue was purified by flash column chromatography 
on silica gel (100:0 — 95:5 hexanes/EtOAc). Compound 1.119f (80.8 mg, 89%) was 
isolated as a yellow solid (mp 33 — 35 °C). 1H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 
14.8 Hz, 1H), 7.92 (d, J = 7.8 Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.42 (d, J = 7.5 Hz, 1H), 
7.37 (t, J = 7.5 Hz, 1H), 6.73 (d, J = 14.8 Hz, 1H), 4.35 (t, J = 6.4 Hz, 2H), 2.30 (td, J = 
7.0, 2.6 Hz, 2H), 1.98 (t, J = 2.5 Hz, 1H), 1.95 — 1.88 (m, 2H), 1.72 (quint, J = 7.1 Hz, 
2H); 13C NMR (100 MHz, CDCl3) δ 167.0, 144.5, 139.5, 132.6, 130.9, 128.2, 128.0, 
127.8, 84.0, 79.1, 69.1, 65.0, 27.9, 25.3, 18.4; IR (film, cm–1) 3298, 3066, 2953, 2116, 
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1718, 1599, 1561, 1447, 1280, 1254, 1132, 1074, 944. 743, 638; HRMS (ESI+) m/z 
calc’d for [M+Na]+ C15H15IO2Na: 377.0009, found 377.0014. 
HCl·H2N  
5-Hexyn-1-amine Hydrochloride (4.5). 6-Phthalimido-1-hexyne (4.4)189 (3.03 g, 
13.3 mmol) was suspended in a mixture of isopropanol and water (6:1, 67 mL), and 
NaBH4 (2.52 g, 66.6 mmol) was added. The mixture was stirred overnight under ambient 
atmosphere before the addition of glacial acetic acid (15 mL). After gas evolution ceased, 
the solution was heated to 80 °C and stirred at this temperature for 2 h. The reaction 
mixture was then cooled to room temperature and treated with NaOH solution (1 N) until 
pH = 12. The basic aqueous solution was extracted with 1:1 EtOAc/hexanes. The 
combined organic layer was washed with brine, dried over Na2SO4, and concentrated 
under vacuum. The residue was dissolved in a minimum amount of Et2O, treated with 
HCl solution (2 M in Et2O), and cooled in an ice-water bath. Compound 4.5 (1.46 g, 
82%) precipitated as light brown crystals and was collected by vacuum filtration. 1H 
NMR (400 MHz, D2O, N-H missing) δ 3.06 (t, J = 7.5 Hz, 2H), 2.41 (t, J = 2.6 Hz, 1H), 
2.31 (td, J = 7.0, 2.6 Hz, 2H), 1.85 — 1.78 (m, 2H), 1.67 — 1.60 (m, 2H); 13C NMR (100 
MHz, DMSO-d6) δ 84.0, 71.7, 38.2, 26.1, 24.9, 17.3; LRMS (ESI+) m/z calc’d for [M-
Cl]+ C6H12N: 98.1, found 98.1. 
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N
H
PMB
 
N-(4-Methoxybenzyl)-5-hexyn-1-amine (4.6). Hydrochloride 4.5 (400 mg, 2.99 
mmol) was dissolved in MeOH (15 mL) and cooled to 0 °C. Triethylamine (0.42 mL, 303 
mg, 2.99 mmol) was added and the solution was stirred at 0 °C for 10 min before 4-
methoxybenzaldehye (0.40 mL, 448 mg, 3.29 mmol) was added. The reaction was 
allowed to warm to room temperature, stirred for 3 h, and re-cooled to 0 °C. NaBH4 (452 
mg, 12.0 mmol) was added in 2 portions. The reaction was left under ambient conditions 
overnight, quenched with 10% K2CO3, and extracted with Et2O. The combine organic 
layer was washed with brine, dried over Na2SO4, and concentrated under vacuum. The 
residue was purified by flash column chromatography on silica gel (60:40:1 
hexanes/EtOAc/Et3N). Compound 4.6 (432 mg, 66%) was isolated as a yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 7.23 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 3.80 (s, 
3H), 3.72 (s, 2H), 2.63 (t, J = 6.7 Hz, 2H), 2.20 (td, J = 6.8, 2.5 Hz, 2H), 1.94 (t, J = 2.6 
Hz, 1H), 1.66 — 1.53 (m, 4H), 1.35 (br, 1H); 13C NMR (100 MHz, CDCl3) δ 158.8, 
132.8, 129.4, 113.9, 84.6, 68.6, 55.5, 53.6, 48.9, 29.3, 26.4, 18.5; IR (film, cm–1) 3636, 
3293, 3031, 2999, 2936, 2116, 1612, 1510, 1463, 1301, 1247, 1177, 1110, 1036, 820. 
I
O
N
H
 
(E)-N-(5-Hexyn-1-yl)-2-(2-iodovinyl)benzamide (1.119i).  Acid 4.3 (300 mg, 1.09 
mmol), 1-hydroxybenzotriazole (296 mg, 2.19 mmol) and EDCl (420 mg, 2.19 mmol) 
were dissolved in DCM (5 mL) and stirred at room temperature for 30 min. To the above 
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solution was added a solution of hydrochloride 4.5 (219 mg, 1.64 mmol) and 
diisopropylethylamine (0.67 mL, 495 mg, 3.83 mmol) in DCM/DMF (1:1, 8 mL). The 
reaction mixture was stirred overnight, quenched with aqueous HCl solution (1 N), and 
extracted with DCM. The combined organic layer was washed with brine, dried over 
MgSO4, and concentrated under vacuum. The residue was purified by flash column 
chromatography on silica gel (100:0 — 70:30 hexanes/EtOAc). Compound 1.119i (341 
mg, 89%) was isolated as a light yellow solid (mp 77 — 80 °C). 1H NMR (400 MHz, 
CDCl3) δ 7.76 (d, J = 14.8 Hz, 1H), 7.43 — 7.37 (m, 3H), 7.33 — 7.30 (m, 1H), 6.84 (d, 
J = 14.8 Hz, 1H), 5.84 (s, 1H) 3.47 (q, J = 6.4 Hz, 2H), 2.28 (td, J = 6.8, 2.2 Hz, 2H), 
1.97 (t, J = 2.3 Hz, 1H), 1.79 — 1.71 (m, 2H), 1.67 — 1.60 (m, 2H); 13C NMR (100 
MHz, CDCl3) δ 169.0, 142.7, 135.9, 134.8, 130.4, 128.4, 127.6, 126.6, 84.1, 79.6, 69.1, 
39.7, 28.8, 25.9, 18.3; IR (film, cm–1) 3304, 3054, 2986, 1660, 1519, 1422, 1265, 896, 
738; HRMS (ESI+) m/z calc’d for [M+Na]+ C15H16INONa: 376.0169, found 376.0163. 
I
O
N
PMB
 
(E)-N-(5-Hexyn-1-yl)-2-(2-iodovinyl)-N-(4-methoxybenzyl)benzamide (1.119j).  
Acid 4.3 (149 mg, 0.543 mmol), 1-hydroxybenzotriazole (147 mg, 1.09 mmol) and EDCl 
(209 mg, 1.09 mmol) were dissolved in DCM (3 mL) and stirred at room temperature for 
30 min. To the above solution was added a solution of amine 4.6 (166 mg, 0.764 mmol) 
and diisopropylethylamine (0.19 mL, 141 mg, 1.09 mmol) in DCM (3 mL). The reaction 
mixture was stirred overnight, quenched with aqueous HCl solution (1 N), and extracted 
with DCM. The combined organic layer was washed with brine, dried over MgSO4, and 
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concentrated under vacuum. The residue was purified by flash column chromatography 
on silica gel (100:0 — 75:25 hexanes/EtOAc). Compound 1.119j (213 mg, 83%) was 
isolated as a colorless oil (1:1 amide rotamers). 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J 
= 14.8 Hz, 0.5H), 7.45 — 7.39 (m, 1.5H), 7.36 — 7.30 (m, 3H), 7.28 — 7.22 (m, 1H), 
7.00 (d, J = 8.5 Hz, 1H), 6.94 (d, J = 8.5 Hz, 1H), 6.91 — 6.83 (m, 2H), 5.11 (br, 0.5 H), 
4.39 (br, 0.5H), 4.20 (s, 1H), 3.82 (s, 1.5H), 3.79 (s, 1.5H), 3.70 (br, 0.5H), 3.28 (br, 
0.5H), 2.92 (t, J = 7.4 Hz, 1H), 2.27 (td, J = 7.0, 2.5 Hz, 1H), 2.01 (td, J = 6.9, 2.5 Hz, 
1H), 1.97 (t, J = 2.5 Hz, 0.5H), 1.92 (t, J = 2.5 Hz, 0.5H), 1.77 (quint, J = 7.3 Hz, 1H), 
1.62 — 1.56 (m, 2H), 1.25 (quint, J = 7.2 Hz, 1H); IR (film, cm–1) 3300, 3058, 2938, 
2116, 1629, 1512, 1418, 1247, 1176, 1034, 954, 736, 645; HRMS (ESI+) m/z calc’d for 
[M+Na]+ C23H24INO2Na: 496.0744, found 496.0758. 
Synthesis of Substrate 1.119g 
OCHI3, CrCl2
THF, 0 °C I
O
CHO
4.7 (E /Z)-1.119g
MeOH, 50 °C
K2CO3 O
I
1.119g  
O
I  
(E)-1-(5-Hexyn-1-yloxy)-2-(2-iodovinyl)benzene (1.119g). CrCl2 (1.56 g, 12.72 
mmol) was suspended in THF (10 mL) and cooled to 0 °C. To the above mixture was 
slowly added a solution of 2-(5-hexyn-1-yloxy)benzaldehyde (4.7)190 (214 mg, 1.06 
mmol) and iodoform (1.67 g, 4.24 mmol) in THF (10 mL). The resultant red-brown 
solution was stirred at 0 °C for 3 h, diluted with brine, and extracted with EtOAc. The 
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combined organic layer was dried over MgSO4 and concentrated under vacuum. The 
residue was purified by flash column chromatography on silica gel (100:0 — 80:20 
hexanes/DCM) to afford 1-(5-hexyn-1-yloxy)-2-(2-iodovinyl)benzene (168 mg, 48%) as 
a 1:1 E/Z isomer mixture. 
The E/Z mixture (164 mg, 0.503 mmol) was dissolved in MeOH (5 mL), mixed with 
K2CO3 (347 mg, 2.51 mmol), and heated at 50 °C overnight. The solvent was evaporated 
under vacuum and the residue was purified by flash column chromatography on silica gel 
(100:0 — 80:20 hexanes/DCM). Compound 1.119g (57.0 mg, 35%) was isolated as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 14.9 Hz, 1H), 7.28 — 7.22 (m, 
2H), 6.92 (d, J = 14.9 Hz, 1H), 6.91 (t, J = 7.6 Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H), 4.02 (d, 
J = 6.3 Hz, 2H), 2.30 (td, J = 6.9, 2.5 Hz, 2H), 2.01 (t, J = 2.4 Hz, 1H), 1.99 — 1.94 (m, 
2H), 1.74 (quint, J = 7.1 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 155.9, 140.8, 129.6, 
127.8, 126.8, 120.8, 112.1, 84.2, 78.1, 69.1, 67.9, 28.4, 25.3, 18.3; IR (film, cm–1) 3298, 
3061, 2947, 2117, 1597, 1453, 1245, 1103, 1051, 953, 750, 631; HRMS (ESI+) m/z 
calc’d for [M+Na]+ C14H15IONa: 349.0060, found 349.0047. 
Synthesis of Substrate 1.119k 
I
4.8
4-pentynoic acid, PPh3
DEAD, THF, rt I
1.119k
O
O
OH
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O
O
 
(E)-6-Iodo-5-hexen-1-yl 4-Pentynoate (1.119k). 6-Iodo-5-hexen-1-ol (4.8)191 (150 
mg, 0.664 mmol), 4-pentynoic acid (78.0 mg, 0.796 mmol), and PPh3 (209 mg, 0.796 
mmol) were dissolved in THF (6.6 mL) and the solution was cooled to 0 °C. A solution 
of DEAD (40% in toluene, 0.36 mL, 138 mg, 0.796 mmol) was added and the mixture 
was stirred for 5 min before the cold bath was removed. The reaction was left overnight 
and the solvent was removed under vacuum. The residue was purified by flash column 
chromatography on silica gel (100:0 — 95:5 hexanes/EtOAc). Compound 1.119k (194 
mg, 95%) was isolated as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.50 (dt, J = 
14.3, 7.2 Hz, 1H), 6.02 (dt, J = 14.4, 1.4 Hz, 1H), 4.11 (t, J = 6.5 Hz, 2H), 2.58 — 2.48 
(m, 4H), 2.09 (qd, J = 7.3, 1.2 Hz, 2H), 1.98 (t, J = 2.5 Hz, 1H), 1.68 — 1.61 (m, 2H), 
1.51 — 1.44 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 172.0, 146.1, 82.7, 75.2, 69.2, 64.5, 
35.7, 33.5, 28.1, 24.9, 14.6; IR (film, cm–1) 3296, 2919, 1733, 1605, 1358, 1166, 1058, 
950; HRMS (ESI+) m/z calc’d for [M+Na]+ C11H15IO2Na: 329.0009, found 329.0023. 
Synthesis of Substrate 1.119l 
CuI, Et3N, rt
OH
I
TMS, PdCl2(PPh3)2
OH
TMS
toluene, rt
4.8, PPh3, DEAD
4.9
O
TMS
4.10
I
MeOH, rt
K2CO3
O I
1.119l  
   100 
OH
TMS  
2-((Trimethylsily)ethynyl)phenol (4.9). To a stirred suspension of 2-iodophenol 
(700 mg, 3.18 mmol), PdCl2(PPh3)2 (112 mg, 0.159 mmol), and CuI (60.6 mg, 0.318 
mmol) in triethylamine (10 mL) was added trimethylsilylacetylene (0.67 mL, 468 mg, 
4.77 mmol). The mixture was stirred at room temperature overnight, quenched with 
saturated NH4Cl solution, and extracted with Et2O. The combined organic layer was 
washed with aqueous HCl solution (1N), brine, dried over Na2SO4, and concentrated 
under vacuum. The residue was purified by flash column chromatography on silica gel 
(100:0 — 97:3 hexanes/EtOAc). Compound 4.9 (519 mg, 86%) was isolated as a light 
brown liquid, which solidified (mp 46 — 47 °C) slowly upon storage in a refrigerator. 1H 
NMR (400 MHz, CDCl3) δ 7.35 (d, J = 7.6 Hz, 1H), 7.25 (t, J = 7.4 Hz, 1H), 6.95 (d, J = 
8.2 Hz, 1H), 6.86 (t, J = 7.5 Hz, 1H), 5.86 (s, 1H), 0.29 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 157.3, 131.8, 130.9, 120.4, 114.7, 109.7, 102.6, 99.1, 0.2; IR (film, cm–1) 3511, 
3065, 2960, 2151, 1577, 1484, 1251, 1097, 1031, 870, 843, 776, 753. 
O
TMS
I
 
(E)-1-(6-Iodo-5-hexyn-1-yloxy)-2-((trimethylsilyl)ethynyl)benzene (4.10). Phenol 
4.9 (110 mg, 0.578 mmol), alcohol 4.8 (157 mg, 0.694 mmol), and PPh3 (182 mg, 0.694 
mmol) were dissolved in toluene (5.8 mL) and the solution was cooled to 0 °C. A 
solution of DEAD (40% in toluene, 0.32 mL, 121 mg, 0.694 mmol) was added and the 
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mixture was stirred for 5 min before the cold bath was removed. The reaction was left 
overnight and the solvent was removed under vacuum. The residue was purified by flash 
column chromatography on silica gel (100:0 — 95:5 hexanes/EtOAc). Compound 4.10 
(210 mg, 91%) was isolated as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J 
= 7.6, 1.3 Hz, 1H), 7.27 — 7.23 (m, 1H), 6.87 (t, J = 7.5 Hz, 1H), 6.82 (d, J = 8.4 Hz, 
1H), 6.54 (dt, J = 14.3, 7.2 Hz, 1H), 6.03 (d, J = 14.4 Hz, 1H), 4.01 (t, J = 6.0 Hz, 2H), 
2.16 (q, J = 7.2 Hz, 2H), 1.87 — 1.80 (m, 2H), 1.67 (quint, J = 7.7 Hz, 2H), 0.26 (s, 9H); 
13C NMR (100 MHz, CDCl3) δ 160.2, 146.4, 133.9, 130.1, 120.5, 112.9, 112.1, 101.5, 
98.6, 75.1, 68.3, 36.0, 28.7, 25.2, 0.3; IR (film, cm–1) 3052, 2954, 2158, 1594, 1490, 
1250, 1204, 1113, 842, 752, 645; HRMS (ESI+) m/z calc’d for [M+Na]+ C17H23IOSiNa: 
421.0455, found 421.0475. 
O I
 
(E)-1-Ethynyl-2-(6-iodo-5-hexyn-1-yloxy)benzene (1.119l). To a solution of 
compound 4.10 (285 mg, 0.715 mmol) in MeOH (3.6 mL) was added K2CO3 (198 mg, 
1.43 mmol). The mixture was stirred overnight, diluted with water, and extracted with 
EtOAc. The combined organic layer was washed with brine, dried over Na2SO4, and 
concentrated under vacuum. The residue was purified by flash column chromatography 
on silica gel (100:0 — 95:5 hexanes/EtOAc). Compound 1.119l (197 mg, 84%) was 
isolated as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.46 (dd, J = 7.5, 1.1 Hz, 1H), 
7.31 — 7.27 (m, 1H), 6.90 (t, J = 7.5 Hz, 1H), 6.85 (d, J = 8.4 Hz, 1H), 6.54 (dt, J = 14.3, 
7.1 Hz, 1H), 6.04 (d, J = 14.3 Hz, 1H), 4.03 (t, J = 6.2 Hz, 2H), 3.27 (s, 1H), 2.16 (q, J = 
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7.2 Hz, 2H), 1.88 — 1.81 (m, 2H), 1.63 (quint, J = 7.6 Hz, 2H); 13C NMR (100 MHz, 
CDCl3) δ 160.2, 146.4, 134.3, 130.3, 120.6, 112.1, 111.8, 81.3, 80.3, 75.2, 68.5, 35.8, 
28.4, 25.0; IR (film, cm–1) 3287, 3051, 2939, 2106, 1595, 1490, 1280, 1252, 1110, 751; 
HRMS (ESI+) m/z calc’d for [M+Na]+ C14H15IONa: 349.0060, found 349.0067. 
Synthesis of Substrates 1.119m and 1.119n 
Ph
I
OH 5-hexynoic acid, PPh3
DEAD, THF, rt
Ph
I
O
4.11
O
1.119m
Ph
I
OH MsCl, Et3N
DCM, –78 °C
4.11
Ph
I
OMs
4.12
3-butyn-1-ol, NaHMDS
THF, 0 °C to rt
Ph
I
O
1.119n  
Ph
I
O
O
 
(Z)-3-Iodo-2-phenylallyl 5-Hexynoate (1.119m). 3-Iodo-2-phenyl-2-propen-1-ol 
(4.11)192 (189 mg 0.726 mmol), 5-hexynoic acid (80 µL, 81 mg, 0.73 mmol), and PPh3 
(190 mg, 0.726 mmol) were dissolved in THF (7.3 mL) and the solution was cooled to 0 
°C. A solution of DEAD (40% in toluene, 0.33 mL, 126 mg, 0.726 mmol) was added and 
the mixture was stirred for 5 min before the cold bath was removed. The reaction was left 
overnight and the solvent was removed under vacuum. The residue was purified by flash 
column chromatography on silica gel (100:0 — 90:10 hexanes/EtOAc). Compound 
1.119m (193 mg, 75%) was isolated as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.35 
— 7.30 (m, 5H), 6.79 (s, 1H), 5.16 (s, 2H), 2.38 (t, J = 7.4 Hz, 2H), 2.14 (td, J = 7.0, 2.6 
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Hz, 2H), 1.93 (t, J = 2.6 Hz, 1H), 1.74 (quint, J = 7.2 Hz, 2H); 13C NMR (100 MHz, 
CDCl3) δ 172.7, 146.2, 138.8, 128.7, 128.5, 126.6, 83.6, 83.3, 69.3, 67.8, 32.8, 23.7, 17.9; 
IR (film, cm–1) 3301, 3061, 2942, 2118, 1736, 1596, 1442, 1204, 1152, 1027, 974, 729, 
700; HRMS (ESI+) m/z calc’d for [M+Na]+ C15H15IO2Na: 377.0009, found 377.0005. 
Ph
I
OMs
 
(Z)-3-Iodo-2-phenylallyl Methanesulfonate (4.12). To a solution of alcohol 4.11 
(84.7 mg, 0.326 mmol) in DCM (3.3 mL) were added sequentially triethylamine (91 µL, 
66 mg, 0.65 mmol) and methanesulfonyl chloride (38 µL, 56 mg, 0.49 mmol) at –78 °C. 
The solution was stirred at –78 °C for 2 h before it was quenched with saturated NaHCO3 
solution. The reaction mixture was warmed to room temperature and extracted with Et2O. 
The combined organic layer was washed with brine, dried over MgSO4, and concentrated 
under vacuum to afford a crude product. This crude compound 4.12 (99.5 mg, 90%) was 
directly used for the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 
7.38 (s, 5H), 6.98 (s, 1H), 5.30 (s, 2H), 2.95 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
144.2, 137.9, 129.0 (overlapping), 126.6, 86.4, 72.6, 38.1; IR (film, cm–1) 3061, 2963, 
1355, 1262, 1174, 1025, 802; HRMS (ESI+) m/z calc’d for [M+Na]+ C10H11IO3SNa: 
360.9366, found 360.9368. 
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(Z)-4-((3-iodo-2-phenylallyl)oxy)-1-butyne (1.119n). To a solution of 3-butyn-1-ol 
(17 µL, 016 mg, 0.23 mmol) in THF (1.1 mL) was added NaHMDS (1.0 M in THF, 0.23 
mL, 0.23 mmol) at 0 °C. The solution was stirred at 0 °C for 1 h before mesylate S13 
(73.0 mg, 0.216 mmol) in THF (1.1 mL) was added. The reaction was left at room 
temperature overnight, quenched with saturated NH4Cl solution, and extracted with 
EtOAc. The combined organic layer was washed with brine, dried over MgSO4, and 
concentrated under vacuum. The residue was purified by flash column chromatography 
on silica gel (100:0 — 95:5 hexanes/EtOAc). Compound 1.119n (40.3 mg, 60%) was 
isolated as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.43 — 7.41 (m, 2H), 7.36 — 
7.31 (m, 3H), 6.78 (s, 1H), 4.62 (s, 2H), 3.60 (t, J =6.9 Hz, 2H), 2.43 (td, J = 6.9, 2.6 Hz, 
2H), 1.95 (t, J = 2.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 147.4, 139.3, 128.7, 128.3, 
126.8, 83.2, 81.4, 74.1, 69.6, 68.2, 20.0; IR (film, cm–1) 3298, 3058, 2917, 2867, 2120, 
1592, 1493, 1442, 1201, 1099, 753, 698, 636; HRMS (ESI+) m/z calc’d for [M+Na]+ 
C13H13IONa: 334.9903, found 334.9936. 
4.2.3 Castro–Stephens/Alkyne Reduction Tandem Reaction 
I
linker linkerCu(OAc)2, ligand, HCO2Na
1.119 1.120
K2CO3, DMF, 120 °C
 
General Procedure 2: Conditions A: Cu(OAc)2 (0.2 equiv), phanephos (0.3 equiv), 
HCO2Na (4 equiv), K2CO3 (1.5 equiv) were suspended in DMF (100 mL per 1 mmol of 
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iodide 1.119). This suspension was heated with stirring at 120 °C for 30 min. In a 
separate container, iodide 1.119 (1 equiv) was dissolved in DMF (100 mL per 1 mmol of 
iodide 1.119) and the solution was transferred dropwise via syringe to the above 
suspension in one portion. The reaction was further stirred at 120 °C for the time listed in 
Table 1–5 and Table 1–6, and then cooled to room temperature. To the cooled reaction 
mixture was added saturated NH4Cl solution. The mixture was stirred at room 
temperature for 15 min, diluted with water and extracted with hexanes/EtOAc (1:1). The 
combined organic layer was sequentially washed with NH4Cl/NH3 buffer (3:1 mixture of 
saturated NH4Cl/28% aqueous ammonium hydroxide), water, and brine, dried over 
MgSO4, and concentrated under vacuum. The crude product was purified by flash column 
chromatography on silica gel. 
Conditions B were the same as Conditions A except that Cu(OAc)2 (0.3 equiv) and 
BINAP (0.5 equiv) were employed instead of Cu(OAc)2 (0.2 equiv) and phanephos (0.3 
equiv). 
Conditions C were the same as Conditions A except that Cu(OAc)2 (1 equiv) and 
PPh3 (3 equiv) were employed instead of Cu(OAc)2 (0.2 equiv) and phanephos (0.3 
equiv). 
Conditions D were the same as Conditions A except that Cu(OAc)2 (0.3 equiv) and 
dppe (0.5 equiv) were employed instead of Cu(OAc)2 (0.2 equiv) and phanephos (0.3 
equiv). 
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(7Z,9E)-14-Methoxy-3,4,5,6-tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one 
(1.120a). Prepared from iodide 1.119a (26.2 mg, 0.0682 mmol) using Conditions A. 
Compound 1.120a (12.7 mg) was isolated as a colorless oil or white waxy solid after 
flash column chromatography (100:0 — 90:10 hexanes/EtOAc). 1H NMR (400 MHz, 
CDCl3) δ 7.29 (t, J = 8.0 Hz, 1H), 6.92 — 6.80 (m, 3H), 6.53 (d, J = 16.2 Hz, 1H), 6.15 
(t, J = 10.4 Hz, 1H), 5.65 (dt, J = 10.8, 7.4 Hz, 1H), 4.50 (t, J = 5.1 Hz, 2H), 3.84 (s, 3H), 
2.35 (q, J = 6.9 Hz, 2H), 1.85 — 1.80 (m, 2H), 1.71 (quint, J = 6.6 Hz, 2H); 13C NMR 
(100 MHz, CDCl3) δ 168.8, 156.9, 137.9, 133.0, 131.1, 130.3, 128.7, 128.5, 122.8, 120.7, 
109.8, 66.2, 56.2, 27.5, 26.4, 26.2; IR (film, cm–1) 3061, 3008, 2956, 1725, 1571, 1469, 
1267, 1113, 1063, 954, 736; HRMS (ESI+) m/z calc’d for [M+Na]+ C16H18O3Na: 
259.1148, found 259.1151. 
O
OMeO
 
(6Z,8E)-13-Methoxy-4,5-dihydrobenzo[c][1]oxacycloundecin-1(3H)-one (1.120b). 
Prepared from iodide 1.119b (29.8 mg, 0.0805 mmol) using Conditions A. Compound 
1.120b (12.1mg, 62%) was isolated as a colorless oil or white waxy solid after flash 
column chromatography (100:0 — 90:10 hexanes/EtOAc). 1H NMR (400 MHz, CDCl3) δ 
7.30 (t, J = 8.2 Hz, 1H), 6.90 (d, J = 7.6 Hz, 1H), 6.84 (d, J = 8.3 Hz, 1H), 6.79 — 6.73 
(m, 1H), 6.55 (d, J = 16.3 Hz, 1H), 6.22 — 6.17 (m, 1H), 5.86 — 5.81 (m, 1H), 4.34 (t, J 
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= 5.4 Hz, 2H), 3.85 (s, 3H) , 2.44 (q, J = 7.2 Hz, 2H), 1.92 — 1.86 (m, 2H); 13C NMR 
(100 MHz, CDCl3) δ 169.1, 156.5, 139.3, 133.9, 132.5, 130.3, 129.3, 128.1, 124.3, 120.2, 
109.9, 64.8, 56.2, 29.2, 23.3; IR (film, cm–1) 3010, 3058, 3011, 2959, 1724, 1571, 1469, 
1263, 1106, 1086, 1059, 734; HRMS (ESI+) m/z calc’d for [M+Na]+ C15H16O3Na: 
267.0992, found 267.0996. 
O
OMeO
 
(5Z,7E)-12-Methoxy-3,4-dihydro-1H-benzo[c]oxecin-1-one (1.120c). Prepared 
from iodide 1.119c (59.4 mg, 0.167 mmol) using Conditions D. Compound 1.120c (10.7 
mg, 28%) was isolated as a yellow oil after flash column chromatography (100:0 — 
90:10 hexanes/EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.30 (t, J = 8.0 Hz, 1H), 6.89 — 
6.82 (m, 3H), 6.49 — 6.44 (m, 1H), 6.37 (d, J = 16.6 Hz, 1H), 5.78 (dtd, J = 10.5, 7.6, 
1.4 Hz, 1H), 4.45 (br, 2H), 3.86 (s, 3H), 2.66 (br, 2H); 13C NMR (100 MHz, CDCl3) δ 
168.6, 157.9, 140.4, 135.8, 131.7, 130.7, 129.3, 125.7, 124.5, 121.5, 110.4, 66.6, 56.2, 
26.0; IR (film, cm–1) 3062, 3008, 2954, 2840, 1721, 1599, 1568, 1469, 1437, 1266, 1251, 
1106, 1085, 1061, 1002, 846, 725; HRMS (ESI+) m/z calc’d for [M+Na]+ C14H14O3Na: 
253.0835, found 253.0848. 
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(8Z,10E)-15-Methoxy-4,5,6,7-tetrahydrobenzo[c][1]oxacyclotridecin-1(3H)-one 
(1.120d). Prepared from iodide 1.119d (26.2 mg, 0.0658 mmol) using Conditions C. 
Compound 1.120d (8.3 mg, 53%) was isolated as a colorless oil or white waxy solid after 
flash column chromatography (100:0 — 90:10 hexanes/EtOAc). 1H NMR (400 MHz, 
CDCl3) δ 7.28 (t, J = 8.0 Hz, 1H), 6.82 (d, J = 7.7 Hz, 1H), 6.81 (d, J = 8.3 Hz, 1H), 6.74 
(dd, J = 16.0, 10.8 Hz, 1H), 6.50 (d, J = 16.0 Hz, 1H), 6.20 (t, J = 10.8 Hz, 1H), 5.64 — 
5.57 (m, 1H), 4.44 (t, J = 5.1 Hz, 2H), 3.83 (s, 3H), 2.19 (br, 2H), 1.92 (br, 2H), 1.46 — 
1.43 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 169.1, 157.0, 135.9, 133.4, 131.0, 130.2, 
130.0, 129.3, 123.0, 122.0, 110.1, 66.7, 56.4, 27.8, 27.5, 24.6, 22.0; IR (film, cm–1) 3060, 
2941, 1726, 1575, 1463, 1268, 1114, 1068, 736; HRMS (ESI+) m/z calc’d for [M+Na]+ 
C17H20O3Na: 295.1305, found 295.1308. 
O
O
 
(7Z,9E)-3,4,5,6-Tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one (1.120f). 
Prepared from iodide 1.119f (39.8 mg, 0.112 mmol) using Conditions C. Compound 
1.120f (15.3 mg, 60%) was isolated as a colorless oil after flash column chromatography 
(100:0 — 60:40 hexanes/DCM). 1H NMR (400 MHz, CDCl3) δ 7.79 (dd, J = 7.7, 1.0 Hz, 
1H), 7.50 (d, J = 6.8 Hz, 1H), 7.45 (td, J = 7.1, 1.2 Hz, 1H), 7.31 — 7.27 (m, 1H), 6.93 
(d, J = 16.2 Hz, 1H), 6.44 (dd, J = 16.2, 5.5 Hz, 1H), 6.13 (ddd, J = 11.0, 5.5, 0.8 Hz, 
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1H), 5.75 (dt, J = 10.9, 8.3 Hz, 1H), 4.38 (t, J = 5.6 Hz, 2H), 2.38 (q, J = 8.1 Hz, 2H), 
1.87 — 1.81 (m, 2H), 1.72 — 1.66 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 170.0, 137.9, 
133.7, 131.7, 131.5, 130.9, 130.8, 128.9, 128.1, 127.2, 127.1, 67.0, 29.0, 27.4, 26.6; IR 
(film, cm–1) 3055, 2930, 1707, 1600, 1265, 1124, 737, 705; HRMS (ESI+) m/z calc’d for 
[M+Na]+ C15H16O2Na: 251.1043, found 251.1049. 
O
 
(6Z,8E)-2,3,4,5-Tetrahydrobenzo[b][1]oxacycloundecine (1.120g). Prepared from 
iodide 1.119g (26.3 mg, 0.0806 mmol) using Conditions A except that Cu(OAc)2 (0.1 
equiv) and phanephos (0.15 equiv) were used. Compound 1.120g (10.0 mg, 62%) was 
isolated as a colorless oil or white waxy solid after flash column chromatography (100:0 
— 80:20 hexanes/DCM). 1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 7.4 Hz, 1H), 7.21 — 
7.17 (m, 1H), 7.12 — 7.08 (m, 2H), 6.96 (d, J = 16.7 Hz, 1H), 6.46 (dd, J = 16.7, 4.6 Hz, 
1H), 6.21 (dd, J = 10.5, 4.5 Hz, 1H), 5.95 — 5.88 (m, 1H), 4.04 (t, J = 5.4 Hz, 2H), 2.23 
(q, J = 7.8 Hz, 2H), 1.95 — 1.88 (m, 2H), 1.79 — 1.73 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 158.1, 134.4, 132.1, 130.6, 129.1, 128.4, 128.1, 127.0, 124.5, 122.4, 72.4, 28.2, 
25.9, 25.6; IR (film, cm–1) 3062, 3008, 2931, 1599, 1454, 1232, 1219, 1202, 994, 745, 
732, 703; HRMS (EI) m/z calc’d for [M·]+ C14H16O: 200.1196, found 200.1196. 
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(7Z,9E)-14-Hydroxy-3,4,5,6-tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one 
(1.120h). Prepared from iodide 1.119h (30.7 mg, 0.0829 mmol) using Conditions C. 
Compound 1.120h (2.5 mg, 12%) was isolated as a colorless oil or white waxy solid after 
flash column chromatography (100:0 — 50:50 hexanes/DCM). 1H NMR (400 MHz, 
CDCl3) δ 10.9 (s, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.04 (d, J = 16.6 Hz, 1H), 7.03 (d, J = 7.3 
Hz, 1H), 6.89 (d, J = 8.3 Hz, 1H), 6.30 (dd, J = 16.1, 4.2 Hz, 1H), 6.09 (dd, J = 10.8, 4.2 
Hz, 1H), 5.76 (dt, J =10.9, 8.4 Hz, 1H), 4.41 (t, J = 5.9 Hz, 2H), 2.37 (q, J = 8.2 Hz, 2H), 
1.88 — 1.83 (m, 2H), 1.74 — 1.68 (m, 2H); ); 13C NMR (100 MHz, CDCl3) δ 171.9, 
162.3, 140.9, 134.4, 133.7, 133.4, 129.0, 127.4, 118.6, 116.6, 112.0, 67.3, 29.6, 27.6, 
26.4; IR (film, cm–1) 3431, 2926, 1655, 1451, 1264, 1211, 1120; HRMS (ESI+) m/z 
calc’d for [M+Na]+ C15H16O3Na: 267.0992, found 267.0997. 
N
O PMB
 
(7Z,9E)-2-(4-Methoxybenzyl)-3,4,5,6-tetrahydrobenzo[c][1]azacyclododecin-
1(2H)-one (1.120j). Prepared from iodide 1.119j (21.6 mg, 0.0456 mmol) using 
Conditions A. Compound 1.120j (12.5mg, 79%) was isolated as a colorless oil after flash 
column chromatography (100:0 — 75:25 hexanes/EtOAc). 1H NMR (400 MHz, acetone-
d6) δ 7.37 — 7.23 (m, 4H), 7.14 — 7.07 (m, 3H), 6.87 (d, J = 8.6 Hz, 2H), 6.60 (d, J = 
16.3 Hz, 1H), 6.31 (t, J = 10.4 Hz, 1H), 5.72 — 5.65 (m, 1H), 4.40 (dt, J = 14.3, 5.3 Hz, 
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1H), 4.20 (d, J = 15.6 Hz, 1H), 4.04 (d, J = 15.6 Hz, 1H), 3.77 (s, 3H), 2.78-2.71 (m, 1H), 
2.54 — 2.44 (m, 1H), 2.16 — 2.10 (m, 1H), 1.74 — 1.70 (m, 1H), 1.64 — 1.42 (m, 3H); 
13C NMR (100 MHz, acetone-d6) δ 172.4, 160.2, 136.5, 135.5, 134.4, 131.5, 130.4, 
130.3, 129.5, 129.5, 129.4, 128.5, 128.3, 128.0, 114.9, 55.6, 50.2, 40.8, 27.0, 26.8, 23.9; 
IR (film, cm–1) 3009, 2933, 1618, 1513, 1458, 1249, 1175, 1034, 737; m/z calc’d for 
[M+Na]+ C23H25NO2Na: 370.1778, found 370.1783. 
O
O
 
(5Z,7E)-Oxa-5,7-cyclododecadien-2-one (1.120k). Prepared from iodide 1.119k 
(27.4 mg, 0.0895 mmol) using Conditions B. Compound 1.120k (11.3 mg, 70%) was 
isolated as a colorless oil after flash column chromatography (100:00 — 30:70 
hexanes/DCM). 1H NMR (400 MHz, CDCl3) δ 6.61 (dd, J =15.9, 10.8 Hz, 1H), 6.18 (t, J 
= 10.6 Hz, 1H), 5.74 (dt, J = 16.0, 4.9 Hz, 1H), 5.51 — 5.45 (m, 1H), 4.00 (t, J = 5.3 Hz, 
2H), 2.61 — 2.55 (m, 2H), 2.44 — 2.40 (m, 2H), 2.15 (q, J = 4.8 Hz, 2H), 1.84 — 1.79 
(m, 2H), 1.74 — 1.68 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 172.8, 130.8, 129.9, 
127.0, 126.1, 64.9, 36.2, 29.5, 27.4, 23.5, 21.8; IR (film, cm–1) 3013, 2932, 1732, 1655, 
1462, 1432, 1339, 1156, 1021, 724; HRMS (ESI+) m/z calc’d for [M+Na]+ C11H16O2Na: 
203.1043, found 203.1043. 
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O
 
(6E,8Z)-2,3,4,5-Tetrahydrobenzo[b][1]oxacycloundecine (1.120l). Prepared from 
iodide 1.119l (37.7 mg, 0.116 mmol) using Conditions D. Compound 1.120l (19.0 mg, 
82%) was isolated as a colorless oil after flash column chromatography (100:0 — 80:20 
hexanes/DCM). 1H NMR (400 MHz, CDCl3) δ 7.24 — 7.19 (m, 2H), 6.93 (td, J = 7.6, 
0.9 Hz, 1H), 6.87 (d, J = 8.2 Hz, 1H), 6.31 — 6.24 (m, 2H), 6.10 (ddd, J = 16.0, 6.3, 1.2 
Hz, 1H), 5.68 (dt, J = 15.9, 6.3 Hz, 1H), 4.17 (br, 2H), 2.21 (br, 2H), 1.85 — 1.82 (m, 
4H). 13C NMR (100 MHz, CDCl3) δ 156.2, 132.5, 132.1, 130.1, 128.8, 128.5, 126.7, 
125.4, 120.2, 112.7, 70.4, 31.6, 28.3, 28.0; IR (film, cm–1) 3054, 2934, 1652, 1600, 1490, 
1453, 1265, 1123, 972, 736, 704; HRMS (ESI+) m/z calc’d for [M+Na]+ C14H16ONa: 
223.1093, found 223.1105. 
When prepared using Conditions A, an inseparable mixture of compound 1.120l and 
enyne 1.123 (71% combined yield, 1.120l:1.123 = 11:1) was obtained. 
O
 
(Z)-Benzo[b][1]oxa-6-cycloundecen-8-yne (1.123). 1H NMR (400 MHz, CDCl3) δ 
7.36 (dd, J = 7.6, 1.5 Hz, 1H), 7.10 — 7.04 (m, 4H), 6.41 (dt, J = 10.2, 7.6 Hz, 1H), 4.19 
(br, 2H), 2.38 (q, J = 7.0 Hz, 2H), 1.85 — 1.82 (m, 4H). 
   113 
OPh
 
(4Z,6Z)-7-Phenyl-3,8-dihydro-2H-oxocine (1.120n). Prepared from iodide 1.119n 
(17.8 mg, 0.0570 mmol) using Conditions A. Compound 1.120n (3.2 mg, 30%) was 
isolated as a yellow oil after flash column chromatography (100:0 — 30:70 
hexanes/DCM). 1H NMR (400 MHz, CDCl3) δ 7.56 — 7.52 (m, 2H), 7.35 (d, J = 7.4 Hz, 
2H), 7.28 (d, J = 7.5 Hz, 1H), 6.46 (d, J = 4.2 Hz, 1H), 6.18 (dd, J = 11.3, 4.3 Hz, 1H), 
5.89 (dt, J = 11.1, 7.4 Hz, 1H), 4.40 (s, 2H), 3.65 (t, J = 5.0 Hz, 2H), 2.39 — 2.35 (m, 
2H); 13C NMR (100 MHz, CDCl3) δ 141.73, 138.09, 131.23, 128.64, 128.22, 127.50, 
127.09, 126.18, 69.6, 64.2, 31.5; IR (film, cm–1) 3011, 2924, 1459, 1089, 759, 727, 698; 
HRMS (EI) m/z calc’d for [M·]+ C13H14O: 186.1139, found 186.1141. 
O
Ph O
Ph
 
(3Z,11Z)-3,11-Diphenyl-1,9-dioxa-3,11-cyclohexadecadien-5,13-diyne (1.124). 
Dimer 1.124 (3.6 mg, 34%) was isolated as a white wax. 1H NMR (400 MHz, CDCl3) δ 
7.52 — 7.50 (m, 4H), 7.36 — 7.29 (m, 6H), 6.10 (t, J = 2.3 Hz, 2H), 4.77 (s, 4H), 3.81 (t, 
J = 6.0 Hz, 4H), 2.72 (td, J = 5.9, 2.3 Hz, 4H). LC-MS m/z calc’d for [M+H]+ C26H25O2: 
369, found 369. 
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4.2.4 Stepwise Castro–Stephens/Alkyne Reduction Sequence 
I
linker linkerCu(OAc)2, phanephos
MeO MeO
K2CO3, DMF, 120 °C
linker
MeOIPrCuCl, NaOtBu
PMHS, tBuOH
PhMe, 45 °C
1.119 1.120  
General Procedure 3: A suspension of iodide substrate (1 equiv), Cu(OAc)2 (0.2 
equiv), phanephos (0.3 equiv), and K2CO3 (1.5 equiv) in DMF (200 mL per 1 mmol of 
iodide) was stirred at 120 °C overnight, and then cooled to room temperature. To the 
cooled reaction mixture was added saturated NH4Cl solution. The mixture was stirred at 
room temperature for 15 min, diluted with water and extracted with hexanes/EtOAc (1:1). 
The combined organic layer was washed with NH4Cl/NH3 buffer (3:1 mixture of 
saturated NH4Cl/28% aqueous ammonium hydroxide), water, and brine, dried over 
MgSO4, and concentrated under vacuum to afford the crude enyne intermediate. 
The crude enyne, polymethylhydrosiloxane (PMHS, equiv), and tert-butanol (equiv) 
were dissolved in toluene (0.5 mL). To a separate container was added chloro[1,3-
bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper(I) (IPrCuCl, 0.05 equiv), NaOtBu 
(0.05 equiv) and THF (0.1 mL). The copper catalyst solution was stirred at room 
temperature for 15 min and then transferred to the enyne solution via syringe. The 
combined mixture was heated with stirring at 45 °C for 8 h, after which it was cooled to 
room temperature and concentrated under vacuum. The residue was purified by flash 
column chromatography on silica gel (100:0 — 40:60 hexanes/DCM) to afford the pure 
diene product. 
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O
O
 
(4E,9Z,11E)-16-Methoxy-3,6,7,8-tetrahydro-1H-benzo[c][1]oxacyclotetradecin-1-
one (1.120e). Prepare from iodide 1.119e (28.2 mg, 0.0687 mmol) following General 
Procedure 3. Compound 1.120e (13.2 mg, 68%) was isolated as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 7.27 (t, J = 8.0 Hz, 1H, overlapping with solvent), 6.82 — 6.75 (m, 
3H), 6.47 (d, J = 16.0 Hz, 1H), 6.13 (t, J = 10.8 Hz, 1H), 5.75 — 5.68 (m, 1H), 5.49 — 
5.41 (m, 1H), 7.36 (dt, J = 10.2, 8.3 Hz, 1H), 4.80 (d, J = 7.2 Hz, 2H), 3.84 (s, 3H), 2.29 
— 2.23 (m, 2H), 2.10 (q, J = 6.6 Hz, 2H), 1.66 — 1.59 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 168.5, 156.7, 137.0, 136.8, 133.6, 130.6, 130.1, 129.7, 129.1, 126.4, 122.3, 
121.8, 109.8, 66.3, 56.3, 30.3, 25.7, 25.5; IR (film, cm–1) 3004, 2925, 2850, 1729, 1571, 
1465, 1268, 1111, 1092, 1059, 740; HRMS (ESI+) m/z calc’d for [M+Na]+ C18H20O3Na: 
307.1305, found 307.1303. 
MeO
O
O
 
(12Z,14E)-19-Methoxy-4,5,6,7,8,9,10,11-
octahydrobenzo[c][1]oxacycloheptadecin-1(3H)-one (1.120p). Prepare from iodide 
1.119p (17.9 mg, 0.0394 mmol) following General Procedure 3. Compound 1.120p (6.0 
mg, 41%) was isolated as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.32 (t, J = 8.1 
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Hz, 1H), 6.98 (d, J = 7.8 Hz, 1H), 6.84 — 6.78 (m, 2H), 6.54 (d, J = 15.4 Hz, 1H), 6.14 
(t, J = 10.8 Hz, 1H), 5.50 (dt, J = 10.6, 7.9 Hz, 1H), 4.32 (t, J = 5.7 Hz, 2H), 3.84 (s, 3H), 
2.29 (q, J = 6.8 Hz, 2H), 1.66 — 1.59 (m, 2H), 1.55 — 1.47 (m, 2H), 1.32 — 1.15 (m, 
10H); 13C NMR (100 MHz, CDCl3) δ 168.4, 156.3, 137.9, 134.7, 130.6, 130.2, 129.0, 
128.9, 122.7, 120.1, 110.0, 65.8, 56.3, 28.9, 28.4, 27.6, 27.2, 27.1, 26.4, 25.8, 25.6; IR 
(film, cm–1) 3050, 2925, 2853, 1729, 1574, 1470, 1270, 1156, 1072; HRMS (ESI+) m/z 
calc’d for [M+Na]+ C21H28O3Na: 351.1931, found 351.1935. 
4.3 Chapter 2 
I
HO  
(E)-5-Iodo-4-penten-1-ol (2.30). A mixture of 4-pentyn-1-ol (2.28, 1.7 mL, 1.5 g, 18 
mmol), Bn3SnH (7.2 mL, 7.8 g, 27 mmol), and AIBN (292 mg, 1.78 mmol) was stirred in 
a vial at 90 °C for 28 h, and then cooled to room temperature. The resultant liquid 
containing stannane 2.29 was used for the next step without further purification. 
The crude stannane 2.29 was transferred to a round-bottomed flask and diluted with 
DCM (89 mL). To this solution was added I2 (6.78 g, 26.7 mmol) in one portion. The 
mixture was stirred at 0 °C for 1 h and quenched with saturated Na2S2O3 solution. The 
organic layer was separated, and the aqueous layer was extracted with DCM. The 
combined organic layer was washed with brine, dried over MgSO4, and concentrated 
under vacuum. The residue was dissolved in a minimal amount of DCM and passed 
through a short column of silica gel (100:0 — 70:30 hexanes/EtOAc) to remove organic 
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stannanes. The eluting solvent was evaporated under vacuum to afford the crude alcohol 
2.30 as a mixture of E/Z isomers. 
The above mixture was dissolved in MeOH (36 mL) and NaOMe (0.5 M in MeOH, 
53.4 mL, 26.7 mmol) was added. The solution was refluxed overnight before it was 
cooled and quenched with saturated NH4Cl solution. The aqueous layer was extracted 
with EtOAc. The combined organic layer was washed with brine, dried over MgSO4, and 
concentrated under vacuum. The residue was purified by flash column chromatography 
on silica gel (100:0 — 70:30 hexanes/EtOAc). Compound 2.30 (2.20 g, 58%) was 
isolated as a colorless liquid. 1H NMR (400 MHz, CDCl3) δ 6.50 (dt, J = 14.4, 7.2 Hz, 
1H), 6.02 (dt, J = 14.4, 1.3 Hz, 1H), 3.61 (t, J = 6.4 Hz, 2H), 2.13 (qd, J = 7.2, 1.2 Hz, 
2H), 1.95 (s, 1H), 1.67 — 1.60 (m, 2H). 
I
O  
(E)-5-Iodo-4-pentenal (2.31). To a solution of oxalyl chloride (0.93 mL, 1.4 g, 11 
mmol) in DCM (73 mL) was added DMSO (1.5 mL, 1.7 g, 22 mmol) dropwise at –78 °C. 
The solution was stirred for 10 min, after which alcohol 2.30 (1.54 g, 7.25 mmol) was 
added over 5 min. The solution was further stirred for 30 min. Triethylamine (6.6 mL, 4.8 
g, 47 mmol) was added over 5 min and the solution was further stirred for 1 h at –78 °C. 
The reaction was allowed to warm to room temperature and stirred for another 1 h before 
it was quenched with saturated NH4Cl solution. The organic layer was separated, and the 
aqueous layer was extracted with DCM. The combined organic layer was washed with 
brine, dried over MgSO4, and concentrated under vacuum. The residue was purified by 
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flash column chromatography on silica gel (100:0 — 90:10 hexanes/EtOAc). Compound 
2.31 (1.38 g, 90%) was isolated as a nearly colorless oil. 1H NMR (400 MHz, CDCl3) δ 
9.77 (t, J = 1.2 Hz, 1H), 6.52 (dt, J = 14.4, 7.2 Hz, 1H), 6.12 (dt, J = 14.4, 1.5 Hz, 1H), 
2.59 — 2.55 (m, 2H), 2.41 — 2.35 (m, 2H). 
I
EtO O  
Ethyl (2E,6E)-7-Iodo-2,6-heptadienoate (2.32). To a solution of aldehyde 2.31 
(1.06 g, 5.04 mmol) in DCM (50 mL) was added (ethoxycarbonylmethylene)triphenyl-
phosphorane (2.64 g, 7.56 mmol) in one portion and the solution was stirred at room 
temperature for 1 h. The mixture was quenched with saturated NH4Cl solution and 
extracted with DCM. The combined organic layer was washed with brine, dried over 
MgSO4, and concentrated under vacuum. The residue was purified by flash column 
chromatography on silica gel (100:0 — 90:10 hexanes/EtOAc). Compound 2.32 (1.32 g, 
93%) was isolated as a light yellow oil. 1H NMR (400 MHz, CDCl3) δ 6.90 (dt, J = 15.7, 
6.6 Hz, 1H), 6.50 (dt, J = 14.4, 6.9 Hz, 1H), 6.08 (dt, J = 14.4, 1.4 Hz, 1H), 5.83 (dt, J = 
15.7, 1.6 Hz, 1H), 4.19 (q, J = 7.2 Hz, 2H), 2.33 — 2.28 (m, 2H), 2.24 — 2.19 (m, 2H), 
1.28 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 166.4, 147.1, 144.6, 122.4, 76.1, 
60.4, 34.4, 30.9, 14.4; IR (film, cm–1) 3058, 2980, 2935, 2905, 2848, 1717, 1655, 1606, 
1367, 1269, 1182, 976, 948. 
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I
HO O  
(2E,6E)-7-Iodo-2,6-heptadienoic Acid (2.25). Ester 2.32 (572 mg, 2.04 mmol) and 
bis(tributyltin) oxide (2.1 mL, 2.4 g, 4.1 mmol) were dissolved in toluene. The solution 
was heated with stirring at 105 °C for 48 h. The mixture was cooled to room temperature 
and partitioned between aqueous HCl solution (1 M) and EtOAc. The aqueous layer was 
extracted with EtOAc. The organic layers were combined, washed with brine, dried over 
MgSO4, and concentrated under vacuum. The residue was purified by flash column 
chromatography on silica gel (100:0 — 70:30 hexanes/EtOAc). Compound 2.25 (364 mg, 
71%) was isolated as white crystals (mp 155 °C). 1H NMR (400 MHz, CDCl3) δ 11.08 
(br, 1H), 7.03 (dt, J = 15.6, 6.6 Hz, 1H), 6.50 (dt, J = 14.4, 7.1 Hz, 1H), 6.10 (d, J = 14.4 
Hz, 1H), 5.85 (d, J = 15.7 Hz, 1H), 2.38 — 2.32 (m, 2H), 2.27 — 2.22 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 172.1, 150.3, 144.5, 121.8, 76.4, 34.4, 31.1; IR (film, cm–1) 
3054, 2986, 1697, 1654, 1421, 1262, 896, 750; HRMS (ESI+) m/z calc’d for [M–
H+2Na]+ C7H8IO2Na2: 296.9359, found 296.9372. 
I
HO  
(E)-7-Iodo-6-hepten-1-ol (2.35). A mixture of 6-heptyn-1-ol (2.33, 696 mg, 6.21 
mmol), Bn3SnH (2.5 mL, 2.7 g, 9.3 mmol), and AIBN (30.6 mg, 0.186 mmol) was stirred 
in a vial at 90 °C for 24 h, and then cooled to room temperature. The resultant liquid 
containing stannane 2.34 was used for the next step without further purification. 
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The crude stannane 2.34 was transferred to a round-bottomed flask and diluted with 
DCM (6.2 mL). To this solution was added I2 (2.52 g, 9.94 mmol) in one portion. The 
mixture was stirred at 0 °C for 1 h and quenched with saturated Na2S2O3 solution. The 
organic layer was separated, and the aqueous layer was extracted with DCM. The 
combined organic layer was washed with brine, dried over MgSO4, and concentrated 
under vacuum. The residue was dissolved in a minimal amount of DCM and passed 
through a short column of silica gel (100:0 — 70:30 hexanes/EtOAc) to remove organic 
stannanes. The eluting solvent was evaporated under vacuum to afford the crude alcohol 
2.35 as a mixture of E/Z isomers. 
The above mixture was dissolved in MeOH (12 mL) and KOH (3.48 g, 62.1 mmol) 
was added. The solution was refluxed overnight before it was cooled and quenched with 
saturated NH4Cl solution. The aqueous layer was extracted with Et2O. The combined 
organic layer was washed with brine, dried over MgSO4, and concentrated under vacuum. 
The residue was purified by flash column chromatography on silica gel (100:0 — 95:5 
DCM/EtOAc). Compound 2.35 (711 mg, 48%) was isolated as a colorless liquid. 1H 
NMR (400 MHz, CDCl3) δ 6.49 (dt, J = 14.3, 7.2 Hz, 1H), 5.97 (dt, J = 14.3, 1.3 Hz, 
1H), 3.61 (t, J = 6.6 Hz, 2H), 2.05 (qd, J = 7.1, 1.2 Hz, 2H), 1.59 (s, 1H), 1.58 — 1.51 
(m, 2H), 1.45 — 1.30 (m, 2H, contaminated by unidentified impurity); 13C NMR (100 
MHz, CDCl3) δ 146.6, 74.8, 62.9, 36.1, 32.6, 28.3, 25.2. 
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I
HO O  
(E)-7-Iodo-6-heptenoic Acid (2.24). To a solution of alcohol 2.35 (631 mg, 2.63 
mmol) in acetone (26 mL) was added Jones reagent (2.76 M CrO3 in H2SO4, 3.8 mL, 
10.5 mmol) at 0 °C and the mixture was stirred at this temperature for 3 h. The reaction 
mixture was then diluted with water and extracted with DCM. The combined organic 
layer was washed with brine, dried over MgSO4, and concentrated under vacuum. The 
residue was purified by flash column chromatography on silica gel (100:0 — 80:20 
hexanes/EtOAc). Compound 2.24 (601 mg, 89%) was isolated as white crystals (mp 64 
— 65 °C). 1H NMR (400 MHz, CDCl3) δ 10.31 (br, 1H), 6.50 (dt, J = 14.4, 7.1 Hz, 1H), 
6.02 (d, J = 14.4 Hz, 1H), 2.36 (t, J = 7.3 Hz, 2H), 2.09 (q, J = 7.2 Hz, 2H), 1.69 — 1.61 
(m, 2H), 1.50 — 1.42 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 180.1, 146.0, 75.2, 35.8, 
33.9, 27.9, 24.1; IR (film, cm–1) 3047, 2937, 1699, 1412, 1291, 1210, 950; HRMS (ESI+) 
m/z calc’d for [M–H+2Na]+ C7H10IO2Na2: 298.9515, found 298.9521. 
O
N
OO  
(S,E)-4-Isopropyl-3-(2-methyl-2-pentenoyl)-2-oxazolidinone (2.38). A solution of 
(E)-2-methyl-2-pentenoic acid (2.36, 1.33 g, 11.6 mmol) and triethylamine (3.3 mL, 2.4 
g, 24 mmol) in THF (26 mL) was cooled to –20 °C and pivaloyl chloride (1.4 mL, 1.4 g, 
12 mmol) was added. The resultant white slurry was stirred at –20 °C for 1 h before the 
addition of LiCl (984 mg, 23.2 mmol) and (S)-4-isopropyl-2-oxazolidinone (2.37, 1.00 g, 
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7.74 mmol). The reaction mixture was allowed to warm to room temperature, stirred 
overnight, quenched with aqueous HCl solution (0.2 N), and extracted with EtOAc. The 
combined organic layer was washed sequentially with saturated NaHCO3 solution and 
brine, dried over MgSO4, and concentrated under vacuum. The residue was purified by 
flash column chromatography on silica gel (100:0 — 85:15 hexanes/EtOAc). Compound 
2.38 (1.49 g, 85%) was isolated as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.08 (td, 
J = 7.2, 1.1 Hz, 1H), 4.54 — 4.49 (m, 1H), 4.31 (t, J = 8.9 Hz, 1H), 4.17 (dd, J = 9.0, 5.5 
Hz, 1H), 2.37 (septd, J = 7.0, 4.4 Hz, 1H), 2.04 (quint, J = 7.5 Hz, 2H), 1.90 (s, 3H), 1.05 
(t, J = 7.6 Hz, 3H), 0.92 (d, J = 6.7 Hz, 3H), 0.90 (d, J = 6.4 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 172.1, 153.8, 141.3, 130.4, 63.5, 58.4, 28.4, 21.8, 18.0, 15.2, 13.6, 12.9. 
TBSO
N
OO
 
(S)-3-((1E,3E)-1-((tert-Butyldimethylsilyl)oxy)-2-methyl-1,3-pentadien-1-yl)-4-
isopropyl-2-oxazolidinone (2.1). To a solution of imide 2.38 (1.48 g, 6.57 mmol) in 
THF (60 mL) was added NaHMDS (1.0 M in THF, 9.9 mL, 9.9 mmol) at –78 °C. After 
stirring for 90 min, a solution of TBSCl (2.97 g, 19.7 mmol) in THF (24 mL) was added 
and stirring was continued for another 90 min. The reaction mixture was quenched with 
saturated NH4Cl solution, warmed to room temperature, and extracted with EtOAc. The 
combined organic layer was washed with brine, dried over Na2SO4, and concentrated 
under vacuum. The residue was purified by flash column chromatography on silica gel 
(100:0 — 90:10 hexanes/EtOAc). Compound 2.1 (2.18 g, 98%) was isolated as a 
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colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.21 (d, J = 15.6 Hz, 1H), 5.63 (qd, J = 15.5, 
6.6 Hz, 1H), 4.32 (t, J = 8.7 Hz, 1H), 4.12 (t, J = 8.3 Hz, 1H), 4.05 — 3.95 (m, 1H), 1.98 
— 1.90 (m, 1H), 1.79 — 1.77 (m, 6H), 0.98 (s, 9H), 0.92 (d, J = 7.7 Hz, 6H), 0.19 (s, 
3H), 0.14 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 156.1, 134.8, 128.3, 124.4, 115.1, 64.5, 
59.5, 29.5, 25.8, 18.9, 18.4, 18.2, 16.4, 12.4, –4.2, –4.8. 
O
N
OO
OH
 
(S)-3-((4S,5R,E)-5-Hydroxy-2,4-dimethyl-2-hexenoyl)-4-isopropyl-2-
oxazolidinone (2.39). At –78 °C, to a solution of acetaldehyde (0.898 g, 20.4 mmol) in 
DCM (25 mL) were sequentially added TiCl4 solution (1 M in DCM, 5.1 mL, 5.1 mmol) 
and a solution of vinylketene silyl N,O-acetal 2.1 (1.73 g, 5.09 mmol) in DCM (25 mL). 
The resultant dark orange solution was stirred at –78 °C for 24 h, after which the color 
turned bright yellow. The reaction was quenched with aqueous saturated Rochelle salt 
solution and stirred at room temperature for several hours until precipitates disappeared. 
The mixture was extracted with DCM. The combine organic layer was washed with 
brine, dried over MgSO4, and concentrated under vacuum. The residue was purified by 
flash column chromatography on silica gel (90:10 — 60:40 hexanes/EtOAc). Compound 
15 (1.10 g, 80%) was isolated as a colorless oil. [α] D
21  = +11 (c 0.30, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 5.79 (dq, J = 10.4, 1.5 Hz, 1H), 4.58 (ddd, J = 8.9, 5.8, 4.6Hz, 1H), 
4.34 (t, J = 9.0 Hz, 1H), 4.19 (dd, J = 9.0, 5.8 Hz, 1H), 3.51 (quint, J = 6.6 Hz, 1H), 3.24 
(s, 1H), 2.49 (ddq, J = 10.4, 8.3, 6.6 Hz, 1H), 2.34 (septd, J = 7.0, 4.5 Hz, 1H), 1.95 (d, J 
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= 1.4 Hz, 3H), 1.25 (d, J = 6.1 Hz, 3H), 0.97 (d, J = 6.6 Hz, 3H), 0.93 (d, J = 7.1 Hz, 3H), 
0.91 (d, J = 6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.6, 154.6, 142.0, 131.3, 71.6, 
63.6, 58.1, 41.9, 28.5, 20.1, 17.8, 16.2, 15.2, 14.0; IR (film, cm–1) 3517, 2968, 2931, 
2876, 1773, 1685, 1390, 1366, 1301, 1210; HRMS (ESI+) m/z calc’d for [M+Na]+ 
C14H23NO4Na: 292.1519, found 292.1514. 
O
N
OO
TBDPSO
 
(S)-3-((4S,5R,E)-5-((tert-Butyldiphenylsilyl)oxy)-2,4-dimethyl-2-hexenoyl)-4-
isopropyl-2-oxazolidinone (2.40c). A solution of alcohol 2.39 (1.02 g, 3.79 mmol), 
imidazole (774 mg, 11.4 mmol) and DMAP (92.5 mg, 0.757 mmol) in DCM (19 mL) was 
cooled to 0 °C and tert-butylchlorodiphenylsilane (1.9 mL, 2.1 g, 7.6 mmol) was added. 
The solution was stirred at room temperature overnight and then water was added. The 
mixture was extracted with DCM. The combine organic layer was washed with brine, 
dried over MgSO4, and concentrated under vacuum. The residue was purified by flash 
column chromatography on silica gel (100:0 — 85:15 hexanes/EtOAc). Compound 2.40c 
(1.78 g, 92%) was isolated as a colorless syrup. [α] D
21  = +16 (c 0.50, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 7.72 — 7.68 (m, 4H), 7.45 — 7.36 (m, 6H), 6.08 — 6.05 (m, 1H), 
4.52 (ddd, J = 8.8, 5.5, 4.3 Hz, 1H), 4.32 (t, J = 8.9 Hz, 1H), 4.18 (dd, J = 9.0, 5.6 Hz, 
1H), 3.89 (qd, J = 6.4, 3.4 Hz, 1H), 2.54 (dqd, J = 10.2, 6.8, 3.4 Hz, 1H), 2.37 (septd, J = 
6.9, 4.2 Hz, 1H), 1.70 (d, J = 1.4 Hz, 3H), 1.07 (s, 9H), 1.06 (d, J = 6.4 Hz, 3H), 1.06 (d, 
J = 7.0 Hz, 3H), 0.93 (d, J = 7.0 Hz, 3H), 0.91 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, 
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CDCl3) δ 172.2, 153.7, 141.2, 136.1, 134.7, 134.2, 131.1, 129.8, 129.6, 127.7, 127.6, 
72.2, 63.5, 58.3, 40.1, 28.3, 27.2, 20.5, 19.6, 18.0, 15.3, 15.2, 13.6; IR (film, cm–1) 3072, 
3049, 2964, 2931, 1789, 1683, 1428, 1300, 1111, 703; HRMS (ESI+) m/z calc’d for 
[M+Na]+ C30H41NO4SiNa: 530.2697, found 530.2703. 
CHO
TBDPSO
 
(4S,5R,E)-5-((tert-Butyldiphenylsilyl)oxy)-2,4-dimethyl-2-hexenal (2.27c). A 
solution of compound 2.40c (1.16 g, 2.28 mmol) in DCM (50 mL) was cool to –78 °C 
and DIBAL-H solution (1.49 M in toluene, 3.3 mL, 4.9 mmol) was added dropwise. The 
reaction was stirred at –78 °C for 20 min before it was quenched by MeOH and then 
aqueous saturated Rochelle salt solution. The mixture was stirred at room temperature 
until precipitates disappeared and then extracted with DCM. The combine organic layer 
was washed with brine, dried over Na2SO4, and concentrated under vacuum. The residue 
was purified by flash column chromatography on silica gel (100:0 — 95:5 
hexanes/EtOAc). Compound 2.27c (761 mg, 88%) was isolated as a colorless oil. [α] D
21   = 
+1.5 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 9.36 (s, 1H), 7.70 — 7.65 (m, 4H), 
7.46 — 7.35 (m, 6H), 6.40 (dq, J = 9.8, 1.3 Hz, 1H), 3.85 (qd, J = 6.2, 4.4 Hz, 1H), 2.71 
(dqd, J = 9.8, 6.8, 4.4 Hz, 1H), 1.60 (d, J = 1.4 Hz, 3H), 1.06 (d, J = 6.4 Hz, 3H), 1.05 (s, 
9H), 1.04 (d, J = 6.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 195.7, 157.1, 139.3, 136.1 
134.6, 133.9, 130.0, 129.8, 127.8, 127.7, 72.4, 41.2, 27.2, 21.0, 19.6, 15.6, 9.5; IR (film, 
cm–1) 3071, 3050, 2964, 2931, 2858, 2820, 2708, 1690, 1641, 1428, 1377, 1111, 1025, 
703; HRMS (ESI+) m/z calc’d for [M+Na]+ C24H32O2SiNa: 403.2064, found 403.2064. 
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OH
TBDPSO
 
(3S,4S,7S,8R,E)-8-((tert-Butyldiphenylsilyl)oxy)-3,5,7-trimethyl-5-nonen-1-yn-4-
ol ((4S)-2.26c). Anhydrous THF used in this reaction was pretreated with 3Å molecular 
sieves (20% M/V) overnight. A solution of palladium acetate (11.2 mg, 0.0500 mmol) 
and triphenylphosphine (13.1 mg, 0.0500 mmol) in THF (18 mL) was cooled to –78 °C. 
To this solution were sequentially added mesylate (R)-2.42136 (0.15 mL, 178 mg, 1.20 
mmol), a solution of aldehyde 2.27c (382 mg, 1.00 mmol) in THF (2mL), and diethylzinc 
(1.0 M in hexanes, 3.0 mL, 3.0 mmol). The mixture was stirred at –78 °C for 10 min, 
warmed up to –20 °C, and stirred at this temperature for 20 h. The sealed reaction 
container was then left in a 0 °C refrigerator for another 16 h before EtOAc and saturated 
NH4Cl solution were added. The organic layer was separated, and the aqueous layer was 
extracted with EtOAc. The combined organic layer was washed with brine, dried over 
MgSO4, and concentrated under vacuum. The residue was purified by flash column 
chromatography on silica gel (100:0 — 90:10 hexanes/EtOAc). An inseparable mixture 
of compound (4S)-2.26 and its C4-epimer (342 mg, 79%, d.r. = 82:18) was isolated as a 
colorless oil. [α] D
21  = +2.9 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.71 — 7.66 (m, 
4H), 7.44 — 7.34 (m, 6H), 5.32 — 5.29 (m, 1H), 3.80 (qd, J = 6.3, 4.0 Hz, 1H), 3.76 (d, J 
= 8.0 Hz, 1H), 2.65 — 2.55 (m, 1H), 2.47 (dqd, J = 9.6, 6.8, 4.1 Hz, 1H), 2.12 (d, J = 2.4 
Hz, 1H), 1.86 (br, 1H), 1.39 (d, J = 1.3 Hz, 3H), 1.06 (d, J = 7.1 Hz, 3H), 1.06 (s, 9H), 
1.01 (d, J = 6.2 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 136.1, 
134.9, 134.5, 134.1, 132.0, 129.7, 129.6, 127.7, 127.6, 86.3, 81.2, 72.5, 70.7, 39.3, 31.3, 
27.3, 19.9, 19.6, 17.7, 15.6, 11.3; IR (film, cm–1) 3308, 3071, 2964, 2932, 2858, 1473, 
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1460, 1428, 1376, 1111, 1027, 961, 822, 739, 702, 612; HRMS (ESI+) m/z calc’d for 
[M+Na]+ C28H38O2SiNa: 457.2533, found 457.2528. 
OH
TBDPSO
 
(3S,4R,7S,8R,E)-8-((tert-Butyldiphenylsilyl)oxy)-3,5,7-trimethyl-5-nonen-1-yn-4-
ol ((4R)-2.26c). Featured 1H NMR (400 MHz, CDCl3) peaks: δ 5.39 — 5.36 (m, 1H), 
3.91 (d, J = 7.0 Hz, 1H), 1.96 (d, J = 2.5 Hz, 1H), 1.42 (d, J = 1.4 Hz, 3H), 1.17 (d, J = 
6.9 Hz, 3H). The minor isomer is in an inseparable mixture and therefore not all signals 
are visible in the spectrum. 
I
O O
TBDPSO
*
 
(3S,4R,7S,8R,E)-8-((tert-Butyldiphenylsilyl)oxy)-3,5,7-trimethyl-5-nonen-1-yn-4-
yl (E)-7-Iodo-6-heptenoate (2.22). A solution of alcohol (4S)-2.26 (78.8 mg, 0.181 
mmol), acid 2.24 (139 mg, 0.543 mmol), and triphenylphosphine (142 mg, 0.543 mmol) 
in toluene (1.8 mL) was cooled to 0 °C and DEAD (40% in toluene, 0.25 mL, 95 mg, 
0.54 mmol) was added. The mixture was stirred at room temperature for 20 h before the 
solvent was evaporated. The residue was purified by flash column chromatography on 
silica gel (100:0 — 50:50 hexanes/DCM). Compound 2.22 along with its inseparable 
epimer (77.8 mg, 64%, d.r. = 93:7) was isolated as a colorless oil. [α] D
22  = +7.4 (c 0.50, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.70 — 7.66 (m, 4H), 7.44 — 7.34 (m, 6H), 6.48 
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(dt, J = 14.2, 7.1 Hz, 1H), 6.02 (dt, J = 14.3, 1.5 Hz, 1H), 5.40 (d, J = 9.6 Hz, 1H), 5.06 
(d, J = 7.8 Hz, 1H), 3.78 (qd, J = 6.3, 3.3 Hz, 1H), 2.75 (quintd, J = 6.9, 2.4 Hz, 1H), 2.43 
(dqd, J = 9.9, 6.8, 3.4 Hz, 1H), 2.31 (td, J = 7.5, 1.8 Hz, 2H), 2.06 (qd, J = 7.3, 1.6 Hz, 
2H), 1.92 (d, J = 2.4 Hz, 1H), 1.66 — 1.58 (m, 2H), 1.45 — 1.37 (m, 5H), 1.14 (d, J = 
6.9 Hz, 3H), 1.06 (s, 9H), 1.02 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.3 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 172.3, 146.0, 136.1, 134.9, 134.4, 132.7, 131.4, 129.7, 129.6, 127.9, 
127.5, 85.1, 80.9, 75.1, 72.3, 70.4, 39.0, 35.8, 34.3, 29.1, 27.9, 27.2, 24.4, 19.8, 19.6, 
17.1, 15.4, 12.5; IR (film, cm–1) 3308, 3070, 2931, 2857, 1736, 1427, 1110, 702, HRMS 
(ESI+) m/z calc’d for [M+Na]+ C35H47IO3SiNa: 693.2231, found 693.2236. 
TBDPSO
 
tert-Butyldiphenyl(((2R,3S,4E)-3,5,7-trimethyl-4,6-nonadien-8-yn-2-yl)oxy)silane 
(2.46). Elimination product 2.46 (15.9 mg, 21%) was isolated as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 7.73 — 7.68 (m, 4H), 7.52 — 7.30 (m, 6H), 6.12 (br, 1H), 5.51 (d, J 
= 9.7 Hz, 1H), 3.80 (qd, J = 6.2, 4.1 Hz, 1H), 3.15 (s, 1H), 2.55 (dqd, J = 9.5, 6.8, 4.2, 
1H), 1.95 (d, J = 1.4 Hz, 3H), 1.84 (d, J = 1.4 Hz, 3H), 1.08 (s, 9H), 1.02 (d, J = 6.8 Hz, 
3H), 1.01 (d, J = 6.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 141.7, 127.2, 136.2, 135.1, 
134.5, 133.8, 129.7, 129.6, 127.7, 127.6, 112.9, 85.0, 82.5, 72.6, 39.8, 27.3, 25.9, 20.0, 
19.6, 15.6, 15.1. 
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I
O O
TBDPSO
*
 
(3S,4R,7S,8R,E)-8-((tert-Butyldiphenylsilyl)oxy)-3,5,7-trimethyl-5-nonen-1-yn-4-
yl (2E,6E)-7-Iodo-2,6-heptadienoate (2.23). A solution of alcohol (4S)-2.26 (56.8 mg, 
0.131 mmol), acid 2.25 (98.8 mg, 0.392 mmol), and triphenylphosphine (103 mg, 0.392 
mmol) in toluene (1.3 mL) was cooled to 0 °C and DEAD (40% in toluene, 0.18 mL, 69 
mg, 0.39 mmol) was added. The mixture was stirred at room temperature for 22 h before 
the solvent was evaporated under vacuum. The residue was purified by flash column 
chromatography on silica gel (100:0 — 50:50 hexanes/DCM). Compound 2.23 along 
with its inseparable epimer (54.2 mg, 62%, d.r. = 92:8) was isolated as a colorless oil. 1H 
NMR (400 MHz, CDCl3) δ 7.70 — 7.65 (m, 4H), 7.43 — 7.34 (m, 6H), 6.92 (dt, J = 
15.6, 6.5 Hz, 1H), 6.49 (dt, J = 14.4, 7.2 Hz, 1H), 6.07 (dt, J = 14.4, 1.5 Hz, 1H), 5.84 (d, 
J = 15.6 Hz, 1H), 5.42 (d, J = 9.4 Hz, 1H), 5.12 (d, J = 7.9 Hz, 1H), 3.78 (qd, J = 6.2, 3.2 
Hz, 1H), 2.78 (quintd, J = 7.0, 2.5 Hz, 1H), 2.43 (dqd, J = 9.8, 6.7, 3.2 Hz, 1H), 2.31 — 
2.26 (m, 2H), 2.23 — 2.19 (m, 2H), 1.93 (d, J = 2.4 Hz, 1H), 1.42 (d, J = 1.5 Hz, 3H), 
1.16 (d, J = 6.9 Hz, 3H), 1.06 (s, 9H), 1.02 (d, J = 6.8, 3H), 0.95 (d, J = 6.3 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 165.4, 147.6, 144.7, 136.1, 135.0, 134.4, 132.9, 131.4, 129.7, 
129.6, 127.7, 127.6, 122.4, 85.1, 81.1, 76.2, 72.4, 70.5, 39.1, 34.5, 31.0, 29.3, 27.3, 19.8, 
19.6, 17.2, 15.4, 12.5; HRMS (ESI+) m/z calc’d for [M+Na]+ C35H45IO3Si: 691.2075, 
found 691.2096. 
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O O
TBDPSO
 
(7E,9Z,11S,12R)-12-((4S,5R,E)-5-((tert-Butyldiphenylsilyl)oxy)-4-methyl-2-
hexen-2-yl)-11-methyloxa-7,9-cyclododecadien-2-one (2.47). A suspension of copper 
acetate (13.4 mg, 0.0738 mmol), BINAP (69.7 mg, 0.112 mmol), sodium formate (60.9 
mg, 0.896 mmol) and potassium carbonate (46.4 mg, 0.336 mmol) in DMF (22 mL) was 
stirred at 120 °C for 30 min, after which a solution of ester 2.2 (150 mg, 0.224 mmol) in 
DMF (23 mL) was added dropwise in one portion. The resultant mixture was stirred at 
120 °C for an additional period of 4h before it was cooled and quenched with saturated 
NH4Cl solution. After stirring at room temperature for 15 min, the mixture was diluted 
with water and extracted with EtOAc/hexanes (1:1). The combine organic layer was 
sequentially washed with NH4Cl/NH3 buffer (3:1 mixture of saturated NH4Cl/28% 
aqueous ammonium hydroxide), water and brine, dried over MgSO4, and concentrated 
under vacuum. The residue was purified by flash column chromatography on silica gel 
(100:0 — 50:50 hexanes/DCM). Compound 2.47 (102 mg, 83%) was isolated as a 
colorless oil. [α] D
22  = –25 (c 0.50, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.72 — 7.66 
(m, 4H), 7.44  — 7.35 (m, 6H), 6.21 (dd, J = 15.8, 10.5 Hz, 1H), 6.10 (t, J = 10.4 Hz, 
1H), 5.74 (dt, J = 15.8, 5.3 Hz, 1H), 5.30 (d, J = 9.6 Hz, 1H), 5.10 (d, J = 5.0 Hz, 1H), 
4.99 (t, J = 10.0 Hz, 1H), 3.78 (qd, J = 6.2, 3.1 Hz, 1H), 3.38 — 3.29 (m, 1H), 2.44 — 
2.23 (m, 4H), 2.04 — 1.93 (m, 2H), 1.90 — 1.84 (m, 1H), 1.59 — 1.50 (m, 2H), 1.35 (d, 
J = 1.3 Hz, 3H), 1.07 (s, 9H), 1.01 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 6.3 Hz, 3H), 0.91 (d, J 
= 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 173.3, 136.2, 136.1, 135.0, 134.4, 133.6, 
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131.6, 131.3, 131.1, 130.1, 129.7, 129.6, 127.7, 127.6, 126.7, 83.5, 72.5, 39.2, 33.6, 33.4, 
30.5, 27.2, 24.1, 23.2, 20.1, 19.6, 17.8, 15.6, 14.3; IR (film, cm–1) 3071, 2962, 2930, 
2857, 1728, 1427, 1376, 1200, 1111, 739, 702; HRMS (ESI+) m/z calc’d for [M+Na]+ 
C35H48O3SiNa: 567.3265, found 567.3267. 
O O
OH
 
(7E,9Z,11S,12R)-12-((4S,5R,E)-5-Hydroxy-4-methyl-2-hexen-2-yl)-11-methyloxa-
7,9-cyclododecadien-2-one (1.42). To a vial containing lactone 2.47 (71.5 mg, 0.131 
mmol) was added TBAF solution (1.0 M in THF, 3.4 mL, 3.4 mmol). The solution was 
then heated with stirring at 50 °C for 4 h. The mixture was cooled, diluted with water, 
and extracted with EtOAc. The combined organic layer was washed with brine, dried 
over MgSO4, and concentrated under vacuum. The residue was purified by flash column 
chromatography on silica gel (100:0 — 85:15 hexanes/EtOAc). Compound 1.42 (34 mg, 
85%) was isolated as a colorless oil. [α] D
22  = –85 (c 0.10, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 6.21 (dd, J = 15.6, 10.5 Hz, 1H), 6.12 (t, J = 10.4 Hz, 1H), 5.74 (dt, J = 15.6, 
5.2 Hz, 1H), 5.24 (d, J = 9.8 Hz, 1H), 5.13 (d, J = 5.0 Hz, 1H), 5.05 (t, J = 9.9 Hz, 1H), 
3.58 (quint, J = 6.2 Hz, 1H), 3.40 — 3.32 (m, 1H), 2.41 (dquint, J = 9.9, 6.7 Hz, 1H), 
2.34 — 2.24 (m, 3H), 2.04 — 1.96 (m, 2H), 1.93 — 1.83 (m, 1H), 1.64 (d, J = 1.1 Hz, 
3H), 1.59 — 1.48 (m, 3H), 1.16 (d, J = 6.2 Hz, 3H), 0.96 (d, J = 6.8, 3H), 0.95 (d, J = 
6.8, 3H); 13C NMR (100 MHz, CDCl3) δ 173.3, 133.3, 133.0, 131.6, 131.3, 130.3, 126.7, 
83.3, 71.7, 40.2, 33.5, 33.4, 30.5, 24.1, 23.2, 20.4, 17.9, 16.6, 14.8; IR (film, cm–1) 3449, 
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3008, 2966, 2929, 2876, 1726, 1453, 1376, 1201, 1146, 1093, 994, 955; HRMS (ESI+) 
m/z calc’d for [M+Na]+ C19H30O3Na: 329.2087, found 329.2085. 
O O
OH
 
(7E,9Z,11S,12S)-12-((4S,5R,E)-5-Hydroxy-4-methyl-2-hexen-2-yl)-11-methyloxa-
7,9-cyclododecadien-2-one (epi-1.42). The epimer (2.5 mg, 6%) was isolated as a 
colorless oil. [α] D
22  = +16 (c 0.050, CHCl3); 1H NMR (400 MHz, CDCl3) δ 6.23 (dd, J = 
15.2, 10.8 Hz, 1H), 6.13 (t, J = 10.4 Hz, 1H), 5.75 (dt, J = 15.6, 5.2 Hz, 1H), 5.24 (d, J = 
9.8 Hz, 1H), 5.15 (d, J = 4.9 Hz, 1H), 5.05 (t, J = 9.9 Hz, 1H), 3.55 (quint, J = 6.3 Hz, 
1H), 3.41 — 3.33 (m, 1H), 2.41 (dquint, J = 9.8, 6.8 Hz, 1H), 2.38 — 2.25 (m, 3H), 2.05 
— 1.95 (m, 2H), 1.93 — 1.81 (m, 1H), 1.66 (s, 3H, overlapping with water signal), 1.60 
— 1.52 (m, 3H), 1.17 (d, J = 6.2 Hz, 3H), 0.96 (d, J = 6.5 Hz, 6H). 
4.4 Chapter 3 
Bu3Sn OH  
(E)-5-(Tributylstannyl)-4-penten-1-ol ((E)-2.29). Pd2dba3 (50.3 mg, 0.0549 mmol), 
tricyclohexylphosphonium tetrafluoroborate (79.2 mg, 0.215 mmol) and DIPEA (0.30 
mL, 220 mg, 1.7 mmol) were dissolved in DCM (100 mL) and the solution was stirred at 
room temperature for 10 min. 4-Pentyn-1-ol (1.0 mL, 900 mg, 11 mmol) was added and 
the reaction mixture was cooled to 0 °C. A solution of Bu3SnH (3.5 mL, 3.8 g, 13 mmol) 
in DCM (30 mL) was added dropwise via syringe over 15 min. The reaction mixture was 
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then stirred at 0 °C for 4 h before it was concentrated to afford a crude product. This 
crude compound (E)-2.29 was directly used for the next step without further purification. 
Bu3Sn O  
(E)-5-(Tributylstannyl)-4-pentenal (3.55). To a solution of the above crude alcohol 
(E)-2.29 in DCM (30 mL) was added triethylamine (7.6 mL, 5.5 g, 54 mmol) and DMSO 
(30 mL). The mixture was cooled to 0 °C, and SO3·Py (52.0 mg, 0.324 mmol) was added 
in portions over 2 min. The mixture was stirred at 0 °C for an additional period of 1 h, 
and then diluted with hexanes (100 mL) and phosphate (pH = 7) buffer (20 mL). The 
organic layer was separated, and the aqueous layer was extracted with hexanes. The 
combined organic layer was dried over Na2SO4 and concentrated under vacuum to afford 
a bright yellow crude product. This crude compound 3.55 was directly used for the next 
step without further purification. 
Bu3Sn  
(E)-Tributyl(1,5-hexadien-1-yl)stannane (3.54). Methyltriphenylphosphonium 
bromide (8.50 g, 23.8 mmol) was suspended with stirring in THF (30 mL) at 0 °C and a 
solution of KOtBu (1.0 M in THF, 22 mL, 22 mmol) was added over 3 min. After the 
addition was completed, the bright yellow mixture was stirred at 0 °C for 30 min. A 
solution of crude aldehyde 3.55 from the previous step in THF (30 mL) was then added 
dropwise over 10 min. The reaction mixture was stirred at 0 °C and warmed to room 
temperature overnight before it was diluted with hexanes (100 mL) and quenched with 
phosphate (pH = 7) buffer (50 mL). The organic layer was separated, and the aqueous 
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layer was extracted with hexanes. The combined organic layer was dried over Na2SO4 
and concentrated under vacuum to afford a crude product. This crude compound 3.54 was 
directly used for the next step without further purification. 
O
O
O
 
(E)-5-(1,5-Hexadien-1-yl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (3.53). A 
mixture of Pd(PPh3)4 (78.0 mg, 0.0675 mmol), LiCl (286 mg, 6.75 mmol), and 2,2-
dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl trifluoromethanesulfonate (1.68)58, 91 (439 
mg, 1.35 mmol) in degassed DMF (6.8 mL) was stirred at room temperature for 15min, 
after which crude stannyl diene 3.54 (0.56 mL, ca. 600 mg, 1.6 mmol) was added 
dropwise via syringe. The resulting mixture was stirred and heated at 70 °C for 24 h, 
cooled to room temperature, and diluted with water and hexanes. The aqueous layer was 
extracted with EtOAc/hexanes (1:1). The combined organic layer was washed with brine, 
dried over Na2SO4, and concentrated under vacuum. The residue was purified by flash 
column chromatography on silica gel (100:0 — 90:10 hexanes/EtOAc). Compound 3.53 
(215 mg, 62%) was isolated as a colorless oil, which solidified slowly upon storage in a 
refrigerator. 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 15.8 Hz, 1H), 7.41 (t, J = 8.0 Hz, 
1H), 7.22 (d, J = 7.8 Hz, 1H), 6.81 (d, J = 8.1 Hz, 1H), 6.22 (dt, J = 15.6, 6.7 Hz, 1H), 
5.87 (ddt, J = 17.0, 10.4, 6.5 Hz, 1H), 5.07 (d, J = 17.1 Hz, 1H), 5.00 (d, J = 10.2 Hz, 
1H), 2.41 — 2.36 (m, 2H), 2.29 — 2.24 (m, 2H), 1.70 (s, 6H). 
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O
O
OMOM
OPMB
 
(3S,4S)-1-((4-Methoxybenzyl)oxy)-4-(methoxymethoxy)-5-hexen-3-yl 2-((tert-
Butyldimethylsilyl)oxy)-6-((E)-1,5-hexadien-1-yl)benzoate (3.52). A solution of 
alcohol 1.6640 (91.1 mg, 0.308 mmol) in THF (0.5 mL) was cooled to 0 °C and NaHMDS 
(1.0 M in THF, 0.59 mL, 0.59 mmol) was added. After stirring at 0 °C for 30 min, a 
solution of salicylate 3.53 (75.7 mg, 0.293 mmol) in THF (0.5 mL) was added dropwise 
via syringe. The reaction was warmed to room temperature, and stirred for 2 h before 
TBSCl (88.3 mg, 0.586 mmol) and imidazole (39.9 mg, 0.586 mmol) were added as 
solids. The mixture was stirred overnight and then diluted with water and hexanes. The 
organic layer was separated, and the aqueous layer was extracted with EtOAc. The 
combined organic layer was washed with brine, dried over Na2SO4, and concentrated 
under vacuum. The residue was purified by flash column chromatography on silica gel 
(100:0 — 90:10 hexanes/EtOAc). Compound 3.52 (115 mg, 64%) was isolated as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 7.4 Hz, 2H), 7.16 (t, J = 8.0 Hz, 
1H), 7.08 (d, J = 7.7 Hz, 1H), 6.87 (d, J = 8.6 Hz, 2H), 6.71 (d, J = 8.0 Hz, 1H), 6.41 (d, 
J = 15.7 Hz, 1H), 6.17 (dt, J = 15.7, 6.6 Hz, 1H), 5.86 — 5.77 (m, 2H), 5.36 — 5.27 (m, 
3H), 5.04 (dd, J = 17.2, 1.8 Hz, 1H), 4.98 (dd, J = 10.3, 1.7 Hz, 1H), 4.68 (d, J = 6.7 Hz, 
1H), 4.59 (d, J = 6.7 Hz, 1H), 4.49 — 4.41 (m, 2H), 4.31 (dd, J = 6.9, 4.7 Hz, 1H), 3.80 
(s, 3H), 3.67 — 3.57 (m, 2H), 3.32 (s, 3H), 2.29 — 2.10 (m, 5H, overlapping with 
residual acetone), 2.04 — 1.97 (m, 1H), 0.98 (s, 9H), 0.23 (s, 3H), 0.22 (s, 3H). 
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(3S,4S,5E,9E)-14-((tert-Butyldimethylsilyl)oxy)-3-(2-((4-methoxybenzyl)oxy) 
ethyl)-4-(methoxymethoxy)-3,4,7,8-tetrahydro-1H-benzo[c][1]oxacyclododecin-1-
one (3.50). A solution of ester 3.52 (604 mg, 0.989 mmol) and second-generation Grubbs 
catalyst (42.0 mg, 0.0495 mmol) in toluene (620 mL) was degassed and heated to reflux. 
The refluxing solution was stirred for 26 h and then cooled to room temperature. DMSO 
(0.18 mL, 190 mg, 2.4 mmol) was added into the reaction flask, and the mixture was 
stirred at room temperature overnight before the solvent was removed under vacuum. The 
residue was purified by flash column chromatography on silica gel (100:0 — 80:20 
hexanes/EtOAc). Compound 3.50 (392 mg, 68%) was isolated as a light yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 7.29 (d, J = 8.4 Hz, 2H), 7.13 (t, J = 8.0 Hz, 1H), 6.89 — 
6.85 (m, 3H), 6.68 (d, J = 8.2, 1H), 6.22 (d, J = 15.9 Hz, 1H), 5.77 (dt, J = 15.9, 6.2 Hz, 
1H), 5.50 (dt, J = 15.8, 6.2 Hz, 1H), 5.35 — 5.27 (m, 2H), 4.67 (d, J = 6.7 Hz, 1H), 4.57 
(d, J = 6.8 Hz, 1H), 4.51 (d, J = 11.4 Hz, 1H), 4.43 (d, J = 11.4 Hz, 1H), 4.40 — 4.38 (m, 
1H), 3.81 (s, 3H), 3.68 — 3.59 (m, 2H), 3.35 (s, 3H), 2.41 — 2.30 (m, 2H), 2.24 — 2.13 
(m, 4H), 0.98 (s, 9H), 0.24 (s, 3H), 0.23 (s, 3H). 
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(3S,4S,5E,9E)-14-((tert-Butyldimethylsilyl)oxy)-3-(2-hydroxyethyl)-4-
(methoxymethoxy)-3,4,7,8-tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one (3.56). 
To a flask containing macrocyclic diene 3.50 (385 mg, 0.661 mmol) was added DCM (20 
mL) and H2O (2 mL). The mixture was cooled to 0 °C and DDQ (165 mg, 0.727 mmol) 
was added in one portion. The cooling bath was removed and the reaction was stirred at 
room temperature for 1 h. The reaction mixture was diluted with saturated NaHCO3 
solution and then extracted with DCM. The combined organic layer was washed with 
brine, dried over MgSO4, and concentrated under vacuum. The residue was purified by 
flash column chromatography on silica gel (100:0 — 65:35 hexanes/EtOAc). Compound 
3.56 (188 mg, 61%) was isolated as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.13 (t, 
J = 8.0 Hz, 1H), 6.89 (d, J = 7.6 Hz, 1H), 6.69 (d, J = 8.2 Hz, 1H), 6.20 (d, J = 15.9 Hz, 
1H), 5.79 (dt, J = 15.7, 5.9 Hz, 1H), 5.53 (dt, J = 15.7, 5.8 Hz, 1H), 5.35 — 5.29 (m, 2H), 
4.69 (d, J = 6.6 Hz, 1H), 4.57 (d, J = 6.8 Hz, 1H), 4.39 — 4.37 (m, 1H), 3.83 — 3.72 (m, 
2H), 3.38 (s, 3H), 2.59 (s, 1H), 2.43 — 2.33 (m, 2H), 2.23 — 2.13 (m, 2H), 2.12 — 2.00 
(m, 2H), 0.97 (s, 9H), 0.26 (s, 3H), 0.23 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 169.6, 
152.3, 137.7, 132.3, 131.6, 131.0, 130.3, 130.0, 125.4, 118.7, 117.4, 95.0, 77.4, 75.7, 
58.9, 56.3, 34.1, 30.6, 29.9, 26.0, 18.7, –3.87, –3.94. 
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(3S,4S,5E,9E)-14-((tert-Butyldimethylsilyl)oxy)-3-(3-hydroxypropyl)-4-
(methoxymethoxy)-3,4,7,8-tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one (3.57). 
To a flask containing macrocyclic diene 3.51172 (68.1 mg, 0.114 mmol) was added DCM 
(3 mL) and H2O (0.3 mL). The mixture was cooled to 0 °C and DDQ (28.4 mg, 0.125 
mmol) was added in one portion. The cooling bath was removed and the reaction was 
stirred at room temperature for 1 h. The reaction mixture was diluted with saturated 
NaHCO3 solution and then extracted with DCM. The combined organic layer was 
washed with brine, dried over MgSO4, and concentrated under vacuum. The residue was 
purified by flash column chromatography on silica gel (100:0 — 65:35 hexanes/EtOAc). 
Compound 3.57 (27.7 mg, 51%) was isolated as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.13 (t, J = 8.0, 1H), 6.86 (d, J = 7.6 Hz, 1H), 6.68 (d, J = 8.2 Hz, 1H), 6.23 (d, 
J = 16.0 Hz, 1H), 5.77 (dt, J = 15.9, 6.1 Hz, 1H), 5.51 (dt, J = 15.6, 6.0 Hz, 1H), 5.34 (dd, 
J = 15.7, 5.0 Hz, 1H), 5.17 (td, J = 7.0, 3.1 Hz, 1H), 4.70 (d, J = 6.8 Hz, 1H), 4.59 (d, J = 
6.8 Hz, 1H), 4.44 — 4.42 (m, 1H), 3.75 — 3.65 (m, 2H), 3.40 (s, 3H), 2.41 — 2.30 (m, 
2H), 2.28 — 2.16 (m, 2H), 2.07 — 1.98 (m, 1H), 1.92 — 1.83 (m, 1H), 1.80 — 1.66 (m, 
2H), 1.47 (br, 1H), 0.97 (s, 9H), 0.23 (s, 3H), 0.22 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 168.6, 152.3, 137.8, 132.5, 132.1, 131.0, 129.9, 129.5, 125.8, 119.1, 117.4, 95.1, 77.4, 
76.2, 63.0, 56.4, 30.8, 30.3, 28.9, 27.0, 26.0, 18.5, –3.9, –4.1. 
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2-((3S,4S,5E,9E)-14-((tert-Butyldimethylsilyl)oxy)-4-(methoxymethoxy)-1-oxo-
3,4,7,8-tetrahydro-1H-benzo[c][1]oxacyclododecin-3-yl)ethanal (3.58). To a solution 
of alcohol 3.56 (188 mg, 0.406 mmol) in DCM (4.1 mL) was added Dess–Martin 
periodinane (259 mg, 0.610 mmol) as solid. The resultant mixture was stirred at room 
temperature for 2.5 h before it was filtered. The filtrate was concentrated under vacuum. 
The residue was purified by flash column chromatography on silica gel (100:0 — 80:20 
hexanes/EtOAc). Compound 3.58 (165 mg, 88%) was isolated as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 9.82 (s, 1H), 7.16 (t, J = 8.0, 1H), 6.88 (d, J = 7.6 Hz, 1H), 6.69 (d, 
J = 8.2 Hz, 1H), 6.14 (d, J = 15.9 Hz, 1H), 5.76 (dt, J = 15.9, 6.2 Hz, 1H), 5.57 (dt, J = 
15.9, 6.2 Hz, 1H), 5.52 — 5.48 (m, 1H), 5.30 (dd, J = 15.8, 6.3 Hz, 1H), 4.66 (d, J = 6.7 
Hz, 1H), 4.51 — 4.49 (m, 2H), 3.32 (s, 3H), 3.07 (ddd, J = 17.3, 4.8, 2.1 Hz, 1H), 2.83 
(ddd, J = 17.3, 4.8, 2.1 Hz, 1H), 2.43 — 2.34 (m, 2H), 2.16 — 2.05 (m, 2H), 0.96 (s, 9H), 
0.234 (s, 3H), 0.230 (s, 3H). 
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3-((3S,4S,5E,9E)-14-((tert-Butyldimethylsilyl)oxy)-4-(methoxymethoxy)-1-oxo-
3,4,7,8-tetrahydro-1H-benzo[c][1]oxacyclododecin-3-yl)propanal (3.59). To a 
solution of alcohol 3.57 (28.4 mg, 0.0596 mmol) in DCM (1.2 mL) was added Dess–
Martin periodinane (37.9 mg, 0.0894 mmol) as solid. The resultant mixture was stirred at 
room temperature for 3 h before it was filtered. The filtrate was concentrated under 
vacuum. The residue was purified by flash column chromatography on silica gel (100:0 
— 80:20 hexanes/EtOAc). Compound 3.59 (20.3 mg, 72%) was isolated as a colorless 
oil. [α] D
21  = +150 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 9.80 (s, 1H), 7.14 (t, J = 
7.9 Hz, 1H), 6.86 (d, J = 7.7 Hz, 1H), 6.70 (d, J = 8.2 Hz, 1H), 6.23 (d, J = 15.9 Hz, 1H), 
5.76 (dt, J = 15.9, 6.2 Hz, 1H), 5.55 — 5.48 (m, 1H), 5.32 (dd, J = 15.6, 5.3 Hz, 1H), 
5.16 (ddd, J = 7.8, 5.8, 3.2 Hz, 1H), 4.69 (d, J = 6.8 Hz, 1H), 4.58 (d, J = 6.8 Hz, 1H), 
4.43 — 4.41 (m, 1H), 3.39 (s, 3H), 2.68 — 2.63 (m, 2H), 2.41 — 2.30 (m, 2H), 2.23 — 
2.13 (m, 4H), 0.98 (s, 9H), 0.24 (s, 3H), 0.23 (s, 3H). 
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(3S,4S,5E,9E)-14-((tert-Butyldimethylsilyl)oxy)-3-((E)-3-iodoallyl)-4-
(methoxymethoxy)-3,4,7,8-tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one (3.60). 
To a suspension of CrCl2 (350 mg, 2.84 mmol) in THF (1.7 mL) was added a solution of 
aldehyde 3.58 (109 mg, 0.237 mmol) and iodoform (373 mg, 0.947 mmol) in dioxane 
(10.2 mL). The resultant mixture was stirred at room temperature for 22 h, quenched with 
brine, and then extracted with EtOAc. The combined organic layer was washed with 
brine, dried over MgSO4, and concentrated under vacuum. The residue was purified by 
flash column chromatography on silica gel (100:0 — 95:5 hexanes/EtOAc). Compound 
3.60 (120 mg, 86%) was isolated as a colorless oil (E/Z = 9:1 vinyl iodide isomers). [α] D
23  
= +96.7 (c 1.19, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.14 (t, J = 8.0 Hz, 1H), 6.86 (d, 
J = 7.7 Hz, 1H), 6.68 (d, J = 8.0 Hz, 1H), 6.60 (dt, J = 14.4, 7.2 Hz, 1H), 6.25 (d, J = 14.4 
Hz, 1H), 6.17 (d, J = 15.9 Hz, 1H), 5.77 (dt, J = 15.7, 6.1 Hz, 1H), 5.52 (dt, J = 15.7, 6.1 
Hz, 1H), 5.30 (dd, J = 15.8, 5.6 Hz, 1H), 5.04 (ddd, 8.5, 5.4, 3.1 Hz, 1H), 4.70 (d, J = 6.8 
Hz, 1H), 4.58 (d, J = 6.7, 1H), 4.42 — 4.40 (m, 1H), 3.41 (s, 3H), 2.78 — 2.70 (m, 1H), 
2.59 — 2.52 (m, 1H), 2.42 — 2.32 (m, 2H), 2.20 — 2.12 (m, 2H), 0.98 (s, 9H), 0.244 (s, 
3H), 0.237 (s, 3H); 13C NMR (100 MHz, CDCl3) 168.3, 152.3, 141.0, 137.8, 132.4, 
132.2, 131.1, 130.1, 129.9, 125.5, 119.0, 117.2, 95.1, 78.7, 76.4, 75.6, 56.5, 36.7, 30.9, 
30.3, 26.0, 18.4, –3.8, –4.2; IR (film, cm–1) 3064, 2928, 2856, 1730, 1574, 1466, 1290, 
1255, 1107, 1036, 841, 784; HRMS (ESI+) m/z calc’d for [M+Na]+ C26H37IO5SiNa: 
607.1347, found 607.1357. 
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(3S,4S,5E,9E)-14-((tert-Butyldimethylsilyl)oxy)-3-((E)-4-iodo-3-buten-1-yl)-4-
(methoxymethoxy)-3,4,7,8-tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one (3.61). 
To a suspension of CrCl2 (114 mg, 0.924 mmol) in THF (0.55 mL) was added a solution 
of aldehyde 3.59 (36.7 mg, 0.0770 mmol) and iodoform (121 mg, 0.308 mmol) in 
dioxane (3.3 mL). The resultant mixture was stirred at room temperature for 23 h, 
quenched with brine, and then extracted with EtOAc. The combined organic layer was 
washed with brine, dried over MgSO4, and concentrated under vacuum. The residue was 
purified by flash column chromatography on silica gel (100:0 — 95:5 hexanes/EtOAc). 
Compound 3.61 (38.9 mg, 84%) was isolated as a colorless oil (E/Z = 9:1 vinyl iodide 
isomers). [α] D
22  = +110 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.13 (t, J = 8.0 Hz, 
1H), 6.85 (d, J = 7.6 Hz, 1H), 6.68 (d, J = 8.1 Hz, 1H), 6.55 (dt, J = 14.1, 6.9 Hz, 1H), 
6.24 (d, J = 15.7 Hz, 1H), 6.08 (d, J = 14.4 Hz, 1H), 5.77 (dt, J = 15.8, 6.1 Hz, 1H), 5.53 
— 5.46 (m, 1H), 5.32 (dd, J = 15.7, 5.1 Hz, 1H), 5.14 (td, J = 6.9, 3.1 Hz, 1H), 4.69 (d, J 
= 6.8 Hz, 1H), 4.57 (d, J = 6.8 Hz, 1H), 4.40 — 4.38 (m, 1H), 3.39 (s, 3H), 2.42 — 2.13 
(m, 6H), 2.00 — 1.89 (m, 2H), 0.97 (s, 9H), 0.23 (s, 3H), 0.22 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 168.4, 152.4, 145.5, 137.7, 132.6, 132.4, 131.0, 129.9, 129.1, 125.8, 
119.1, 117.4, 95.1, 76.4, 76.2, 75.4, 56.4, 32.4, 30.7, 30.3, 29.2, 26.0, 18.6, –3.8, –4.0; IR 
(film, cm–1) 3065, 2929, 2857, 1728, 1573, 1466, 1032, 841; HRMS (ESI+) m/z calc’d 
for [M+Na]+ C27H39IO5SiNa: 621.1504, found 621.1509. 
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(3S,4S,5E,9E)-14-((tert-Butyldimethylsilyl)oxy)-4-hydroxy-3-((E)-3-iodoallyl)-
3,4,7,8-tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one (3.62). To a flask containing 
iodide 3.60 (117 mg, 0.200 mmol) was added iPrOH (4 mL) and CBr4 (266 mg, 0.801 
mmol) in one portion. The mixture was heated with stirring at 75 °C for 2 h, cooled to 
room temperature, and then concentrated under vacuum. The residue was purified by 
flash column chromatography on silica gel (100:0 — 85:15 hexanes/EtOAc). Compound 
3.62 (93.1 mg, 86%) was isolated as a colorless oil. [α] D
22  = +37.6 (c 1.22, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 7.16 (t, J = 8.0 Hz, 1H), 6.87 (d, J = 7.7 Hz, 1H), 6.70 (d, J = 
8.3 Hz, 1H), 6.57 (ddd, J = 15.0, 8.5, 6.8 Hz, 1H), 6.28 (d, J = 14.4 Hz, 1H), 6.21 (d, J = 
16.1 Hz, 1H), 5.75 (dt, J = 15.8, 5.8 Hz, 1H), 5.47 (s, 2H), 5.13 (ddd, J = 9.9, 4.9, 2.0 Hz, 
1H), 4.36 (s, 1H), 2.77 — 2.69 (m, 1H), 2.50 — 2.43 (m, 1H), 2.38 — 2.23 (m, 4H), 1.73 
(br, 1H), 0.98 (s, 9H), 0.25 (s, 3H), 0.24 (3H); 13C NMR (100 MHz, CDCl3) δ 167.9, 
152.4, 140.7, 137.6, 133.2, 132.9, 130.4, 130.1, 129.5, 125.4, 119.0, 117.2, 79.4, 75.7, 
71.0, 37.1, 30.9, 30.0, 25.9, 18.4, –3.8, –4.2; IR (film, cm–1) 3435, 2955, 2929, 2856, 
1726, 1645, 1573, 1466, 1253, 1106, 840, 783; HRMS (ESI+) m/z calc’d for [M+Na]+ 
C24H33IO4SiNa: 563.1085, found 563.1085. 
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(3S,4S,5E,9E)-14-((tert-Butyldimethylsilyl)oxy)-4-hydroxy-3-((E)-4-iodo-3-buten-
1-yl)-3,4,7,8-tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one (3.63). To a flask 
containing iodide 3.61 (38.9 mg, 0.0650 mmol) was added iPrOH (1.3 mL) and CBr4 
(86.2 mg, 0.260 mmol) in one portion. The mixture was heated with stirring at 75 °C for 
2 h, cooled to room temperature, and then concentrated under vacuum. The residue was 
purified by flash column chromatography on silica gel (100:0 — 85:15 hexanes/EtOAc). 
Compound 3.62 (34.5 mg, 96%) was isolated as a colorless oil. [α] D
21  = +31 (c 0.50, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.16 (t, J = 8.0 Hz, 1H), 6.86 (d, J = 7.7 Hz, 1H), 
6.72 (d, J = 8.2 Hz, 1H), 6.54 (dt, J = 14.1, 7.0 Hz, 1H), 6.26 (d, J = 15.6 Hz, 1H), 6.08 
(d, J = 14.4 Hz, 1H), 5.79 — 5.72 (m, 1H), 5.55 — 5.43 (m, 2H), 5.19 (td, J = 7.1, 2.0 
Hz, 1H), 4.31 (d, J = 8.8 Hz, 1H), 2.41 — 2.13 (m, 6H), 1.98 — 1.86 (m, 2H), 1.65 (d, J 
= 9.7 Hz, 1H), 0.97 (s, 9H), 0.233 (s, 3H), 0.227 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 168.1, 152.5, 145.4, 137.5, 133.3, 132.8, 130.3, 130.0, 129.6, 125.6, 119.2, 117.5, 76.6, 
75.6, 72.3, 32.5, 30.8, 30.1, 29.6, 26.0, 18.6, –3.8, –4.0; IR (film, cm–1) 3326, 3065, 2954, 
2928, 2856, 1730, 1572, 1465, 1106, 840; HRMS (ESI+) m/z calc’d for [M+Na]+ 
C25H35IO4SiNa: 577.1242, found 577.1246. 
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(3S,4S,5E,9E)-4,14-Bis((tert-butyldimethylsilyl)oxy)-3-((E)-3-iodoallyl)-3,4,7,8-
tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one (3.48). A solution of alcohol 3.62 
(76.9 mg, 0.142 mmol) and 2,6-lutidine (33 µL, 30.5 mg, 0.28 mmol) in DCM (1.4 mL) 
was cool to –78 °C and TBSOTf (65 µL, 75.2 mg, 0.28 mmol) was added. The solution 
was stirred at –78 °C for 3 h and then left in a 0 °C refrigerator overnight. EtOAc was 
added and the organic mixture was washed with saturated NaHCO3 solution. The 
aqueous layer was re-extracted with EtOAc. The combined organic layer was washed 
with brine, dried over MgSO4, and concentrated under vacuum. The residue was purified 
by flash column chromatography on silica gel (100:0 — 95:5 hexanes/EtOAc). 
Compound 3.48 (72.3 mg, 78%) was isolated as a colorless oil. [α] D
22  = +79.8 (c 1.02, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.17 (t, J = 7.9 Hz, 1H), 6.88 (d, J = 7.5 Hz, 1H), 
6.71 (d, J = 8.2 Hz, 1H), 6.54 (dt, J = 14.6, 7.3 Hz, 1H), 6.18 (d, J = 14.5 Hz, 1H), 6.13 
(d, J = 15.8 Hz, 1H), 5.76 — 5.69 (m, 1H), 5.48 — 5.39 (m, 1H), 5.32 (dd, J = 15.7, 6.7 
Hz, 1H), 4.84 (ddd, J = 7.4, 6.2, 3.7 Hz, 1H), 4.46 (dd, J = 6.6, 3.7 Hz, 1H), 2.74 — 2.61 
(m, 1H), 2.59 — 2.43 (m, 1H), 2.41 — 2.25 (m, 2H), 2.21 — 1.91 (m, 2H), 0.98 (s, 9H), 
0.88 (s, 9H), 0.24 (s, 6H), 0.06 (s, 3H), 0.01 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 168.5, 152.0, 141.8, 138.1, 133.5, 132.3, 131.5, 130.6, 130.0, 126.0, 119.1, 117.5, 78.6, 
78.0, 72.9, 36.2, 31.1, 30.7, 26.1, 26.0, 18.44, 18.37, –3.5, –3.9, –4.1, –4.7. 
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(3S,4S,5E,9E)-4,14-Bis((tert-butyldimethylsilyl)oxy)-3-((E)-4-iodo-3-buten-1-yl)-
3,4,7,8-tetrahydro-1H-benzo[c][1]oxacyclododecin-1-one (3.49). A solution of alcohol 
3.63 (34.5 mg, 0.0622 mmol) and 2,6-lutidine (14 µL, 13 mg, 0.12 mmol) in DCM (0.6 
mL) was cool to –78 °C and TBSOTf (29 µL, 33 mg, 0.12 mmol) was added. The 
solution was stirred at –78 °C for 3 h and then left in a 0 °C refrigerator overnight. EtOAc 
was added and the organic mixture was washed with saturated NaHCO3 solution. The 
aqueous layer was re-extracted with EtOAc. The combined organic layer was washed 
with brine, dried over MgSO4, and concentrated under vacuum. The residue was purified 
by flash column chromatography on silica gel (100:0 — 95:5 hexanes/EtOAc). 
Compound 3.49 (35.1 mg, 84%) was isolated as a colorless oil. [α] D
21  = +75 (c 0.50, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.16 (t, J = 7.9 Hz, 1H), 6.86 (d, J = 7.6 Hz, 1H), 
6.71 (d, J = 8.1 Hz, 1H), 6.54 (dt, J = 14.4, 7.2 Hz, 1H), 6.22 (d, J = 16.2 Hz, 1H), 6.04 
(d, J = 14.4 Hz, 1H), 5.73 (dt, J = 15.9, 6.4 Hz, 1H), 5.47 — 5.33 (m, 2H), 4.95 (ddd, J = 
7.8, 5.4, 3.6 Hz, 1H), 4.43 (dd, J = 5.5, 3.7 Hz, 1H), 2.37 — 2.01 (m, 6H), 1.94 — 1.80 
(m, 2H), 0.97 (s, 9H), 0.89 (s, 9H), 0.23 (s, 3H), 0.22 (s, 3H), 0.06 (s, 3H), 0.02 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 168.5, 152.2, 145.8, 138.1, 132.52, 132.50, 131.3, 131.2, 
129.9, 126.2, 119.3, 117.6, 78.1, 75.2, 73.5, 32.7, 30.9, 30.7, 28.7, 26.1, 26.0, 18.6, 18.4, 
–3.8, –3.9, –4.0, –4.7; IR (film, cm–1) 3066, 2955, 2929, 2857, 1728, 1465, 1107, 840, 
779; HRMS (ESI+) m/z calc’d for [M+Na]+ C31H49IO4Si2Na: 691.2106, found 691.2120. 
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(2Z,4E)-N-((E)-3-((3S,4S,5E,9E)-4,14-Dihydroxy-1-oxo-3,4,7,8-tetrahydro-1H-
benzo[c][1]oxacyclododecin-3-yl)-1-propen-1-yl)-4-(methoxyimino)-2-butenamide 
(3.46). To a flask containing iodide 3.48 (71.4 mg, 0.109 mmol), amide 1.7491, 193 (69.8 
mg, 0.545 mmol), CuI (41.5 mg, 0.218 mmol) and Cs2CO3 (178 mg, 0.545 mmol) was 
charged dimethylacetamide (DMA) (11 mL). The resultant mixture was degassed under 
high vacuum for 5 min before N,N’-dimethylethylenediamine (DMEDA) (59 µL, 48 mg, 
0.55 mmol) was added. The reaction was stirred at room temperature for 24 h and then 
water was added. The crude mixture was extracted with EtOAc. The combined organic 
layer was washed with brine, dried over MgSO4, and concentrated under vacuum. The 
crude bis-TBS enamide was directly used in the next step without further purification. 
The crude bis-TBS enamide was dissolved in THF (1 mL) and 5 M HF·Py solution 
(1:2:4.7 mixture of HF·Py (70% HF)/pyridine/THF, 1.3 mL, 6.5 mmol) was added. The 
reaction was stirred for 48 h and quenched with phosphate (pH = 7) buffer.  The aqueous 
layer was extracted with EtOAc. The organic extracts were washed with brine, dried over 
MgSO4, and concentrated under vacuum. The residue was purified by flash column 
chromatography on silica gel (100:0 — 40:60 hexanes/EtOAc). Compound 3.46 (18.6 
mg, 40%) was isolated as a colorless syrup. [α] D
21  = –45.4 (c 0.372, CHCl3); 1H NMR 
(400 MHz, acetone-d6) δ 9.90 (s, 1H), 9.33 (d, J = 10.4 Hz, 1H), 9.08 (d, J = 10.2 Hz, 
1H), 7.27 (t, J = 8.0 Hz, 1H), 6.90 (dd, J = 14.4, 10.3 Hz, 1H), 6.81 (d, J = 7.4 Hz, 1H), 
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6.79 (d, J = 8.2 Hz, 1H), 6.60 (d, J = 15.8 Hz, 1H), 6.47 (t, J = 10.8 Hz, 1H), 6.12 (d, J = 
11.5 Hz, 1H), 5.76 — 5.67 (m, 1H), 5.64 — 5.51 (m, 2H), 5.37 (dt, J = 14.4, 7.2 Hz, 1H), 
5.17 (ddd, J = 7.7, 5.9, 3.2 Hz, 1H), 4.38 (s, 1H), 4.20 (d, J = 6.4 Hz, 1H), 3.87 (s, 3H), 
2.74 — 2.67 (m, 1H), 2.60 — 2.50 (m, 1H), 2.42 – 2.20 (m, 4H); 13C NMR (100 MHz, 
acetone-d6) δ 170.4, 162.6, 159.4, 148.5, 141.1, 134.9, 134.2, 133.3, 132.5, 132.1, 131.5, 
126.5, 126.1, 119.5, 117.0, 115.9, 109.8, 78.5, 72.5, 62.5, 32.5, 31.4, 30.7; IR (film, cm–1) 
3419, 2928, 2852, 1652, 1526, 1465, 1259, 1118, 1043, 966, 819; HRMS (ESI+) m/z 
calc’d for [M+Na]+ C23H26N2O6Na: 449.1683, found 449.1686. 
HO
O
O NH
O
N
MeO
OH
 
(2Z,4E)-N-((E)-4-((3S,4S,5E,9E)-4,14-Dihydroxy-1-oxo-3,4,7,8-tetrahydro-1H-
benzo[c][1]oxacyclododecin-3-yl)-1-buten-1-yl)-4-(methoxyimino)-2-butenamide 
(3.47). To a flask containing iodide 3.49 (18.6 mg, 0.0278 mmol), amide 1.7491, 193 (17.8 
mg, 0.139 mmol), CuI (10.6 mg, 0.0556 mmol) and Cs2CO3 (45.3 mg, 0.139 mmol) was 
charged DMA (2.8 mL). The resultant mixture was degassed under high vacuum for 5 
min before DMEDA (15 µL, 12 mg, 0.14 mmol) was added. The reaction was stirred at 
room temperature for 24 h and then water was added. The crude mixture was extracted 
with EtOAc. The combined organic layer was washed with brine, dried over MgSO4, and 
concentrated under vacuum. The crude bis-TBS enamide was directly used in the next 
step without further purification. 
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The crude bis-TBS enamide was dissolved in THF (0.28 mL) and 5 M HF·Py 
solution (1:2:4.7 mixture of HF·Py (70% HF)/pyridine/THF, 0.17 mL, 0.83 mmol) was 
added. The reaction was stirred for 48 h and quenched with phosphate (pH = 7) buffer.  
The aqueous layer was extracted with EtOAc. The organic extracts were washed with 
brine, dried over MgSO4, and concentrated under vacuum. The residue was purified by 
flash column chromatography on silica gel (100:0 — 40:60 hexanes/EtOAc). Compound 
3.47 (3.7 mg, 30%) was isolated as a white solid. [α] D
22  = –62 (c 0.050, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 10.48 (s, 1H), 9.01 (d, J = 10.3 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 
7.12 — 7.05 (m, 1H), 6.88 — 6.77 (m, 3H), 6.65 (d, J = 15.7 Hz, 1H), 6.50 (dd, J = 11.3, 
10.5 Hz, 1H), 5.84 (d, J = 11.5 Hz, 1H), 5.66 — 5.57 (m, 2H), 5.49 (dd, J = 15.7, 5.7 Hz, 
1H), 5.28 (dt, J = 14.2, 7.1 Hz, 1H), 5.21 (ddd, J = 7.6, 5.4, 3.9 Hz, 1H), 4.36 (d, J = 5.0 
Hz, 1H), 3.94 (s, 3H), 2.47 — 2.33 (m, 2H), 2.28 — 2.15 (m, 4H), 2.11 — 2.03 (m, 1H), 
1.90 — 1.83 (m, 1H), 1.79 (d, J = 4.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 171.0, 
161.8, 161.4, 147.9, 141.9, 135.7, 135.3, 134.3, 130.0, 129.8, 126.1, 124.5, 123.1, 120.1, 
118.5, 116.4, 113.4, 77.1, 72.7, 62.6, 32.7, 30.0, 29.2, 26.4; IR (film, cm–1) 3306, 3044, 
2928, 2855, 1652, 1603, 1450, 1217, 1122, 1045, 965, 821, 778; HRMS (ESI+) m/z 
calc’d for [M+Na]+ C24H28N2O6Na: 463.1840, found 463.1840. 
4.5 Cytotoxicity Assay 
The human cancer cell lines leukemia (HL-60), breast (MCF-7), melanoma (SK-
MEL-28 and SK-MEL-5) were obtained from the NCI and grown in normal RPMI 1640 
culture medium containing 10% fetal bovine serum. The cells, in the exponential-phase 
maintenance culture, were dissociated with 0.25% trypsin and harvested by centrifugation 
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at 125 × g for 5 min. Trypsin was removed and the cells were resuspended in new culture 
medium. The cell density was adjusted to 1 × 105 and dispensed in triplicate on 96-well 
plates in 50 µL volumes. After incubation overnight at 37 °C under 5% CO2, 50 µL of 
culture medium containing various concentrations of the tested compounds were added. 
Paclitaxel (Taxol®) and oximidine II were used as positive controls. After 48 h 
incubation, the relative cell viability in each well was determined by using the 
AlamarBlue Assay Kit. Optical densities were then measured photometrically (excitation 
= 530 nm, emission = 590 nm) on the plate reader. The IC50 of each compound was 
determined by fitting the relative viability of the cells to the drug concentration using a 
dose-response model. 
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